



2016

Consequences of Estrogen Receptor Beta Phosphorylation in the Aged Female Brain and Heart

Elena Pinceti
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss



Part of the [Neurosciences Commons](#)

Recommended Citation

Pinceti, Elena, "Consequences of Estrogen Receptor Beta Phosphorylation in the Aged Female Brain and Heart" (2016). *Dissertations*. 2144.

https://ecommons.luc.edu/luc_diss/2144

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.



This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License](#).
Copyright © 2016 Elena Pinceti

LOYOLA UNIVERSITY CHICAGO

CONSEQUENCES OF ESTROGEN RECEPTOR BETA PHOSPHORYLATION
IN THE AGED FEMALE BRAIN AND HEART

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

INTEGRATIVE CELL BIOLOGY PROGRAM

BY

ELENA PINCETI

CHICAGO, ILLINOIS

AUGUST 2016

Copyright by Elena Pinceti, 2016
All rights reserved.

ACKNOWLEDGEMENTS

I would like to first thank my parents and siblings that with our weekend Skype calls often kept me from getting overwhelmed with the research. The determination and curiosity that helped me in my studies are a result of what they taught me. I also am thankful for all the special friends that have cheered me up when experiments failed and celebrated with me when I accomplished my goals.

Next, I would not have been able to complete this dissertation work if it hadn't been for the invaluable perspective of my committee members: Dr. Wendy Kartje, Dr. Pieter deTombe, Dr. Clodia Osipo and Dr. Melinda Wilson. Your guidance and advice have taught me a lot and made me think deeply about my results.

Finally I would like to thank the person that has been the greatest mentor I could have imagine, Dr. Toni Pak. I was extremely lucky to be part of the Pak lab and work alongside great students in lab and at conferences. The past years have been unforgettable and I am really thankful to Dr. Pak for the support and guidance inside and outside of lab. The last years are extraordinary and have shaped me personally and professionally. I know that the relationships built at Loyola will last.

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	iii
LIST OF TABLES	vi
LIST OF FIGURES	vii
LIST OF ABBREVIATIONS	x
CHAPTER I: STATEMENT OF THE PROBLEM	1
CHAPTER II: REVIEW OF THE LITERATURE	3
Estrogen Synthesis and Menopause	3
Neuroprotection of Estrogen	4
Cardioprotection of Estrogens	9
The Timing Hypothesis	12
Estrogen Receptor β	13
Phosphorylation of ER β	15
Coregulatory Proteins and ER β	18
Mitogen Activated Kinases	20
Experimental Design	28
Hypothesis and Questions	30
CHAPTER III: PHOSPHORYLATION ALTERS ESTROGEN RECEPTOR B-MEDIATED TRANSCRIPTION IN NEURONS	32
Introduction	32
Results	44
Discussion	51
CHAPTER IV: DIFFERENTIAL EFFECTS OF E2 ON MAPK ACTIVITY IN THE BRAIN AND HEART OF AGED FEMALE RATS	60
Introduction	60
Results	65
Discussion	92
CHAPTER V: QUANTITATIVE MASS SPECTROMETRY FOR <i>IN VIVO</i> ANALYSIS OF PHOSPHORYLATED ERB	98
Introduction	98
Results	104
Discussion	133

CHAPTER VI: FINAL DISCUSSION	134
Summary and Key Findings	134
Phosphorylation of ER β and ligand independent actions	137
Phosphorylation of ER β and the dynamic structure of the N- terminal domain	139
Phosphorylation of ER β and the interacting proteins	143
MAPKs in the aging female brain and heart	144
A potential role for protein phosphatases	146
Mitochondrial dysfunctions with age and estrogen effects	148
Future directions	152
 CHAPTER VII: BROAD CLINICAL IMPLICATIONS	
Clinical potential of ER β	154
Need for better understanding of ER β signaling	156
Closing Remarks	158
 CHAPTER VIII: GENERAL METHODS	160
 REFERENCES	172
VITA	187

LIST OF TABLES

Table 1.	List of ER β expression vectors	40
Table 2.	Schematic summary of reporter assay results	53
Table 3.	F-values and p-values from two factor ANOVA analysis	91
Table 4.	Details of antibodies used in Chapter V	168

LIST OF FIGURES

Figure 1.	Cardioprotective and neuroprotective effects of ER β	12
Figure 2.	The Timing Hypothesis	14
Figure 3.	Domains of ER β	15
Figure 4.	Classical model of ER β 's action	17
Figure 5.	ER β phosphorylation sites	20
Figure 6.	ERK and p38 signaling	27
Figure 7.	Animal Paradigm	29
Figure 8.	Expression of phosphorylated ER β in the dorsal hippocampus of aged female rats	38
Figure 9.	Effects of ER β phosphorylation on ER β -mediated promoter activity at an ERE site	42
Figure 10.	Effects of ER β phosphorylation on ER β -mediated promoter activity at an AP-1 site	45
Figure 11.	Effects of tamoxifen treatment on ER β or ER β mutant-mediated promoter activity at an ERE or AP-1 site	48
Figure 12.	Effects of S87 and S105 phospho-mutation on DNA binding to a consensus ERE sequence	50
Figure 13.	Diagram of the animal paradigm	64
Figure 14.	Effects of age and E2 treatment on ERK protein expression and activation in the hypothalamus	67
Figure 15.	Effects of age and E2 treatment on p38 protein expression and activation in the hypothalamus	69
Figure 16.	Effects of age and E2 treatment on ERK protein expression and activation in the dorsal hippocampus	71
Figure 17.	Effects of age and E2 treatment on p38 protein expression and activation in the dorsal hippocampus	73
Figure 18.	Effects of age and E2 treatment on ERK protein expression and activation in the ventral hippocampus	75

Figure 19.	Effects of age and E2 treatment on p38 protein expression and activation in the ventral hippocampus	77
Figure 20.	Effects of age and E2 treatment on ERK protein expression and activation in the left ventricle	80
Figure 21.	Effects of age and E2 treatment on p38 protein expression and activation in the left ventricle	81
Figure 22.	Effects of age and E2 treatment on ERK mRNA expression	83
Figure 23.	Effects of age and E2 treatment on p38 mRNA expression	85
Figure 24.	ERK activation is differentially regulated by ER isoform specific agonists	87
Figure 25.	p38 activation is differentially regulated by ER isoform specific agonists	89
Figure 26.	Outline of the experiments described in Chapter V	101
Figure 27.	Schematic representation of the Triple Quadrupole mass spectrometer	103
Figure 28.	Theoretical digestion of rER β with 8 available enzymes	104
Figure 29.	Analysis of ER β tryptic peptides	106
Figure 30.	Analysis of Tryptic digestion of ER β for potential missed cleavage sites	107
Figure 31.	Screening of 5 ER β -His6 clones	112
Figure 32.	Screening of eluted fractions after IMAC	113
Figure 33.	Western blot staining of protein from the eluted fractions containing putative ER β	114
Figure 34.	ER β -His6 protein SDS-PAGE gel for in gel-digestion	117
Figure 35.	Representative MALDI-TOF spectrum of gel digestion products of ER β -His6	118
Figure 36.	Characteristics of the four SPWCEAR peptides purchased	119
Figure 37.	Predicted precursor and product ions for the light and heavy unphosphorylated SPWCEAR peptide	121

Figure 38.	Spectrum for the SPWCEAR peptide	123
Figure 39.	Spectra detected in Q3 showing product ions of the 424.66 precursor ion	124
Figure 40.	List of transitions chosen for each target peptide	126
Figure 41.	Chromatographs of the 4 pure peptides showing retention times of each	128
Figure 42.	Spectra of the four transitions monitored for the light unphosphorylated peptide	129
Figure 43.	Sequence of the long peptide synthesise	131
Figure 44.	Successful cleavage of the long phosphorylated peptide	132
Figure 45.	Phosphorylation of ER β increases ERE dependent transcription and abolishes ligand independent inhibition of AP-1 sites	135
Figure 46.	Network Protein Sequence Analysis of the N-terminal domain of ER β	142
Figure 47.	Context dependent effects of Estrogen	145
Figure 48.	Potentials for ER β specific treatment in post-menopausal women	155

LIST OF ABBREVIATIONS

AD	Alzheimer's Disease
AF-1	Activation Function-a
ALS	Amyotrophic Lateral Sclerosis
ANOVA	Analysis of Variance
AP	Alkaline Phosphatase
BDNF	Brain-Derived Neutrophic Factor
CAM	Carbamidomethyl
CD	Cardiovascular Disease
CE	Collision Energy
CHCA	α -cyano-4-hydroxycinnamic acid
CHD	Coronary Heart Disease
CID	Collision Induced Dissociation
COPD	Chronic Obstructive Pulmonary Disease
DBD	DNA-Binding Domain
DH	Dorsal Hippocampus
DNA	deoxyribonucleic acid
DPN	Diarylpropionitrile
DTT	Dithiothreitol
E1	estrone
E2	17 β -estradiol
E3	estriol
EGF	Epydermal Growth Factor
ERE	Estrogen Responsive Elements

ERK	Extracellular signal Regulated Kinase
ERR α	Estrogen Receptor Related α
ER α	Estrogen Receptor α
ER β	Estrogen Receptor β
ET	Estrogen Therapy
HR	Hazard Ratio
ID	Intrinsically disordered
IPTG	Isopropyl β -D-1-thiogalactopyranoside
IQ	intelligence quotient
JNK	c-Jun-NH ₂ -terminal Kinase
LBD	Ligand-Binding Domain
LC	Liquid Chromatography
LV	Left Ventricle
MALDI-	
TOF	Matrix Assisted Laser Desorption Ionization- Time Of Flight
MAPKs	Mitogen Activated Protein Kinases
MCAO	Middle Cerebral Artery Occlusion
MI	Myocardial Infarction
mo	months old
MRM	Multiple Reaction Monitoring
mRNA	Messenger Ribonucleic Acid
MS	Mass Spectrometry
mTOR	mammalian Target Of Rapamycin
MW	Molecular Weight
NCoR	Nuclear Corepressor

NO	Nitric Oxide
NRF-1	Nuclear Respiratory Factor-1
OVX	Ovariectomy
PD	Parkinson's Disease
PPT	propyl pyrazole triol
PTM	Post Translational Modification
RNA	Ribonucleic acid
ROS	Reactive Oxygen Species
SADHART	Sertraline Antidepressant Heart attack Trial
SAPK	Stress-Activated Protein Kinase
SDS-	
PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEM	Standard Error of the Mean
SERM	Selective Estrogen-Receptor Modulators
	Silencing Mediator for Retinoid and Thyroid hormone
SMRT	receptor
SRC	Steroid Receptor Coactivator
SRM	Selected Reaction Monitoring
SSRI	Serotonin Reuptake Inhibitor
TAM	Tamoxifen
TBP	TATA Binding Protein
TGY	Threonine-Glycine-Threonine
VH	Ventral Hippocampus
WHI	Women's Health Initiative
WT	Wild Type

CHAPTER I

STATEMENT OF THE PROBLEM

Female life expectancy in the United States has steadily increased and now averages 81 years, meanwhile the age at which women reach menopause remains constant at 51 years. Therefore, women live over one third of their life in a post-menopausal, low estrogenic state. Both neurological and cardiovascular disorders increase following menopause, affecting women's quality of life and leading to large health care costs.

Various epidemiological and basic science studies show that estrogen administration (Estrogen Therapy (ET)) can have neuroprotective effects and improve cognitive abilities in aging women, as well as reduce heart disease and overall mortality. The Women's Health Initiative (WHI), a large clinical study conducted in menopausal women, had contradicting conclusions but established that age is an important factor in determining positive or negative outcome of ET. This led to the formulation of the "Timing Hypothesis": exposure to estrogens is beneficial for younger women but has detrimental outcomes in post-menopausal women who have experienced an extensive hypo-estrogenic period. While its underlying mechanisms are unclear, it is well accepted that the female brain and heart respond differently to ET before and after menopause, indicating that cellular and molecular components in these tissues undergo some kind of modification during the perimenopausal transition.

The effects of estrogen are mediated by two high affinity nuclear receptors, Estrogen Receptor α (ER α) and Estrogen Receptor β (ER β) and the G-protein coupled estrogen receptor1 (GPER) . Evidence supports that ER β plays an important role in neuroprotection and cardioprotection, but aspects of ER β molecular signaling are still not fully understood. One possibility is that aging and estrogen deprivation alter ER β post translational modifications, such as phosphorylation. Indeed the mitogen activated protein kinases (MAPKs) responsible for phosphorylation of ER β have been shown to be modulated by aging and steroid hormones. The goal of my dissertation is to determine the consequences of ER β phosphorylation and how prolonged estrogen deprivation prior to estrogen treatment alters MAPKs signaling in the brain and heart.

CHAPTER II
LITERATURE REVIEW
ESTROGEN SYNTHESIS AND MENOPAUSE

Estrogens are the primary female sex hormones; they are mostly produced by the ovaries, corpus luteum and placenta in premenopausal women [1]. A smaller amount of estrogens is also produced by non gonadal organs such as the brain, liver, heart and skin. The three major forms of estrogens in women are estrone (E1), 17 β -estradiol (E2) and estriol (E3). The most potent and prevalent estrogen in premenopausal women is E2, which is produced within the ovary by thecal and granulosa cells. Aromatase is the enzyme necessary for the final step of E2 synthesis, and it is expressed in granulosa cells as well as in peripheral organs. During the menstrual cycle, E2 is highest right before ovulation, reaching 110-410 pg/ml. In perimenopause E2 levels fluctuate and then decrease to below 35 pg/ml in postmenopausal women [1, 2]. The average age at menopause is 48-52 in developed countries and reflects the exhaustion of functional follicles in the ovaries. The number of follicular oocytes is set before birth and declines with apoptotic events before and after puberty. When women reach 45-55 years of age the oocytes are exhausted leading to a cascade of events ending with neuroendocrine desynchronization, fluctuations in estrogens levels and ultimately menopause [2].

Following menopause, estrone is the prevalent circulating estrogen; estrone is synthesized from conversion of androstenedione in adipose tissue, neurons and astrocytes [3]. Analyses of post-menopausal women who underwent natural menopause determined that adipose tissue mass correlates with estrone levels, which had osteoprotective effects and increased bone mineral density as well as decreased colorectal cancer risk [4] [5]. However, high estrone levels in post menopausal women also have been found to correlate with increased ER-positive breast cancer [6]. Estrone has higher affinity for ER α than ER β , however it was shown to induce coregulatory protein recruitment to ER β more efficiently than ER α [7, 8]. The third physiological estrogen, estriol, is the weakest activator of ERs and is produced during pregnancy by the fetal liver and adrenal glands [9]. Interestingly, estriol has been found to decrease the symptoms of multiple sclerosis (MS), explaining the improvement of women with MS during pregnancy [10].

NEUROPROTECTION OF ESTROGEN

Learning and Memory

The study of the effects of estrogens on cognitive functions started in the 1950's when a random controlled study on 75-year old women showed that 12 months of treatment with E2 improved their verbal intelligence quotient (IQ) while the IQ scores of the placebo treated women decreased over that same period of time [11]. Since then randomized observational and longitudinal studies have investigated the clinical effects of estrogens on cognitive functions, anxiety, mood, and memory using standard tests of neuropsychological function. Overall 71% of studies concluded a significant

beneficial effects of E2 [12]. However interpretation of these studies is complicated by several confounding variables such as age and dosage, tests used to evaluate cognition, and length of treatment. A more definitive understanding of the molecular effects of E2 is needed to help physicians better treat their patients.

Basic science studies have elucidated some of the mechanisms behind the neuroprotective effects of estrogens. In the 1990s, Catherine Woolley and Bruce McEwen found that E2 levels fluctuating across the estrous cycle correlate with synaptic changes in the hippocampus of female rats [13, 14]. Indeed, higher E2 levels coincided with increased synaptic density, increased dendritic spines and arborization. In an *in vivo* study using ER β -null mice, Liu showed that ER β is required for the E2-enhanced hippocampal synaptic plasticity and hippocampal dependent cognition [15]. These and other studies have therefore linked E2 to synaptic plasticity changes in neuronal circuitry and architecture [16]. Moreover, behavioral experiments using female rats show that changes in their learning strategy vary with natural hormonal fluctuations, such as during the estrous cycle, strongly implying that hippocampal mediated learning and cognition was intrinsically linked with circulating levels of estrogens [17]. In an extensive behavioral analysis, Kiss et al. evaluated the effects of E2 treatment on cognition and depressive-like behaviors in young (3 mo), adult (7 mo) and middle-aged (12 mo) female rats [18]. Their results showed that E2 treatment improved spatial reference memory in all age groups and was beneficial for depressive-like behaviors in young and middle-aged rats. Correlating with the behavioral data with neurochemical evaluations, hippocampal brain-derived neurotrophic factor

(BDNF) levels were increased by E2 treatment at all time points, while decreasing with age. BDNF mediates neuronal growth, survival, and plasticity in the nervous system. Several lines of evidence support an interaction between E2 and BDNF and their downstream neuroprotective, neurotrophic, and neuromodulatory effects [19]. Estrogens and BDNF have similar effects on the hippocampus and in the past years many studies have focused on the idea that BDNF is a mediator of estrogens' effects. [20, 21]. By comparing the immunoreactivity of BDNF in the hippocampus during the estrous cycle, Sharfman showed that BDNF levels also cycle according to cycling estrogens [22].

Pathogenic conditions

Interestingly, studies suggest that E2 might prevent or delay the onset of Alzheimer's disease (AD), the most common cause of dementia in women. In a 1998 meta-analysis Yaffe et al. concluded that treatment with estrogens decreased the risk of developing dementia in postmenopausal women by 29% and that several plausible biological mechanisms exist that could support estrogens' use as a preventative and beneficial treatment of AD [23]. Case-controlled clinical studies have been conducted since then, and a 2001 meta-analysis concluded there is a 34% decreased risk of Alzheimer disease in women taking hormone treatment [24]. Research using animal models has also investigated a putative link between AD and E2 therapy. For instance, a recent study evaluated the use of a nonsteroidal selective androgen receptor agonist together with an ER β agonist in a mouse model of AD, which resulted in improved cognition, reduced anxiety behaviors as well as an increase in Amyloid- β degrading enzymes [25]. The authors speculate that ER β agonists

could be used as a potential therapy of patients with AD by interfering with the progression of the disease through degrading and clearing Amyloid β . In transgenic models of AD, different ER β agonists led to prolonged survival, improved spatial recognition memory, cognition and lowered Amyloid- β accumulation [25, 26]. In the case of Parkinson's disease (PD) and other neurodegenerative diseases, estrogens have been shown to protect the nigrostriatal dopaminergic pathway that is affected by these diseases [27, 28]. It is thought that both ER α and ER β are necessary for this protection; however an animal model of PD showed that treatment with the ER β agonist AC-186 prevented motor and cognitive deficits and mitigated neuronal loss in males but not in females [29, 30].

Other neuroprotective effects of estrogens have been attributed to ER β . For example, several ER β selective agonists have been shown to induce remyelination and repair in animal models of multiple sclerosis [31]. Inflammatory and neuropathic pains are also targets of ER β regulation, as shown *in vivo* using the ER β selective agent ERb-131 [32, 33]. Gliomas, aggressive brain tumors, are more common in males than females, indicating a possible beneficial effect of the higher levels of circulating estrogens in females; interestingly ER β is highly expressed in male and female glioma cells, while ER α is not detected [34]. Indeed treatment with ER β agonists DPN (Diarylpropionitrile) or liquitrigenin reduced proliferation in an *in vitro* glioma model and *in vivo* in mice that had a glioma xenograft [34].

Estrogens have also been shown to be neuroprotective in models of cerebral ischemia. Women overall have a lower incidence of stroke than men, but following menopause this difference decreases [35]. Studies have proven

that E2 exerts dramatic protection if administered either before or after the ischemic injury [36, 37]. For example, E2 treatment for seven days significantly reduced infarct size in a middle cerebral artery occlusion (MCAO) ischemic injury paradigm [37]. Moreover, a 2013 study showed periodic E2 treatment increased neuronal survival following cerebral ischemia via bilateral carotid occlusion and systemic hypotension. [38] The study also demonstrated that learning and memory following ischemic damage was improved when the rats were administered an ER β specific agonist, which might have been mediated by the ER β dependent increase in CREB phosphorylation.

Mood and affective disorders

The role of estrogen in anxiety and depressive disorders has been investigated both in clinical and basic science fields. Women experience increased depression, sleep disturbances, irritability, anxiety and panic disorders after menopause and ET has been shown to improve mood, feelings of wellbeing and an overall increase in activity [39]. However, women in general report higher incidence of depression than men, yet animal models have shown both anxiogenic and anxiolytic actions of E2. These discrepant findings can be partly explained by differential actions mediated by the two estrogen receptor isoforms, ER α and ER β . For instance, a 2005 paper by Lund et al., demonstrated that treatment with an ER β specific agonist decreased anxiety-related behaviors in rats, whereas ER α specific agonists were anxiogenic [39]. Their findings suggest that the conflicting effects of estrogens might be due to inverse actions on anxiety behaviors by the two ERs. Indeed, studies have shown that ER α and ER β have different signaling

pathways and downstream gene targets despite their equivalent binding affinity for E2 [40]. Overall, ER β has beneficial effects on neurological diseases that have very different etiologies and in which different cell types are involved, highlighting its multifaceted functions.

CARDIOPROTECTION OF ESTROGEN

The sex difference in the incidence of cardiovascular disease is well documented, women are less likely to develop heart disease than men, but this advantage is lost after menopause presumably due to significant reduction in circulating E2 [41-43].

Both estrogen receptor isoforms, ER α and ER β , are widely expressed in cardiovascular tissue, in cardiac myocytes, fibroblasts, vascular smooth muscle cells and endothelial cells and can influence gene expression as well as have rapid non genomic effects [44]. ER β deficient mice develop hypertension, vascular dysfunction, and abnormal heart morphology as they age and therefore have been used to reveal the role for this receptor isoform in mediating E2 effects in the cardiovascular system. A study from Dr. E. Murphy found that ER β mediates functional recovery following ischemia/reperfusion injury possibly by its regulation of fatty acid metabolism genes important in ischemic injury [45].

The development of several SERMs (selective estrogen-receptor modulators) also contributed to the understanding of the importance of ER β in the cardiovascular system. ER β -specific agonists reduced arterial pressure in ovariectomized spontaneously hypertensive rats, increased cardiac output and left ventricular stroke volume [46]. The same study also showed that ER β activation also improved vascular reactivity and increased ER β expression in

the aortic ring, both in endothelial cells in the intima and vascular smooth muscle cells [46]. Overall the study showed that ER β specific agonists attenuate hypertension, vascular resistance and cardiac hypertrophy in spontaneously hypertensive rats. The authors also speculated that these positive effects might be mediated by enhanced vascular Nitric Oxide (NO) generation both via genomic and non-genomic mechanisms. Indeed ER increases expression of enzymes responsible for NO synthesis as well as activating them, possibly by recruiting and activating kinases [47].

ER β is necessary for the observed gendered differences in the attenuation of the hypertrophic response to pressure overload and improved recovery from ischemia/reperfusion injury [48, 49]. Furthermore, in animal models of ischemia reperfusion injury, treatment with the ER β specific agonist improves functional recovery and upregulates protective genes such as antiapoptotic proteins, heat shock proteins and cyclooxygenase 2 [50]. These and other studies led to the proposal by Kathryn Sandber and Hong Ji that ER β could be the “Alpha-Dog” in estrogen receptor-mediated protection from hypertension [51].

An additional factor to consider when studying the effects of estrogen in post menopause is the comorbidity of depression and cardiovascular disease (CD) which ranges from 20 to 40% according to different studies. Middle-aged women are particularly susceptible to higher mortality following myocardial infarction (MI) if they have depressive symptoms (50% greater risk) [52-54]. The interesting link between heart disease and depression was analyzed in the SADHART trial (Sertraline AntiDepressant Heart Attack Trial), which was aimed at evaluating the effectiveness of the selective serotonin

reuptake inhibitor (SSRI) Sertraline in treating major depression in patients with acute myocardial infarction (MI) or unstable angina. The trial concluded that Sertraline is safe and efficacious in depressed patients with ischemic heart disease, but could not detect differences in mortality between placebo and Sertraline treated patients because it was underpowered. It is also difficult to determine whether depression is a risk factor for coronary heart disease (CHD) or a cause of it. Kenneth E Freeland and Robert M Carney in a recent report supported the idea that depression predicts worse outcome in patients with CHD and possibly improving the depressive symptoms could determine better cardiovascular prognosis [55]. Not only is comorbidity of depression and CD increasingly prevalent in middle-aged patients, but also menopausal women are particularly susceptible to have both these conditions. The elevated risk of both depression and CD in menopausal women is well accepted but the reason for this or the possible improvement from using HT needs further investigation [53].

Overall, several studies confirm estrogen's positive effects on the cardiovascular system and the importance of ER β in mediating these responses, but how age and timing of ET influences cardioprotection needs further investigation.




Figure 1 Summary of studies depicting the specific cardioprotective and neuroprotective effects of ER β .

THE TIMING HYPOTHESIS

The constant theme in neuroprotection and cardioprotection of estrogens in clinical studies is the importance of the time of initiation of ET (estrogen therapy alone) in women. The concepts referred to as “window of opportunity” or “timing hypothesis” emerged when analyzing several clinical studies and finding that the variety of results was due to the span of ages of the women enrolled in the studies. When analyzing data by grouping for the age of initiation of ET, it was clear that estrogens alone reduced risk of cognitive decline and dementia when administered to women in the early stage of menopause [56]. Postmenopausal women receiving ET in a 2012 Danish study also had significantly reduced risk of mortality and heart failure, without an increased risk of breast cancer or stroke [57]. The WHI ET follow-up showed that women 50-59 of age had statistically significant reduction in coronary heart disease (Hazard Ratio (HR) of 0.59), myocardial infarction (HR 0.54) and overall mortality (0.73) [58]. These are only a few examples of how cognitive and cardiovascular health of menopausal women can be improved if ET is started at the right time (i.e. in early menopause).

Despite the well-established evidence for cardioprotective effects of E2, the large scale clinical trial designed to assess the health benefits of E2 in postmenopausal women – the WHI- was suspended because of an increased risk of stroke and coronary heart disease among the HT participants [59].




Figure 2. The Timing Hypothesis.

Unfortunately, most physicians stopped prescribing ET to their patients after the WHI prematurely interrupted its study in 2002 and published their early results that showed adverse effects and increased mortality. A recent analysis by Dr. Phillip Sarrel published in the American Journal of Public health made the news when the author stated that avoiding ET by women in 2002-2011 caused the premature death of 50000 women [60]. He then emphasized the need to call attention to the beneficial effects of ET for women 50-59 which should prompt doctors to prescribe it to their patients in that age group. A better understanding of the contribution of age on the effects of estrogen on cognitive and cardiovascular health are needed to help guide physicians in providing the best care to their patients, and my project will shed light on the molecular mechanisms for this age-related shift in E2 efficacy.

ESTROGEN RECEPTOR BETA

Estrogen receptors are nuclear steroid receptors widely expressed in both reproductive and non-reproductive tissues and act as transcription factors; therefore they play a central role in many life processes including normal physiology [61]. In 1996 a group led by Jan-Ake Gustavsson successfully cloned the second estrogen receptor, expressed in rat prostate and ovary, named ER β [62]. Initially described as a 485 amino acid long protein, further studies revealed an upstream AUG start site, making rER β 530 amino acids long, with a calculated molecular weight (MW) of 59.152 KDa [63]. Subsequent studies identified several splice variants, the first and better characterized being ER β 2, first described in 1998 and widely expressed [64]. In the brain ER β is expressed in several hypothalamic nuclei, hippocampus, cerebellum, olfactory bulb, amygdala, cortex, and spinal cord [65]. Peripherally it is expressed in the cardiovascular system (myocytes, endothelial cells, fibrocytes), ovary, prostate, skeletal system (osteoblasts, osteoclasts and osteocytes), gastrointestinal tract, pancreas, adipose tissue and liver [61].




Figure. 3. Domains of ER β .

The structure of ER β is that of a classical nuclear steroid receptor organized in domains each with a particular structure and specific functions (Fig.3). The N-terminal A and B domains are collectively defined as AF-1 (Activation Function-1, or N-terminal transactivation domain), a highly variable domain amongst the steroid receptor family. Many residues in the AF-1 domain are phosphorylated by various kinases; the AF-1 domain is also fundamental for binding to coregulatory proteins [63, 66]. The AF-1 domain is intrinsically disordered (ID) in solution, therefore its structure is difficult to analyze, but progress is being made in understanding its binding to coregulatory proteins that leads to modulation of its transcriptional regulation [67]. This domain is also thought to mediate the known ligand independent regulation of transcription by ER β [68-70]. The C domain is the DNA-Binding Domain (DBD) involved in DNA recognition and binding. In the case of estrogen receptors the DBD recognizes Estrogen Responsive Elements (EREs), in the promoter of target genes. The DBD is partially conserved with ER α , which can also recognize and bind to ERE sequences. The ERE is an inverted palindromic DNA consensus sequence (5' GGTCAnnnTGACC 3') that the DBD has a high affinity for [71]. The D domain of ER β is the hinge domain, a flexible domain allowing for the conformational changes of the receptor. The E domain is the Ligand Binding Domain (LBD) or AF-2, which is responsible for ligand binding of both agonists and antagonists, dimerization, interactions with coregulatory proteins and conformational changes caused by ligand binding [72]. The precise function of the small C-terminal F domain of ER β has not been identified yet, although it has been proposed to influence ligand binding and coactivator binding [73].

According to the classic model of steroid receptor functioning, ER β is normally present in the cytoplasm bound to chaperone proteins. Following ligand binding it dimerizes and translocates to the nucleus, where it binds to the ERE and, together with coregulatory proteins, activates gene transcription (Fig. 4). Steroid receptors are therefore highly dynamic, being shuttled to and from the nucleus and in proximity of the cell membrane or cellular organelles.




Figure 4. Classical model of ER β 's action.

The ER α and ER β isoforms can often be co-expressed in a tissue and form homo or heterodimers. It was shown in 1997 that ER α and β can form heterodimers on the DNA at ERE sequences and are capable of binding to coregulatory proteins and activating transcription [74]. However the heterodimer is potentially functionally distinct from the homodimer, giving ERs a wider possibility of gene regulation. The characteristics of the heterodimer were analyzed *in vitro* in a 2004 paper by Li et al. showing that heterodimer binding to E2 and activation of ERE were similar to the α - α homodimer [75]. However ER β is known to act as a dominant inhibitor of ER α , and it was initially thought that the function of ER β was to modulate ER α transcriptional activity [76]. This adds to the complexity of estrogens' signaling and determines the variety of effects estrogens can have *in vivo* in different tissues that display different expression of ER α and ER β .

PHOSPHORYLATION OF ER β

Post translational modifications (PTMs) such as phosphorylation, ubiquitination, acetylation and sumoylation have been identified for several steroid receptors, including ERs. These modifications can potentially alter each step of ERs function from ligand binding, dimerization, protein:protein interactions, DNA binding and ultimately ER function [66, 77]. For example, the first evidence that ERs can have ligand independent function was attributed to phosphorylation of the receptor after epidermal growth factor (EGF) treatment [78]. Furthermore EGF treatment to ovariectomized rats mimicked the effects of estrogens, as it leads to proliferation in the uterus [79]. We now know that extracellular factors such as EGF can initiate the

signaling cascade leading to kinase activation and ER phosphorylation and activation.

Although consensus sites for several kinases are present in ER β , only a few have been described and confirmed as actual phosphorylation sites [66]. The experimentally confirmed phosphorylation sites for the human ER β are S87 and S105 [80, 81]. Studies of the phosphorylation of the mouse isoform of ER β have also shown phosphorylation at the homologous sites (S106 and S124) and other sites mostly in the N-terminal domain, which are less characterized [68].

Phosphorylation of ER β has important functional implications. In a 2012 paper by Lam et al. phosphorylation of S105 inhibited breast cancer cell invasion and migration *in vitro* [81]. Phosphorylated S105 is also highly prevalent in human samples of breast cancer tissue, where ER β is known to be antiproliferative [81, 82]. Phosphorylation of hER β at S87 and S105 (mouse S106 S124) was shown to recruit the coregulatory protein steroid receptor coactivator-1 (SRC-1) *in vitro* and increase transcriptional activation at ERE in a ligand independent way [68]. The phosphorylation of ER β has been shown to be mediated by two MAPKs, p38 and ERK, in *in vitro* kinase assays on the human and mouse ER β form [68, 81].



Figure 5. ER β phosphorylation sites.

Overall phosphorylation of steroid receptors is pivotal for their functioning, and the little that is understood about the actual phosphorylation of ER β and how these influence their functioning is mostly from *in vitro* studies using breast cancer cell models. More needs to be done to characterize the molecular functional consequences of phosphorylation and describe ER β phosphorylation in non-cancerous tissues, such as the brain and heart where ER β is known to have important functions. Furthermore, to my knowledge there are no reports describing the effects of age and E2 on ER β phosphorylation.

COREGULATORY PROTEINS

The recruitment of coregulatory proteins to steroid receptors is a fundamental step in their functioning. Coregulatory proteins can activate (coactivators) or repress (corepressors) gene transcription and are required for proper signaling of all steroid receptors. After binding to the steroid receptor they serve as scaffolds for the larger complex of proteins that form the pre-initiation complex on the promoter of the responsive gene. Most of the classic coregulatory proteins for ER belong to the SRC (Steroid Receptor Coregulator) family and were first identified in 1994 in the lab of Myles Brown as estrogen-receptor associated proteins necessary for ER functions [83]. Since then the functions of SRC proteins have been elucidated and their importance in cell physiology has grown. Coregulatory proteins were recently

defined by Dr. Bert O'Malley as "masters of system biology" to emphasize their importance [84]. They are not mere bridges between ER β and the transcriptional machinery but integrate signaling cascades by binding to multiple transcription factors, and their dysregulation can lead to serious consequences such as development of cancer [85]. The coactivators SRC1 and SRC3 interact and positively regulate transcriptional regulation mediated by several steroid receptors, including ER β . Corepressors, such as silencing mediator for retinoid and thyroid hormone receptor (SMRT) and nuclear receptor corepressor (NCoR), repress or silence steroid receptor mediated regulation of transcriptional activity [85].

To date, more than 350 steroid receptor coregulators have been reported. However the ER interactome comprises an impressive amount of proteins, not only classic coregulators but binding partners involved with cell functions ranging from apoptosis to cell structural proteins to metabolic proteins to RNA splicing. For example, over 743 proteins associate with ER β in the ventral hippocampus and several of these interactions are age and estrogen dependent [86]. Other studies have shown that the interactome of ERs in breast cancers is made of hundreds of proteins [87, 88]. These newly discovered interacting partners are an insight to the potentials of ER signaling.

MITOGEN ACTIVATED PROTEIN KINASES

Age and E2 modulate cell signaling pathways critical for regulating basic cellular processes. Mitogen Activated Protein Kinases (MAPKs) are a family of Serine-Threonine protein kinases that link extracellular signals to intracellular responses [89, 90]. They are highly complex and interesting as they regulate cell activities including proliferation, differentiation, apoptosis

and cell survival. Nearly every physiological and pathological event studied involves MAPKs, which indicates not only their essentiality but also their complexity. The MAPK family includes p38 MAPK, extracellular signal-regulated kinase (ERK) and c-Jun NH₂-terminal kinase (JNK), however as only p38 and ERK kinases have been shown to target ER β for phosphorylation we will focus our attention to those [68, 81].

MAPK family members were first discovered and sequenced in the 1980s and 90s after their activation was observed following mitogens stimulation, hence their name [90]. These kinases are regulated themselves by phosphorylation at their Threonine-x-Tyrosine phosphorylation site motif. MAPKs activation is the last of a three step activation cascade from MAP3K to MAP2K to MAPK. Once phosphorylated (i.e. activated) they in turn phosphorylate substrate proteins at Serine or Threonine residues in specific recognition sequences [91]. While MAPKs phosphorylate S/T residues included in a conserved motif, this sequence is variable, allowing for substrate discrimination and a wider pool of targets [92]. The strongest requirement for phosphorylation common to p38 and ERK kinases is the presence of a Proline directly at the C- Terminus of the phosphorylation site. Another characteristic feature of MAPKs is the presence of docking sites in their substrates; the best characterized being D-sites and F-sites [93]. These mediate the interaction between sequence motifs in the target protein far from the phosphorylation sites and region of the kinase separate from the active site. Because of their heterogeneous preference for D- and F- sites, ERK and p38 interact with different target proteins, therefore having differential downstream effects. Furthermore docking sites assure specificity and selectivity of kinase

substrate interactions, reducing the number of potential substrates [93].

Interestingly 30% of human proteins have at least one MAPK phosphorylation site; however fewer have the docking sites necessary for the kinases to interact strongly and phosphorylate them.

The knowledge of the activators, substrates and functions of MAPKs are ever expanding, however when they were first discovered they were deemed stress-activated protein kinases (SAPKs) because of their responsiveness to toxins, physical stresses and inflammatory cytokines [92, 94]. Generally it can be said that ERK1/2 are preferentially activated in response to growth factors and extracellular stimuli while p38 is more responsive to stresses such as osmotic shock, ionizing radiation and cytokines [95]. MAPKs can be present in several cell compartments, such as the nucleus, cytoplasm, mitochondria and close to the cell membrane. Among their targets are other kinases and transcription factors allowing them to integrate signals and activate a variety of responses. While it can be difficult to dissect the effects of MAPKs activation from a specific stimulus, it is known that they can regulate mitosis, apoptosis, survival, differentiation, gene expression and more. MAPKs involvement in human disease has been proven and several kinases have been considered as targets of pharmaceutical modulation [96]. Of note, cancers such as melanoma and breast and ovarian tumors can be brought about by mutations in proteins either participating in the MAPKs pathways or direct targets [97]. Inflammatory related diseases such a COPD (chronic obstructive pulmonary disease), rheumatoid arthritis and systemic lupus also show MAPKs dysregulation.

Interestingly, neurodegenerative disease such as Alzheimer's, Parkinson's and ALS (Amyotrophic lateral sclerosis) are characterized by p38 and ERK alterations. For example, it has been shown that in a model of Alzheimer's disease the oxidative stress induced by Amyloid beta accumulation leads to p38 activation and tau protein phosphorylation [98]. The cardiovascular system is also regulated by MAPKs and these have been considered as potential targets in cases of infarction, hypertrophy and heart failure [99, 100]. Pharmaceutical companies are investigating small molecule inhibitors or activators of MAPKs and several clinical studies are underway to investigate whether these could prevent, treat or decrease the symptoms of the diseases they are involved in.

In mammals, four splice variants of p38 kinase exist: p38 α , p38 β , p38 γ and p38 δ [101]. P38 α was first isolated as a 38 KDa protein that was rapidly phosphorylated in a characteristic Thr-Gly-Tyr (TGY) motif following application of pro inflammatory stimuli [102-105]. The four splice variant proteins have a 60% identity in sequence, but can be differentially activated by upstream kinases and have different target proteins. P38 α and p38 β are widely expressed, while p38 γ and p38 δ are only expressed in certain cell types. Because of the sequence similarity of the different p38 isoforms, it is difficult to separately investigate the functioning of each. The perfect homology in the TGY motif results in the impossibility to raise antibodies for only one of the active isoforms. Therefore phosphop38 antibodies will bind to all p38 isoforms. Further complicating the study of each isoform, small molecule inhibitors also do not discriminate between isoforms.

The extracellular signal regulated kinase subfamily is comprised of the evolutionarily conserved ERK1 and ERK2 which have 83% amino acid identity [95]. Similarly to the p38 isoforms, ERK1 and ERK2 have perfect homology in their activating phosphorylation motif, resulting in antibodies that bind to both active forms.

To our interest p38 has been found to be regulated by aging and estrogen treatment in different cell and animal settings. In a 2011 study, Li et al. hypothesized that p38, a key regulator of pro-inflammatory cytokine biosynthesis, would be activated by the low grade inflammation that is associated with the aging process [106]. By measuring cytokines and markers of inflammation in the lungs of young (2mo) and old (20mo) C57BL/6J mice they showed a significant increase of inflammatory markers with age [106]. They also measured p38 activation in the lung and whole brain homogenate, showing the activation of p38 was doubled in the older mice, confirming their initial hypothesis [106]. Furthermore, Yousin Suh measured age specific changes in MAPKs expression and activity in the brain and liver of 2 mo and 26 mo female Fisher344 rats [107]. Again, p38 expression and activity was increased by 2.5 fold in the aged brain while no change in expression was measured in the liver [107]. In a separate study, the adrenal gland of 24-27 mo rats had increased levels of active p38 compared to younger animals [108]. In contrast to that, age dependent inhibition of p38 activity was detected in the cortex of 24 mo rats compared to 6 and 12 mo animals [109]. MAPKs can be activated by extracellular stimuli and E2 has been shown to activate p38 and ERK in a rapid, non-genomic way in isolated cardiomyocytes as well as in neuronal cells [110] [111].

P38 has also been shown to have a role in reproductive physiology, and it is more highly activated in the granulosa cells of older patients [112]. The same study also examined cellular localization of p38 and found that activated p38 was more highly present in the nucleus of younger cells, while it mostly resided in the cytoplasm in granulosa cells of older patients [113]. The authors concluded that oxidative stress might be the cause for the different subcellular localization of p38, since reactive oxidative species (ROS) are known to induce translocation of p38 to the cytoplasm and are abundant in aged cells. In the cardiovascular system, activated p38 has been implicated in a wide spectrum of pathologies, such as hypertrophy, infarction, and systolic and diastolic heart failure [100, 114-116]. The signaling pathways that p38 regulates could be linked to its role in heart pathology including apoptosis, pro-inflammatory gene regulation, myofilament modulation and remodeling of matrix proteins [115]. Several clinical trials involving p38 inhibitors have not yielded the positive results expected in regards to cardiovascular diseases, however there have been more encouraging results in rheumatoid arthritis treatment [100].

Overall it is well understood that MAPKs signaling plays an integral role in aging, and their aberrant regulation might be involved in age-related disorders. The molecular mechanisms by which p38 activation can be detrimental are not well understood, but we can infer from the literature that the age-dependent activation of MAPKs might be at least part of the cause for cardiovascular disease in post-menopausal women.




Figure 6. ERK and p38 signaling.

EXPERIMENTAL DESIGN

ANIMAL PARADIGM

The Timing Hypothesis originated from clinical data and clearly points to time after onset of menopause as an important factor in HT success. Therefore, we designed an animal paradigm that allows us to discern the relative contributions of age, length of E2 deprivation and subsequent E2 replacement over molecular and physiological responses (Fig. 7). The literature on animal models of menopause indicates that rats are the most appropriate non-primate animal model for menopause [117]. However, unlike primates, aging rats do not undergo a rapid decline in E2 levels so bilateral ovariectomy (OVX) is necessary to abolish endogenous E2, thereby ensuring an equivalent hormonal milieu. Our preliminary data show that a subcutaneous injection of 2.5 µg/kg E2 in aged (18mo) Fisher344 rats achieves circulating E2 levels of 50.56± 8.78 pg/ml, which is within the physiological range for post-menopausal patients receiving HT (17-75pg/ml; [118, 119]). Importantly, this paradigm will allow us to draw conclusions on the effects of duration of E2 deprivation prior to HT. Fisher344 rats (18mo; N = 10/group, total = 90) will be administered E2 or safflower oil (vehicle) once/day x 3 days at 1 week, 4 weeks, 8 weeks or 12 weeks after OVX, reflecting women who begin HT closer to menopause versus those who waited for longer periods of time.




Figure 7. Animal Paradigm.

HYPOTHESIS AND QUESTIONS

Estrogens are neuroprotective and cardioprotective for women, however when administered long after menopause, they fail to improve their health. This age related switch in estrogens' effects after prolonged deprivation has not been explained. It is possible that the estrogen receptors (ER) that mediate the protective effects are modified following menopause and no longer function as in the past. Phosphorylation is the most common protein modification and it can fundamentally alter a protein's activity. The ER β isoform of the receptor is highly expressed in the brain and heart and has been shown to mediate protective neurological and cardiovascular effects. Little is known about ER β phosphorylation, but the Mitogen Activated Protein Kinases can *in vitro* phosphorylate ER β in its N-terminal domain. This part of the protein mediates its interactions with coregulatory proteins that dictate its function as a transcription factor. The MAPKs responsible for this modification respond to cellular and extracellular stresses, which can increase with aging and disease and have been shown to be sensitive to estrogens. Therefore, I hypothesized that ***Mitogen Activated Protein Kinases are sensitive to age and prolonged estrogen deprivation leading to a differential phosphorylation of ER β which results in altered transcriptional regulation.***

These are the questions I sought to answer:

1. Is phosphorylated ER β present *in vivo* in the brain and heart? (see Chapter III)
2. Does site specific phosphorylation of ER β alter its activity as a transcription factor? (see Chapter III)

3. Does phosphorylation of ER β alter its ability to bind to DNA? (see Chapter III)
4. Is the activity of the MAPKs ERK and p38 sensitive to prolonged estrogen deprivation and estrogen treatment? (see Chapter IV)
5. Is the expression of ERK and p38 dependent on prolonged estrogen deprivation and estrogen treatment? (see Chapter IV)
6. Which ER mediates the effects of estrogen on MAPKs activation? (see Chapter IV)
7. Can phosphorylated ER β be detected and quantified *in vivo*? (see Chapter V)

CHAPTER III
PHOSPHORYLATION ALTERS ESTROGEN RECEPTOR B-MEDIATED
TRANSCRIPTION IN NEURONS

Journal of Neuroendocrinology, 2015 Dec;27(12):861-71

INTRODUCTION

Nuclear steroid receptors are master regulators of a broad range of physiological processes through their actions as ligand-activated transcription factors. Estrogen receptors (ER α and ER β) are members of this receptor superfamily and their cognate endogenous ligand is 17 β -estradiol (E2), which is the major circulating form of estrogen in premenopausal women. ER α and ER β are widely expressed in a variety of tissues, although ER α is particularly abundant in breast, uterus and ovary, due to its primary role in mediating the reproductive-related effects of estrogens. By contrast, ER β is highly expressed in many non-reproductive tissues such as nervous, cardiovascular, skeletal, gastric, and adipose tissues, and has been implicated in mediating estrogens effects on anxiety, mood, and memory, as well as numerous other physiological processes [15, 16, 40, 65, 120, 121]. Our basic understanding of ER α structure, function, and signaling pathways has significantly advanced in recent years, however similar aspects of ER β function, especially in non-reproductive tissue/cell types, remain unclear.

The overall goal of these studies was to define the functional consequences of post-translational modifications to ER β , namely site-specific phosphorylation, on its ability to transcriptionally activate gene promoter activity in neuronal cells.

Post-translational modifications (PTMs) such as phosphorylation, ubiquitination, acetylation, and sumoylation have been identified for several nuclear steroid receptors, including ERs [122-126]. These modifications have the potential to alter all aspects of ER function including ligand binding, dimerization, protein:protein interactions, DNA binding and, ultimately, alter ER-mediated transcription. Although several kinase consensus sites have been predicted for ER β , only a few have been experimentally confirmed [66]. Specifically, the serine residues S87 and S105 located in the N-terminal domain of ER β are highly conserved among the mouse, rat, and human, suggesting that ER β phosphorylation at these sites could be a common regulatory mechanism across species [81]. The N-terminal domain of ER β exhibits greater than 80% homology across species and the specific amino acid residues flanking S87 and S105 are highly conserved [127]. By contrast, the N-terminal domain of ER β has relatively low homology with ER α , which could contribute to the divergent actions of the two receptors. These S87 and S105 sites are targets of MAPKs (Mitogen Activated Protein Kinases) and the specific MAPKs, P38 and ERK, have been shown to phosphorylate human and mouse ER β *in vitro* [81, 128]. Functionally, phosphorylation of these sites increased recruitment of the coregulatory protein SRC-1 (steroid receptor coactivator-1), while coincidentally increasing transcriptional activation at an estrogen response element (ERE) [128].

Phosphorylation of ER β has been studied primarily *in vitro* using breast tumor cell models. The only reports of detection of phosphorylation of ER β *in vivo* come from immunohistochemistry analysis of human breast cancer tissue using a human-specific antibody generated against the phosphorylated S105 ER β [81]. However, ER β is highly expressed in non reproductive tissue such as the brain and heart, and its phosphorylation would have important functional consequences on those systems. Therefore, my first goal in these studies was to determine whether ER β is phosphorylated *in vivo* in the brain as well as in the heart of female rats. Using PhosTagTM Acrylamide I was able to detect several phosphorylated species of ER β in the dorsal hippocampus and left ventricle of the heart of aged (18 mo. Old) female rats. This, to my knowledge, is the first report of phosphorylated ER β detection outside of the breast in any species.

Previous work by my laboratory showed that p38 kinase inhibition altered ER β -dependent activation of ERE and AP-1 (activator protein-1) promoter activity in neurons [70]. However p38 kinase inhibitors are broad-spectrum inhibitors and can affect multiple signaling pathways in the cell, thereby making it unclear whether ER β was a direct target of phosphorylation by p38 in those studies. Furthermore ER β phosphorylation states were not determined. Therefore, in these studies I created phospho-mutants of ER β to directly assess the consequences of ER β phosphorylation on its transcriptional activity in neuronal cells. I hypothesized that phosphorylation of ER β at specific sites, S87 and S105, would alter ER β mediated gene regulation in neuronal cells, both directly at a canonical ERE site and also indirectly through protein:protein interactions at an AP-1 site. I also tested

whether phosphorylation of S87 and S105 altered the binding affinity of ER β to a canonical ERE sequence. Collectively, my results demonstrate that phosphorylation of S87 and S105 altered both estrogen-independent and estrogen-dependent ER β mediated transcriptional regulation at ERE and AP-1 sites in neuronal cells, but did not alter the DNA binding affinity to ERE sequences. Taken together, these data suggest that altered kinase activity in the brain, as occurs during aging, has the potential to alter the downstream expression of ER β gene targets resulting in fundamental changes in brain function.

RESULTS

PHOSPHORYLATED SPECIES OF ER β ARE PRESENT IN THE DORSAL HIPPOCAMPUS OF AGED FEMALE RATS.

The detection of phosphorylated ER β in the brain and heart *in vivo* has not been previously demonstrated, likely due to its relatively low expression and the lack of commercially available phospho-specific antibodies targeting rER β . A powerful tool that has recently emerged is PhosTagTM, a phosphate-binding tag that slows the migration of phosphorylated protein during the electrophoretic run on polyacrylamide gels [129]. Use of PhosTagTM acrylamide results in the detection of several bands when analyzed by Western Blot using specific antibodies for the protein of interest, and each band represents the target protein with a different degree of phosphorylation. For instance, higher bands indicate that the target protein contains several phosphate groups, which result in a slower migration through the gel and is visualized as a higher band shift. To verify the specificity of the phosphorylated bands detected, protein samples can be treated with alkaline

phosphatase (AP), which will dephosphorylate the protein and result in the absence of detectable phosphorylated bands on the Western blot. The only band detected will be a lower band representing the non-phosphorylated protein of interest.


I tested whether phosphorylated ER β is present in the dorsal hippocampus and left ventricle of aged female rats to provide rationale for assessing the functional consequences of phosphorylated ER β in neuronal cells. Estradiol (E2) is known to have direct effects on the dorsal hippocampus, a brain region involved in cognition and memory formation and a region where ER β is more highly expressed than ER α [130, 131]. Because E2 therapy is often prescribed to ameliorate the negative cognitive and cardiovascular issues that accompany menopause, I used a model of surgically-induced menopause followed by acute E2 treatment to test whether 1) phosphorylated ER β is present in the brain and heart, and 2) E2 treatment alters ER β phosphorylation levels in the brain. Aged Fisher 344 rats (18 mo. Old) underwent ovariectomy (OVX) followed by acute E2 or vehicle administration for 3 days (see Methods).

Fig. 8 shows a representative PhosTagTM SDS-PAGE blot probed for ER β with the ER β specific antibody. Phosphorylated ER β was detected in the dorsal hippocampus of both the vehicle and E2-treated animals (Fig. 8A, arrow). Following AP treatment this same band disappeared, indicating that the band that shifted was specific for phosphorylated ER β . AP treatment did not diminish the intensity of the lower band, which represents unphosphorylated ER β , however the higher band is very dark indicating that a

large amount of ER β in the aged female dorsal hippocampus was phosphorylated to some degree (Fig. 8A).

In Fig.8B phosphorylated ER β is detected in the left ventricle of aged female rats. Conversely to the dorsal hippocampus, more than one band is absent following AP treatment. This could have different explanation. First, it is possible that an increasing amount of phosphates are bound to ER β . This would result in the several bands detected: the higher being ER β with several phosphates attached which would cause a slower electrophoretic run in the PhosTagTM gel. The other possible explanation is that splice variants of ER β are present in the heart, and that those are also phosphorylated. ER β 2 is a widely expressed splice variant which has as an additional 18 amino acid insertion far from the antibody binding site, therefore it could recognize and bind it as well [132-134]. ER β 2 protein has not been detected in the heart but its mRNA has been detected in the cardiovascular system [134]. I hypothesize that the lower band in the AP treated samples is ER β 1, the band above ER β 2 and bands that are only present in absence of AP treatment a combination of phosphorylated species of ER β 1 and ER β 2.

A)



B)




Figure 8. Expression of phosphorylated ER β in the dorsal hippocampus of aged female rats. Protein isolated from the dorsal hippocampus (50 μ g) was resolved using Phos-TagTM SDS-PAGE electrophoresis and probed for ER β with the ER β specific antibody (SC-150). Phos-TagTM binds phosphate groups and increased protein phosphorylation retards gel migration. Alkaline phosphatase (AP) treatment removes phosphate groups allowing the protein to migrate further through gel. Aliquots of the same dorsal hippocampus protein sample were treated with different amounts of AP. Arrow indicates phosphorylated ER β . Samples not treated with AP show upper band, indicating presence of phosphorylated ER β that is abrogated in samples treated with either 30 or 60 units of AP.

ER β PHOSPHORYLATION ALTERS LIGAND DEPENDENT AND LIGAND INDEPENDENT ACTIVATION OF ERE-MEDIATED TRANSCRIPTION IN NEURONAL CELLS.

To study the functional effects of phosphorylation of ER β in neurons, I used site-directed mutagenesis to mutate S87 and S105 into alanine (A), a residue that cannot be phosphorylated, or glutamic acid E, a residue that resembles a phosphorylated serine because of its similar negative charge and molecular bulk [135]. The expression vector constructs used in the transient transfection analysis are listed in Table 1. ER β acts as a transcription factor *in cis* by directly binding to DNA at consensus ERE sequences and activating downstream gene transcription. To test whether phosphorylation of ER β alters its ability to regulate ERE-mediated transcription, I transiently co-transfected wild type (WT)-ER β or one of the mutants listed in Table 1 with the reporter construct ERE-tk-luc in a hippocampal-derived cell line (HT-22).

Vector name	Characteristics	
ERβ	Wild type ER β	Wild type
87E	Phospho mimetic at S87	Phospho mutants
87A	Phospho null at S87	
105E	Phospho mimetic at S105	
105A	Phospho null at S105	Double mutants
AA	Phospho null at S87 and S105	
EE	Phospho mimetic at S87 and S105	
AE	Phospho null at S87, phospho mimetic at S105	
EA	Phospho mimetic at S87, phospho null at S105	

Table 1. List of ER β expression vectors.

First I analyzed the ERE-mediated promoter activity for each of the phospho-mutants with a single site mutated. A two-factor ANOVA analysis revealed that there was a statistically significant interaction between plasmid and treatment, demonstrating that the effect of E2 on ERE-mediated promoter activity depends on whether ER β is phosphorylated at serine 87 and/or 105 (Fig. 9A; $F(5,74) = 9.790$, $p < 0.001$). Consistent with previous studies, WT-ER β tended to increase ERE-dependent transcription in the absence of ligand (an approximate 2 fold increase) and E2 treatment increased it to a much greater statistically significant extent (an approximate 5.5 fold increase, Fig. 2A) [136]. I then analyzed the ERE-mediated promoter activity for each of the phospho-mutant receptors. Mutation of ER β at serine 87 had differential effects on ERE-mediated promoter activity depending on whether it was phospho-null or phospho-mimetic. First, mutation to alanine (87A, phospho-null) increased ERE-mediated promoter activity to a similar extent as WT-ER β in the absence of E2, whereas E2 treatment significantly increased ERE-mediated activity to a greater extent. These results suggest that phosphorylation at this site hinders the E2-dependent activation of the receptor. Interestingly, the opposite effect was observed for mutations at the serine 105 site. In that case, the phospho-null mutation (105A) was not different from WT-ER β . By stark contrast, the phospho-mimetic (105E) increased not only the E2-independent (by approximately 4 fold), but also the E2-dependent, activation of ER β .




Figure 9. Effects of ER β phosphorylation on ER β -mediated promoter activity at an ERE site. Hippocampal-derived (HT-22) cell lines were transiently co-transfected with an ERE-tk-Luciferase reporter construct and the wild type ER β or (A) single phospho-mutant ER β expression vector (S87A, S87E, S105A, S105E) or (B) double phospho-mutant ER β expression vector (S87A+S105A; S87E+S105E; S87A+S105E, S87E+S105A) (B). Cells were treated with 100 nM E2 or vehicle (0.01% ethanol) for 15 hours. Data are expressed as the mean percent change compared to empty vector control \pm SEM. Different letters denote statistically significant differences as calculated with two-way ANOVA and Tukey post-hoc analysis ($p < 0.05$).

The previous experiments demonstrated the effects of a single amino acid manipulation on ERE- and AP-1-mediated transcription. In those experiments, the phosphorylation status of the opposing site was unknown and entirely dependent on the endogenous kinase activity in the cell. Therefore, in this next series of experiments I tested whether simultaneous phosphorylation (i.e. S87E + S105E (EE)) or complete absence of phosphorylation (i.e. S87A and S105A (AA)) at both serine residues could further alter ER β regulation. In addition, I also tested the effects on ERE-mediated transcription when one site was phosphorylated, but not the other (i.e. S87A + S105E (AE); S87E + S105A (EA)). Each of the double mutant vectors (see table 1) were transiently co-transfected with an ERE-tk-luc reporter construct in HT-22 cells as described before.

A two-factor ANOVA analysis revealed a statistically significant interaction between plasmid and treatment, once again indicating that E2 regulation of promoter activity depends on the phosphorylation status of both ER β S87 and S105 residues (Fig. 9, $F(5,78) = 5.271$, $p < 0.001$). Figure 9B demonstrates the effects of the double mutants on ERE-mediated promoter activity. All of the double mutants increased ERE-mediated transcription in the presence of E2, although the increase was greater when the two serine residues had an opposite phosphorylation status (AE, EA, Fig. 9B). Moreover, the AE mutation increased ERE-mediated activity by more than 2 fold in the absence of ligand.

Overall, these data demonstrate that phosphorylation of ER β at both S87 and S105 has important functional consequences on its ability to transcriptionally activate ERE-mediated promoters in neurons.

ER β PHOSPHORYLATION ALTERS LIGAND DEPENDENT AND LIGAND INDEPENDENT ACTIVATION OF AP-1 DEPENDENT TRANSCRIPTION IN NEURONAL CELLS.

Estrogen receptor β can also act as a transcription factor *in trans* by tethering other transcription factors, thereby regulating a larger subset of genes whose promoters might lack a consensus ERE. For instance, ER β -mediated regulation at AP-1 sites requires ER β interaction with transcription factors of the Fos and Jun families. Similar to my observed results on ERE-mediated promoter activity, a two-factor ANOVA analysis revealed that there was a statistically significant interaction between plasmid and treatment (Fig. 10A; $F(5, 59) = 6.046, p < 0.001$). First, WT-ER β had a constitutive (ligand independent) inhibition of AP-1-mediated promoter activity (an approximate 50% decrease, Fig. 10A), which showed a trend towards a decrease following E2 treatment. These results are consistent with my previous reports of ER β repression of AP-1-mediated promoter activity in neuronal cells [70, 136]. Surprisingly, however, mutation of S87 or S105 to any form (phospho-null or phospho-mimetic) completely abolished the ligand independent inhibition of AP-1-mediated transcriptional regulation, yet the E2-induced reduction was preserved. These results suggest that S87 and S105 are critical residues mediating the ligand independent actions of ER β at an AP-1 site.




Figure 10. Effects of ERβ phosphorylation on ERβ-mediated promoter activity at an AP-1 site. Hippocampal-derived (HT-22) cell lines were transiently co-transfected with an AP-1-tk-Luciferase reporter construct and the wild type ERβ or (A) single phospho-mutant ERβ expression vector (S87A, S87E, S105A, S105E) or (B) double phospho-mutant ERβ expression vector (S87A+S105A; S87E+S105E; S87A+S105E, S87E+S105A) (B). Cells were treated with 100 nM E2 or vehicle (0.01% ethanol) for 15 hours. Data are expressed as the mean percent change compared to empty vector control ± SEM. Different letters denote statistically significant differences as calculated with two-way ANOVA and Tukey post-hoc analysis ($p < 0.05$).

I next tested whether simultaneous phosphorylation (i.e. S87E + S105E (EE)) or complete absence of phosphorylation (i.e. S87A and S105A (AA)) at both serine residues could further alter ER β regulation at an AP-1 site. The regulation of AP-1-mediated transcription by double ER β mutants is shown in Figure 10B. Surprisingly, the ligand independent inhibition of AP-1 was restored when both S87 and S105 were concurrently mutated, while the single mutation of those same sites abolished the constitutive inhibition of AP-1 regulation by WT-ER β (Fig. 10B). Moreover, E2 significantly inhibited the constitutive repression to a greater extent when S105 was mutated to a phospho-mimetic I regardless of the phosphorylation status of S87 (Fig. 10B; $F(5,70) = 3.741, p < 0.005$).

Overall, I show that ER β regulation of AP-1 dependent transcription is fundamentally altered by single, but not double, mutation of S87 and S105.

PHOSPHORYLATION OF ER β ALTERS TAMOXIFEN EFFECTS ON ERE AND AP-1 TRANSCRIPTION IN NEURONAL CELLS.

Next, I tested whether phosphorylation of ER β alters the effects of tamoxifen (TAM), a known selective ER modulator (SERM). TAM can be both agonistic and antagonistic, depending on cell type, ER subtype, and promoter response element [137-141]. I have previously shown that TAM abrogates the constitutive activation of ERE in HT-22 neuronal cells, and this was also true for some of the phospho-mutants tested (Fig. 11) [136]. Similar to the previously described experimental results, a two-factor ANOVA revealed a significant interaction between the two factors, plasmid type and TAM treatment ($F(5, 71) = 12.978, p < 0.001$). Specifically, TAM treatment completely eliminated the constitutive ligand-independent activation (i.e.

vehicle-treated) of ERE-mediated transcription (Fig. 11A). Further, phosphorylation of S105 (105E) increased constitutive activity to the greatest extent (>400%), and also increased TAM dependent activation of ERE-mediated transcription compared to wild type ER β (Fig. 11A). These results suggest that phosphorylation of S105 would alter transcription of ERE regulated genes following TAM treatment.




Figure 11. Effects of tamoxifen treatment on ERβ or ERβ mutant-mediated promoter activity at an ERE or AP-1 site. Hippocampal-derived (HT-22) cell lines were transiently co-transfected with an (A) ERE-tk-Luciferase or (B) AP-1-tk-Luciferase reporter construct and the wild type ERβ or phospho-mutant ERβ expression vector (S87A, S87E, S105A, S105E). 24 hours following transfection, cells were treated with 100 nM 4-OH-tamoxifen (TAM) or vehicle (0.01% ethanol) for 15 hours. Transfection efficiency was normalized using a second renilla luciferase reporter construct (rLUC) in all experiments. Data are expressed as the mean percent change in fLUC/rLUC compared to empty vector control ± SEM taken from 4 independent experiments with 6 replicates/experiment. Different letters denote statistically significant differences as calculated with two-way ANOVA and Tukey post-hoc analysis ($p < 0.05$).

Our previous studies showed that TAM abolished the observed ligand independent inhibition of AP-1 activity by ER β . The current studies confirm that TAM does abolish the ligand independent inhibition of AP-1 activity for the WT-ER β (Fig. 11B). However, mutation of S87 or S105 alone abolished the ligand independent repression of AP-1-mediated transcription (see Figs. 10, 11B vehicle), and treatment with TAM did not have any additional effects.

Phosphorylation of ER β does not alter binding to an ERE sequence

Phosphorylation of nuclear receptors has previously been shown to alter their binding affinity for consensus response elements, such as an ERE, in the promoter regions of their target genes. Moreover, I have previously shown that WT-ER β can bind to consensus ERE sequences both in the absence and presence of E2, but the effects of phosphorylation of S87 or S105 have never been investigated [70, 136]. Therefore, I tested whether phosphorylation of ER β at S87 or S105 altered its ability to bind to consensus ERE sequences using electromobility shift assays. After autoradiography, I observed that all receptor proteins produced an equally strong shift in the position of the ^{32}P -labeled ERE oligonucleotide, demonstrating that phosphorylation of S87 and S105 did not affect ER β :DNA binding to that consensus sequence (Fig. 12).




Figure 12 Effects of S87 and S105 phospho-mutation on DNA binding to a consensus ERE sequence. Vitellogenin ERE consensus sequence was 32P-end labeled and incubated with in vitro translated wild type or phospho-mutant ERβ protein receptor lysates. Receptor lysates were incubated with 100 nM E2 or vehicle for 16 hr. prior to 30 min. incubation with 32P-labeled ERE oligonucleotide and resolved on a 6% retardation gel. Gels were dried and exposed to a phosphorImager screen for 4 hours prior to imaging. Specific binding was confirmed by incubating with a scramble radiolabeled DNA sequence (lane 2) or by addition of a 1000X unlabeled ERE oligonucleotide prior to addition of radiolabeled vitellogenin ERE (lane 3). (Neg: negative control, no lysate). Relative densitometry of gel bands taken from six independent experiments were quantified using IMAGE J (NIH, Bethesda, MD, USA). The data are reported as the mean ± SEM density of pixels. Two-way ANOVA analysis indicated no statistically significant differences.

Unlabeled excess (500 or 1000x) of the same ^{32}P -ERE oligonucleotide competed effectively for ER β binding and no shift was observed when the receptors were incubated with a ^{32}P -labeled scrambled DNA sequence. Densitometry was used to quantify the band width and there were no statistically significant differences in the average densities of each band between the WT-ER β and the phospho-mutants, indicating that phosphorylation at S87 or S105 does not affect ER β binding affinity to consensus ERE sequences (Fig. 12). These experiments were repeated at minimum of 10 times to account for lane-to-lane variability between gels, and the average band density from all gels combined was calculated to determine if phospho-mutation and/or ligand affected ERE binding. I did not observe any statistically significant differences in average band density between vehicle or E2 treatments for either WT-ER β or the ER β phospho-mutants, which is consistent with my previous reports for WT-ER β [70, 136].

DISCUSSION

The overall objective of these studies was to determine the consequences of ER β phosphorylation on its functional capacity to act as a transcription factor at known promoter enhancer sites in neurons. Further, I hypothesized that phosphorylated ER β would be detectable in the brain of aged animals, due to the potential alterations in kinase activity that can occur with aging [107, 142-145]. My data demonstrated the novel finding that phosphorylated ER β is not only present in the brain of aged females, it is likely the major form of ER β expressed in the dorsal hippocampus and phosphorylation tended to increase following E2 treatment. These data provide strong evidence for the physiological relevance of my functional *in*

vitro data, which together demonstrated that phosphorylation of ER β at specific serine residues altered its ability to activate and/or repress promoter activity in neurons. Collectively, these data suggest that age-related changes in hormonal milieu and cellular kinase activity could impact the expression of ER β -regulated genes, such as those mediating stress, anxiety, and cognitive function.

	ERE (DNA binding)		AP1 (Prot-Prot interaction)	
	constitutive	E2 dependent	constitutive	E2 dependent
wtERβ	↑	↑↑	↓	↓↓
S87A	↑	↑↑↑	-	↓↓
S87E	↑	↑↑	-	↓↓
S105A	↑	↑↑	-	↓↓
S105E	↑↑	↑↑↑	-	↓

Table 2. Schematic summary of reporter assay results. Arrows indicate direction of change in relation to wild type ERβ. In grey are highlighted the instances of differences between each mutant compared to wild type ERβ.

Post-translational modifications of nuclear steroid receptors have been widely investigated and these modifications are known to regulate their signaling abilities [66, 122, 125, 126]. Structurally, ER β is similar to other members of the nuclear steroid receptor superfamily. The N-terminal A and B domains are collectively defined as the AF-1 (Activation Function-1, or N-terminal transactivation) domain, which is a highly variable domain amongst the steroid receptor family and is fundamental for binding coregulatory proteins that assist in transcriptional activation or repression [70, 136]. Phosphorylation of mouse ER β at the N-terminal serine 106 and 124 has previously been shown to mediate ligand independent recruitment of the coregulatory protein SRC-1 (steroid receptor coactivator 1) and alter its subsequent transcriptional activity at an ERE in COS-1 cells [128]. In those studies, overexpression of SRC-1 significantly increased ligand independent activation at an ERE site. This effect was dependent on the MAPK phosphorylation of S106 and S124, as the double phospho-null mutation (S106A/S124A) completely abolished the SRC-1-induced activation at an ERE. However, that study did not evaluate the effects of S106A or S124A in the presence of ligand (E2), or the transcriptional activity at an ERE resulting from a S106/S124 phospho-mimetic (i.e. mutation to glutamic acid). In my studies the single mutation of S87A significantly increased E2-induced transcription at an ERE, but there was no effect in the absence of E2. Moreover, there was no difference in ERE-mediated transcription when S87 and S105 were both phospho-null (87A/105A) compared to WT-ER β . The discrepancies between my results and the previously reported could be due to the overexpression of SRC-1 in those studies. In addition, it is possible that

there is a differential endogenous expression of SRC-1 in neurons or that ERs interact with different set of proteins depending on cell-type, resulting in altered signaling.

A similar study evaluated the effects of phosphorylated human ER β at S105 in cancer cell lines [81]. In that study, phosphorylation of hER β at S105 inhibited breast cancer cell invasion and migration *in vitro*, suggesting that phosphorylation of ER β at S105 mediates the anti-proliferative action of ER β in the breast. [81, 128]. Moreover, phosphorylated S105 ER β has been detected both in benign and invasive breast cancer tissue samples using a human-specific phosphoS105 antibody; however no studies to date have detected the presence of phosphorylated ER β in the brain. My results using neuronal cells showed that the phospho-mimetic S105E significantly increased both ligand independent and ligand dependent transcriptional activation at an ERE compared to WT-ER β , whereas conversely, the opposite phospho-null mutation of S105A had no effect. The LBD of ER β lies between residues 223-457, suggesting that phosphorylation of S87 or S105 is unlikely to alter ligand binding. However, cross talk between the N-terminal and C-terminal domain has been demonstrated, suggesting that altered ligand binding is a possible mechanism for phosphorylation-mediated changes in transcriptional activity [9].

It is well accepted that ER β has lower transactivation ability at an ERE site compared to ER α and my data suggest that this discrepancy could be partly explained by the phosphorylation status of ER β in the N-terminal AF-1 domain [137]. For instance, phosphorylation of the N-terminal domain could alter the ability of ER β to bind consensus ERE sites, thereby allowing

preferential binding of ER α to those same sites. This concept is supported by the observation that various types of post translational modifications have been shown to alter DNA binding in other contexts. For example, acetylation of ER α at two lysine residues in the DBD enhanced its ability to bind to an ERE [146]. By contrast, sumoylation of estrogen-related receptor alpha (ERR α) at two sites in the N-terminal domain did not affect its DNA binding ability, yet still altered its transcriptional activity [147]. My results add to existing evidence supporting the idea that post translational modifications in nuclear receptors at regions distant to the DBD alters their ability to modulate transcription, without affecting DNA binding.

Perhaps the most interesting results from this study were the effects of ER β phosphorylation at an AP-1 site. I have previously shown that ER β exerts strong transcriptional repression at an AP-1 site in neuronal cells in the absence of ligand and the results presented here indicate that this might depend on phosphorylation of the N-terminal domain [70, 136]. The single mutation of either S87 or S105 completely abolished ligand independent inhibition of AP-1 mediated transcription compared to WT-ER β . However, AP-1 mediated transcription was equally repressed with WT-ER β as it was with double mutations of AA, EE, or AE. Notably, only the 87E/105A mutation showed a significant difference from the other mutants, suggesting that S87 phosphorylation status is the critical serine residue for mediating ER β -induced repression at an AP-1 site. The precise dynamics of p38 and ERK phosphorylation of ER β are unknown and the folding of singly phosphorylated ER β could render the other site inaccessible to the kinase. Nevertheless, my data suggests that a single phosphorylation change in either S87 or S105

abrogates the ligand independent inhibition of AP-1, whereas no effect is observed due to concurrent phosphorylation of both sites. This could be explained by altered ER β protein-protein interactions with Jun/Fos proteins or with other co-regulatory proteins recruited to the AP-1 complex, such as p160, based on evidence that phosphorylation alters coregulatory protein recruitment to ER β [128]. The next step will be to determine which of these sites are phosphorylated *in vivo* and the precise molecular environment that facilitates those phosphorylation changes.

Recently, Vivar and colleagues identified 3 classes of ER β target genes and discovered that the majority of genes (453) fell into the Class I category, which were genes regulated by unliganded ER β [148]. Further, the Class I genes showed a high enrichment for AP-1 binding sites, demonstrating that ligand independent repression of AP-1-mediated promoter activity is a common mechanism of ER β signaling. Similarly, Zhao et al. showed that over 60% of ER β interacting regions in MCF-7 breast cancer cells contain an AP-1 site [149]. Together these studies underscore the significance of my findings that ER β ligand independent activity at an AP-1 site is abolished when the N-terminal domain is phosphorylated. Aging in women results in dramatic declines in circulating estrogens raising the possibility that the ligand-independent actions of ER β could play a prominent role in regulating gene transcription in the aging brain.

My studies were limited to the investigation of just one type of post-translational modification (phosphorylation) at specific serine residues. However, there is evidence that other post-translational modifications of ER β could also be present, such as acetylation and sumoylation, and these

modifications can create cross talk between different residues of the receptor. For example, phosphorylation at S305 on ER α inhibits subsequent acetylation at K303 leading to enhanced transcriptional regulation [150]. Moreover, phosphorylation of S94 and S106 on mER β leads to recruitment of ubiquinating enzymes to the AF-1 domain resulting in enhanced degradation of the receptor [151]. Future studies are required to determine the precise mechanisms and consequences resulting from post-translational modifications acting in concert to modulate overall ER β function. My *in vitro* studies were conducted using rat ER β expression vectors in a mouse-derived neuronal cell line. Given the high degree of homology between rat and mouse ER β , I expect that similar results would be obtained using rat neuronal cell lines or primary neurons derived from either species [127]. However, it is important to consider these results in this context as both brain-region and species-specific effects of ER β have been observed [152, 153].

Tamoxifen (TAM) has been described as a partial antagonist due to its cell-type specific effects [139, 141, 154-157]. Relevant to these studies, TAM action in the brain has been shown to block the neuroprotective effects of E2, confirming that the beneficial effects of E2 are mediated by classical estrogen receptors [120]. In addition, TAM can activate numerous second messenger signaling pathways, including MAPK, thereby potentially phosphorylating and altering ER β transcriptional activity [158]. My results demonstrated that TAM worked as an antagonist of both the WT and phosphorylated forms of ER β by preventing the ligand independent increase in ERE-mediated transcription. Consistent with my previous studies, TAM also blocked the ligand independent repression of WT-ER β at an AP-1 site. The ligand binding

domain (LBD) of ER α and ER β is more conserved than other domains and X-Ray crystallography studies have shown that both receptors bind several types of selective estrogen receptor modulators (SERMs), including TAM [159]. The structure of TAM complexed with the ER α or ER β LBD have been resolved and TAM:LBD binding resulted in conformational changes that inhibited subsequent binding of coactivator proteins, pointing to a clear mechanism for TAM antagonism [160, 161].

In summary, my results show that phosphorylation of ER β alters its function in neuronal cells both in a ligand dependent and independent manner, and that ER β is phosphorylated *in vivo* in the hippocampus. My work highlights the importance of further understanding the effects of post-translational modifications on nuclear steroid receptors, as these modifications fundamentally alter their function as transcription factors and could result in clinically important physiological changes.

CHAPTER IV

DIFFERENTIAL EFFECTS OF E2 ON MAPK ACTIVITY IN THE BRAIN AND
HEART OF AGED FEMALE RATSPLOS ONE, February 2016 *under review*

INTRODUCTION

Clinical and basic science studies have shown that estrogens are neuroprotective and cardioprotective. Treatment with estrogens (ET) can reduce the incidence of Alzheimer disease, improve survival following ischemic stroke, improve learning and memory, and reduce anxiety and mood disorders [23-25, 36-38, 155]. Moreover, women are less likely to develop heart disease than men, but this advantage is lost after menopause presumably due to a significant reduction in circulating estrogens [41-43]. Clinical correlates have indicated that the decline of circulating estrogens coincident with menopause leads to an increased risk of coronary heart disease, atherosclerosis, hypertension, stroke, neurodegenerative disease, cognitive decline, and mood disorders. However, the first large scale clinical trial designed to assess the health benefits of ET in postmenopausal women (The Women's Health Initiative (WHI)) was prematurely suspended because of an unexpected increased risk of stroke and coronary heart disease among the participants [59].

Subsequent analysis of the clinical data revealed that the age of the participants significantly affected the outcome. Women who began ET at the time of menopause or within 10 years had significant reductions in heart disease and overall mortality [162]. This observation was coined the “Timing Hypothesis”, and postulated that ET administration is beneficial for early postmenopausal women, but detrimental in late postmenopausal women. Importantly, the underlying molecular mechanisms for these observations remain undetermined.

The actions of estrogens are mediated primarily by estrogen receptor (ER) α and ER β . Both receptors can mediate the neuroprotective and cardioprotective effects of estrogens [16, 25, 45, 46, 51, 155, 163]. Estrogens bind ERs to regulate gene transcription through classical genomic pathways, or by modulating cell signaling pathways such as the MAPKs (mitogen activated protein kinases) ERK (extracellular signal-regulated kinase) and p38 [113, 164-170]. Moreover, aging alone modulates similar cell signaling pathways independent of estrogens [107, 110, 113, 143, 144, 169, 171, 172]. One possibility for these age-related changes is that MAPKs are sensitive to proinflammatory and oxidative stimuli, which are increased with age [173]. These converging data suggest that MAPK signaling could be a molecular mechanism underlying the discrepant effects of ET in postmenopausal women.

MAPK family members are activated by phosphorylation at their threonine-x-tyrosine phosphorylation site motif. MAPKs activation is the last of a three step activation cascade from MAP3K to MAP2K to MAPK. Once phosphorylated (i.e. activated) they in turn phosphorylate substrate proteins at

serine or threonine residues in specific recognition sequences [91]. The knowledge of the activators, substrates and functions of MAPKs are ever expanding, however when they were first discovered they were deemed stress-activated protein kinases (SAPKs) because of their responsiveness to toxins, physical stresses and inflammatory cytokines [92, 94]. Generally, ERK1/2 are preferentially activated in response to growth factors and extracellular stimuli, while p38 are more responsive to stresses such as osmotic shock, ionizing radiation and cytokines [95]. MAPKs can be present in several cell compartments, such as the nucleus, the cytoplasm and close to the cell membrane, thereby allowing them to integrate signals to coordinate a variety of physiological responses including mitosis, apoptosis, survival, cellular differentiation, and gene expression.

Activated MAPKs target a wide pool of proteins due to sequence variation in the conserved phosphorylation motif and in the availability of docking sites on their protein targets. The strongest requirement is the presence of a proline directly at the C- Terminus of the target protein phosphorylation site and this feature is a shared requirement for both p38 and ERK kinases. Another characteristic feature differentiating the downstream effects of MAPKs is the presence of docking sites in their substrates; the best characterized being D-sites and F-sites. ERK and p38 phosphorylate different target proteins, leading to differential downstream effects because of their heterogeneous recognition motif and respective preference for D- and F- sites in the targets [93]. Interestingly, 30% of human proteins have at least one MAPK phosphorylation site, yet few have the required docking sites to facilitate phosphorylation by MAPK family members.

The overall goal of this study was to quantify the total expression and activation of MAPKs (ERK and p38) in the brain and heart of aged female rats subjected to a paradigm designed to model the tenets of the Timing Hypothesis (see Fig.13). I hypothesized that the combination of age and low circulating estrogens alters the expression and activation of p38 and ERK kinases in the brain and heart. To test this hypothesis, I used a rat model of surgically-induced menopause and quantified changes in kinase activity following varying lengths of E2 deprivation. My data revealed age- and E2-dependent effects on kinase activity suggesting a potential mechanism explaining the variable effects of E2 following menopause.




Figure 13. Diagram of the animal paradigm. Female Fisher 344 rats were ovariectomized at day 0 (= 18 months old) and subjected to increasingly longer periods of hormone deprivation (1, 4, 8, and 12 weeks). Following the assigned length of deprivation, animals were treated with either vehicle (safflower oil) or 17 β -estradiol (E2; 2.5 μ g/kg) by subcutaneous injection once daily for 3 consecutive days (n=10/treatment group/deprivation time). Animals were euthanized 24 hours following the last treatment.

RESULTS

LENGTH OF E2 DEPRIVATION AND SUBSEQUENT E2 TREATMENT ALTERS ERK AND P38 KINASE ACTIVITY IN THE BRAIN AND HEART OF AGED FEMALE RATS.

I first tested whether the effects of E2 treatment on ERK and p38 kinase activity would depend on the length of time aged animals were deprived of circulating E2 (i.e. time post-ovx). I measured the ratio of phosphorylated and total ERK and p38 proteins as a measure of kinase activity in 3 distinct brain regions (hypothalamus, dorsal hippocampus, ventral hippocampus) and in the left ventricle of the heart. The hypothalamus regulates homeostasis, thermoregulation and stress response which are often dysregulated in post-menopausal women [174]. The hippocampus is functionally divided in two regions, dorsal and ventral [175] and both regions express ERs. The dorsal hippocampus (DH) mediates cognitive functions, while the ventral hippocampus (VH) mediates processes associated with emotional memory and stress [175]. In addition, I focused on the heart because the likeliness of developing heart disease increases in women post-menopause, and sex differences in cardiovascular disease are well characterized. The left ventricle (LV) is the main pumping chamber of the heart and it is most commonly subjected to diseases that accompany aging, such as hypertrophy. Estrogen receptors are highly expressed in the LV and the cardioprotective effects of E2 treatment are evident in the LV [163, 176, 177].

Brain – Hypothalamus. A two-factor ANOVA analysis revealed a significant interaction between length of E2 deprivation and subsequent E2

treatment (all F-values reported in Table 3), demonstrating that the effects of E2 are dependent on when it is administered following prolonged periods of E2 deprivation. Total ERK protein increased in E2-treated animals at the 12-week post-OVX time point, yet total protein in both groups remained stable at all other time points (Fig. 14A). Conversely, E2 treatment had a dramatic effect on the amount of phosphorylated ERK, which is an indicator for the active form of the protein. E2 treatment significantly decreased the amount of phosphorylated ERK to levels that were barely above detection at the 8- and 12-week post-OVX time points (Fig. 14B). The ratio of phosphorylated ERK to total ERK protein was significantly lower at all time points in E2-treated animals (Fig. 14C), representing a large magnitude shift from baseline compared to vehicle-treated controls (Fig. 14D).




Figure 14. Effects of age and E2 treatment on ERK protein expression and activation in the hypothalamus. Total ERK protein (A), phosphorylated ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

By stark contrast to ERK activity in the hypothalamus, total p38 protein was unchanged over time and with treatment (Fig. 15A); however phosphorylated p38 increased 3-fold at the 12-week time point in both vehicle and E2-treated groups (Fig. 15B). The ratio of phospho:total p38 was not altered by E2 treatment (Fig. 15C), however it is notable that it was increased by 170% in the E2-treated animals at 1-week post-OVX compared to vehicle treated animals.




Figure 15. Effects of age and E2 treatment on p38 protein expression and activation in the hypothalamus. Total p38 protein (A), phosphorylated p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

Brain - Dorsal hippocampus. I then measured ERK and p38 protein and phosphoprotein in the dorsal hippocampus (Figs.16, 17). Similar to the results observed in the hypothalamus, a two-factor ANOVA revealed a significant interaction between length of E2 deprivation (i.e. time post-OVX) and subsequent E2 treatment (Table 3). E2 treatment significantly decreased phosphorylated ERK at the 1-week time point, yet there were no changes in total ERK protein in either group (Fig. 16A, B). The ratio of phospho:total ERK was significantly lower than vehicle-treated animals at 1-week post-OVX (Fig. 16C) and the overall levels of phosphoERK were consistently lower in E2-treated animals across the treatment paradigm (Fig. 16D).




Figure 16. Effects of age and E2 treatment on ERK protein expression and activation in the dorsal hippocampus. Total ERK protein (A), phosphorylated ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

Next, I measured p38 expression and activation in the dorsal hippocampus (Fig. 17). A two-factor ANOVA analysis revealed a significant main effect of time post-OVX, yet no significant interaction suggesting the two variables were not dependent on each other (Table 3). Similar to ERK, E2 treatment significantly inhibited phospho-p38 levels 1 week post-OVX (Fig. 17B), yet the ratio of phospho:total p38 was not significantly different at any time point (Fig. 17C, D).




Figure 17. Effects of age and E2 treatment on p38 protein expression and activation in the dorsal hippocampus. Total p38 protein (A), phosphorylated p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

Brain – Ventral hippocampus. A two-factor ANOVA revealed a significant interaction between length of E2 deprivation and subsequent E2 treatment, similar to the results from the other brain regions (hypothalamus and dorsal hippocampus) (Table 3). Specifically, total ERK protein was significantly decreased at 4 weeks post-OVX in both vehicle and E2-treated animals, and these levels increased back to the levels observed at 1-week post-OVX by the 8 and 12-week time points (Fig. 18A). E2 treatment decreased phosphoERK by 70%, at 1-week post-OVX, but both vehicle and E2-treated animals had significantly lower levels of phosphoERK at the 4 and 8 weeks post-OVX time points (Fig. 18B). Interestingly, the ratio of phospho:total ERK was not different between treatment groups or with longer periods of E2 deprivation (Fig. 18C) and this was likely due to parallel changes that occurred in total available ERK protein. The strong inhibitory action of E2 on ERK activation was only present at the early E2 deprivation time point (1 week post-OVX), while at later time points (4 and 8 weeks post-OVX) E2 treatment increased ERK activation (Fig.18D).




Figure 18. Effects of age and E2 treatment on ERK protein expression and activation in the ventral hippocampus. Total ERK protein (A), phosphorylated ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

There were few observed differences between treatment groups or with length of E2 deprivation in total or phospho-p38 levels (Fig. 19A, B). A two-factor ANOVA revealed no significant interaction between the two factors, but there was a significant main effect of time post-OVX (Table 3). E2 treatment significantly decreased the amount of total p38 protein at 12-weeks post-OVX (Fig. 19A) without any corresponding change in the levels of phospho-p38 (Fig. 19B). The ratio of phospho:total p38 was also significantly decreased after 8 weeks of E2 deprivation, but there was no difference between treatment groups (Fig. 19C). Overall, E2-treated animals had lower phosphorylated levels of p38 compared to vehicle treated animals until the 12-week post-OVX time point. At 12 weeks post-OVX there was a dramatic reversal with E2-treated animals having 88% higher levels of phosphorylated p38 compared to vehicle-treated animals (Fig. 19D).




Figure 19. Effects of age and E2 treatment on p38 protein expression and activation in the ventral hippocampus. Total p38 protein (A), phosphorylated p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

Heart – Left ventricle. Total ERK protein levels increased 12 weeks post OVX in the E2-treated animals compared to the vehicle-treated animals (Fig. 20A). In contrast to results obtained in the brain, length of E2 deprivation (i.e. age alone) had the most striking effect on ERK activation, while E2 treatment had a modest, yet statistically significant effect. Moreover, a two-factor ANOVA revealed a significant interaction between length of E2 deprivation and subsequent E2 treatment (Table 3), demonstrating that the effects of E2 replacement on ERK activity are altered following prolonged periods of time post-OVX in both the heart and brain. Specifically, phospho-ERK significantly decreased in both vehicle- and E2-treated groups at 4 and 8 weeks, yet there was a dramatic rebound in phospho-ERK in the E2-treated animals after 12 weeks of E2 deprivation (Fig. 20B). However, after comparing the ratio of active to total ERK it is clear that the length of E2 deprivation was the most important factor regulating ERK activity (Fig. 20C), as both treatment groups showed significant declines (80% decrease) at 4 and 8 weeks that returned to baseline by 12 weeks (Fig. 20D). Notably, E2 treatment led to even further declines in active ERK (to nearly undetectable levels) at 4 and 8 weeks post-OVX (Fig. 20D).




Figure 20. Effects of age and E2 treatment on ERK protein expression and activation in the left ventricle. Total ERK protein (A), phosphorylated ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

Total p38 protein levels were not significantly altered in the heart in my paradigm (Fig. 21A). However, a two-factor ANOVA analysis revealed a significant interaction between the two factors, E2 treatment and length of time post-OVX, on the levels of phospho-p38 in the heart. Consistent with the observations for ERK, p38 activation decreased with longer periods of deprivation post-OVX regardless of treatment in the heart (Fig. 21C). There was a strong main effect of time post-OVX, as the phospho:total p38 declined by more than 40% by the 4-week time point (Fig. 21C). These lower levels were stable up to 12 weeks post-OVX, in E2 and vehicle treated animals, in contrast with ERK whose activation levels were restored 12 weeks post-OVX. Although E2-treatment significantly decreased phospho-p38 at 8 weeks post-OVX, this effect did not have a major impact on the amount of active p38 (Fig. 21B, C, D).




Figure 21. Effects of age and E2 treatment on p38 protein expression and activation in the left ventricle. Total p38 protein (A), phosphorylated p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from vehicle following E2 treatment (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX (A-C). An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

LENGTH OF E2 DEPRIVATION AND SUBSEQUENT E2 TREATMENT ALTERS ERK AND P38 MRNA EXPRESSION

To determine if steady-state mRNA expression paralleled the observed changes in protein levels, I measured ERK (Fig. 22) and p38 (Fig. 23) mRNA in each brain region and in the left ventricle of animals subjected to my E2-deprivation paradigm. A two-factor ANOVA revealed statistically significant differences between treatment groups in the hypothalamus (Fig. 22A) and the heart (Fig. 22D), but not in either region of the hippocampus (Fig. 22B, C). Treatment with E2 increased ERK mRNA 1-week post-OVX, (Fig. 22A, dashed line), however ERK mRNA levels increased progressively over time and this age-related increase was prevented by E2 treatment (Fig. 22A). Similarly, prolonged periods of E2 deprivation increased ERK mRNA in the heart and this was significantly decreased following E2-treatment at the 12 weeks post-OVX time point (Fig. 22D).




Figure 22. Effects of age and E2 treatment on ERK mRNA expression. ERK mRNA was measured using RT-qPCR in the hypothalamus (A), dorsal hippocampus (B), ventral hippocampus (C), and left ventricle (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX. An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

Expression of p38 mRNA levels were also statistically different between groups subjected to my E2-deprivation paradigm (Fig. 23). In the hypothalamus (Fig. 23A) p38 expression was significantly increased 4 and 8 weeks post-OVX, with no significant effect of E2 treatment. In the dorsal hippocampus a significant main effect of time, but not treatment was detected and pairwise comparisons did not reveal statistically significant changes between groups (Fig. 23B). A significant interaction of treatment and time post-OVX was detected in the ventral hippocampus (Table 3), where E2 treatment significantly reduced p38 mRNA at the 12-week time point (Fig. 23C). There were no differences between groups in p38 mRNA expression in the heart (Fig. 23D).




Figure 23. Effects of age and E2 treatment on p38 mRNA expression. P38 mRNA was measured using RT-qPCR in the hypothalamus (A), dorsal hippocampus (B), ventral hippocampus (C), and left ventricle (D). Data are expressed as mean fold change \pm SEM compared to vehicle-treated animals at one week post-OVX. An * indicates statistically significant difference from 1-week time point; # indicates significant difference within the same time point.

ERK AND P38 ACTIVATION ARE DIFFERENTIALLY REGULATED BY ER α AND ER β

The differential effects of ER β and ER α on MAPKs signaling have been previously reported in different experimental systems, and I detected both forms of the receptor in my samples [178, 179]. Therefore, in order to determine the contribution of each estrogen receptor, I treated a set of 18 mo Fisher 344 with the ER β or ER α specific agonists DPN and PPT, 1 week post OVX to compare with the vehicle or E2 treated animals at the same time point. In Fig. 24, the ratio of phosphorylated ERK and total ERK was measured via Western blot in samples from the hypothalamus (A), dorsal hippocampus (B), ventral hippocampus (C) and heart (D). In the hypothalamus, E2 treatment 1 week post OVX determined a significant inhibition of ERK activation, which was replicated in animals treated with the ER α agonist PPT. The ER β specific agonist DPN did not significantly alter the activation of ERK, indicating that in the hypothalamus ER α is the main mediator of the inhibition of ERK activity. In the dorsal hippocampus E2 was found to inhibit ERK activation 1 week post OVX, and in panel B of Fig. 24 ER β and ER α specific agonists show a similar effect. All treatments significantly inhibited ERK activation compared to vehicle treated animals. No significant changes in ERK activation were detected in the ventral hippocampus when animals were treated with E2, DPN or PPT. Although a trend to a decrease was observed in the E2 treated animals. In the heart, E2 treatment does not alter ERK activation 1 week post OVX and neither do DPN PPT (see Fig. 24 D).




Figure 24. ERK activation is differentially regulated by ER isoform specific agonists. Ratio of phospho:totalERK in the hypothalamus (A), dorsal hippocampus (B), ventral hippocampus (C), heart (D) of 18 months old rats treated with V, E2, DPN (ER β agonist) or PPT (ER α agonist) 1 week post OVX. Total and phosphorylated ERK were measured via Western blot; ratio of the two is represented here. Fold change compared to vehicle-treated animals. An * indicates statistically significant difference between groups using one-way ANOVA p < 0.05 (n = 4/6 animals per group)

The ratio of phosphorylated p38 and total p38 was calculated following Western blot analysis in the hypothalamus (A), dorsal hippocampus (B), ventral hippocampus (C) and heart (D) as shown in Fig. 25. In the hypothalamus PPT treatment alone significantly increased p38 activation 5 fold, while in E2 and DPN treated animals levels were similar to the vehicle group. The fact that E2 alone does not increase p38 activation while PPT does might be reflective of E2 binding to heterodimers. The other regions did not show any statistically significant effect of DPN or PPT on p38 activation.




Figure 25. p38 activation is differentially regulated by ER isoform specific agonists. Ratio of phospho:total-p38 in the hypothalamus (A), dorsal hippocampus (B), ventral hippocampus (C), heart (D) of 18 months old rats treated with V, E2, DPN (ER β agonist) or PPT (ER α agonist) 1 week post OVX. Total and phosphorylated p38 were measured via Western blot; ratio of the two is represented here. Fold change compared to vehicle-treated animals. An * indicates statistically significant difference between groups using one-way ANOVA $p < 0.05$ ($n = 4/6$ animals per group)

Consistent with what has been observed throughout this study, ERK activity was more sensitive to my animal paradigm than p38. Interestingly, I found that the ER isoforms differentially alter kinase activity. Overall I found that in the hypothalamus ER α plays a more important role on MAPKs regulation. I have shown that E2 treatment leads to inhibition of ERK likely by activating ER α . Furthermore, stimulation of ER α but not ER β activates p38. However, in the dorsal hippocampus both receptor specific agonists had the same effects as E2.

Table 3. F-values and p values from two factor ANOVA analysis.			
Hypothalamus			
	Interaction Treatment X Time	Main Effect of Treatment	Main effect of Time
ERK mRNA	No	No	Yes F(3, 37)= 3.320, p<0.001
ERK protein	No	No	No
phosphoERK	No	Yes F (1,39)= 18.226 p<0.001	No
Ratio	No	Yes F (1,44)= 15.670 p<0.001	No
p38 mRNA	No	No	Yes F(3, 35)= 6.474, p= 0.001
p38 protein	No	No	Yes F(3,36)= 11.346, p<0.001
phospho p38	No	No	No
Ratio	Yes F (3,33)= 3.558, p=0.025	No	Yes F (3,36)= 3.821, p=0.018
Dorsal Hippocampus			
	Interaction Treatment X Time	Main Effect of Treatment	Main effect of Time
ERK mRNA	No	No	Yes F (3,32)= 4.105, p=0.014
ERK protein	No	No	No
phosphoERK	Yes F (3,39)= 4.012, p=0.014	No	No
Ratio	No	No	No
p38 mRNA	No	No	Yes F(3, 33)= 4.214, p= 0.013
p38 protein	No	No	No
phospho p38	No	No	Yes F(3, 37)= 6.586, p= 0.001
Ratio	No	No	Yes F(3, 37)= 5.653, p= 0.003
Ventral Hippocampus			
	Interaction Treatment X Time	Main Effect of Treatment	Main effect of Time
ERK mRNA	No	No	No
ERK protein	Yes F (3, 31)= 2.915, p= 0.050	Yes F (1, 31)= 6.294 , p= 0.018	Yes F (3, 31)= 12.942, p<0.001
phosphoERK	Yes F (3, 34)= 3.205, p= 0.035	Yes F (1, 34)= 4.806 , p= 0.035	Yes F (3, 34)= 3.955, p= 0.016
Ratio	Yes F (3, 35)= 3.177, p= 0.037	No	No
p38 mRNA	Yes F (3, 37)= 6.621, p= 0.003	Yes F (1, 37)= 7.783, p= 0.008	Yes F (3, 37)= 6.493, p= 0.001
p38 protein	Yes F (3, 33)= 4.624, p= 0.008	No	Yes F (3, 33)= 3.583 p= 0.024
phospho p38	No	No	Yes F (3, 34)= 4.822, p= 0.007
Ratio	Yes F (3, 32)= 3.727, p= 0.021	No	Yes F (3, 32)= 6.713, p= 0.001
Heart			
	Interaction Treatment X Time	Main Effect of Treatment	Main effect of Time
ERK mRNA	Yes F (3, 35)= 3.385, p= 0.029	No	Yes F (3, 35)= 8.502, p<0.001
ERK protein	Yes F (3, 58)= 4.430, p= 0.007	No	Yes F (3, 58)= 6.806, p=0.001
phosphoERK	Yes F (3, 59)= 5.227, p= 0.003	Yes F (1, 59)= 4.893, p= 0.031	Yes F (3, 59)= 20.089, p<0.001
Ratio	No	No	Yes F (3, 60)= 14.834, p<0.001
p38 mRNA	No	No	Yes F(3, 35)= 2.385, p<0.001
p38 protein	No	No	No
phospho p38	Yes F (3, 44)= 3.502, p= 0.023	No	No
Ratio	No	No	Yes F(3, 51)= 5.299, p= 0.003

DISCUSSION

MAPKs are central components of second messenger signaling pathways and are ubiquitously expressed in all cell types, therefore the functional implications for these findings are widespread. Here, I report the novel findings that E2 treatment differentially affects ERK and p38 activation, as well as total protein and mRNA expression, in the brain and the heart dependent on age and length of time following E2 deprivation (i.e. OVX/menopause). Importantly, length of E2 deprivation was a critical factor in every parameter analyzed. For example, ERK and p38 were significantly less active 4 or more weeks following OVX regardless of treatment in the heart, possibly reflecting an age-related change. Age has been shown to both increase and decrease MAPKs activation, depending on tissue analyzed, sex, age and species of the animal model, as well as experimental design [106, 107, 180, 181]. For instance, Li et al. hypothesized that p38, a key regulator of pro-inflammatory cytokine biosynthesis, would be activated by the low grade inflammation that is associated with the aging process. They observed increased levels of inflammatory markers accompanied by doubling in p38 activation in the lung and whole brain homogenate of old (20 mo.) compared to young (2 mo.) C57BL/6J mice [106]. Similarly, p38 expression and activity was increased by 2.5 fold in the brain of 26 mo. compared to 2 mo. Fisher 344 rats [107]. These findings align with my results in the hypothalamus where p38 had a 2.5 fold increase 12 weeks post-OVX, regardless of treatment. However, these results were brain region specific, as I did not observe age-related changes for phospho-p38 in other brain regions analyzed.

Perhaps most intriguing was the observation that E2-induced changes

in activated ERK and p38 were prolonged, given that the last dose of E2 was administered 24 hours before euthanasia. The prevailing view is that the non-genomic actions of E2 occur within minutes and the effects on MAPK phosphorylation are transitory. Indeed, this has been observed repeatedly *in vitro*, however accumulating evidence suggests that the *in vivo* regulation of MAPKs is more complex [110, 114, 169, 182-187]. One possibility is that E2, acting through classical genomic pathways, altered cellular components required for maintaining balance between active and inactive MAPKs. For example, crosstalk between phosphorylation and ubiquitination pathways can exert long-term changes in cellular processes through multiple feedback loops that ultimately impact apoptosis and cell proliferation [188]. Moreover, I along with others have shown that E2 can regulate microRNAs in the brain and the heart, and some of these miRNAs could target components of MAPK signaling pathways [179, 189-192] providing a putative mechanism for sustained activation of these kinases. These results were further corroborated in a 2013 study which showed E2 could regulate long-term activation of MAPKs by altering expression of microRNAs that silence upstream inhibitors of ERK activation [192]. The findings herein combined with other published studies suggest that E2 can exert prolonged changes in MAPKs activation that cannot be explained by the acute non-genomic actions of E2 alone.

The significant interactions observed between the two factors of time and E2 treatment for ERK, but not p38, in nearly every brain region and in the heart could have important functional ramifications for understanding the physiological consequences of ET in postmenopausal women. Specifically, the timing of E2 treatment would not be expected to impact p38 signaling in

these tissues, despite the fact p38 activity was independently altered by E2 and age. Conversely, activated ERK was mainly decreased following E2 treatment and the timing of E2 treatment dictated the magnitude of decline. Activation of ERK induces downstream signaling pathways that mediate both neuro- and cardioprotection. For instance, the formation of dendritic spines was increased by E2 treatment through ERK-mediated mTOR (mammalian target of rapamycin) and this E2-induced synaptic plasticity is a key mechanism underlying memory consolidation and storage [193]. Similarly, activated ERK mediates cardioprotective pathways in the heart and phospho-ERK is increased by E2 in young adult rat cardiomyocytes [110, 170, 194-196]. The E2-induced decrease of activated ERK in the brain and heart following longer periods post-OVX reveal a putative mechanism for memory decline and reduced cardioprotection following ET in late postmenopausal women.

Increased estrogen receptor-mediated gene transcription is the most likely explanation for my observed increases in total ERK and p38 protein levels. Indeed, I found that the mRNA levels of both kinases were significantly altered by E2 treatment and length of deprivation in the brain and heart. Sequence analysis of the ERK and p38 gene promoters revealed an abundance of binding sites for several transcription factors such as NF- κ B and GATA families as well as multiple estrogen response elements (ERE) [197]. The canonical actions of ERs are through direct ERE binding, however ERs can also regulate transcription by tethering to other transcription factors, such as members of the Jun and Fos families acting at AP-1 sites (activator protein-1) [198]. Notably, there are 28 and 34 identified AP-1 sites within 2000

bp upstream of the p38 and ERK translation start sites, respectively. These data demonstrate that there are multiple mechanisms for E2 to regulate ERK and p38 transcription directly at the level of the gene promoter.

In the last decade, sophisticated genomic and proteomic tools have allowed for the quantitative molecular analysis of complex biological samples. These experiments revealed low correlations between mRNA and protein levels in many samples [199]. Similarly, changes in ERK and p38 protein levels did not tightly correlate with their altered mRNA levels in my paradigm. This suggests that age and/or E2 treatment can regulate compensatory factors that affect protein translation or stability. For example I observed a 3 to 5- fold increase of ERK mRNA following prolonged E2 deprivation in the hypothalamus, yet total ERK protein was unchanged. This could be partly explained by the semi-quantitative nature of the techniques (i.e. Western blot). Alternatively, this observation could be due to increased mRNA turnover or translational inhibition. Several mechanisms of post transcriptional regulation of mRNA have been described and microRNAs are interesting example of regulatory molecules that can repress target mRNA translation [200]. My recent work demonstrated that microRNA expression is differentially regulated by prolonged E2 deprivation and subsequent E2 treatment using this same animal treatment paradigm in aged rats [179, 190]. In line with the current findings, several of those E2-regulated microRNAs have the potential to inhibit p38 and ERK mRNA translation, resulting in decreased protein levels. I also identified a subset of microRNAs that are differentially regulated by E2 in young (3 mo.) vs. old (18 mo.) rats using a microRNA microarray platform [190]. Bioinformatics pathway analyses revealed that the MAPK pathway was

predicted as the most represented cellular pathway targeted by the microRNAs I identified as E2 regulated [190]. Regulation of microRNAs is just one possible explanation for the discrepancies seen between mRNA and protein levels in complex biological samples.

I also sought to determine which ERs might be mediating the effects on MAPKs activity in my animal paradigm. My group has recently demonstrated that in animals subject to my experimental paradigm both ER α and ER β are expressed in the brain regions in analysis and in the heart throughout all time points and treatments [178, 201]. Furthermore I have analyzed the expression of ER β 2, a splice variant of ER β , which is a constitutively active form of the receptor, and found that it was regulated by estrogen deprivation following OVX as well as E2 [178]. Here I have determined that 1 week post OVX E2 significantly inhibits ERK activation, likely via ER α whose activation also significantly inhibited ERK activation. Similarly p38 activation was also activated by E2 treatment and ER α agonist PPT in the hypothalamus, while ER β agonist DPN had no effect. In the dorsal hippocampus however both ER α and ER β agonists inhibited ERK activation as did E2. Isoform specific effects of ERs are known, however this is the first *in vivo* analysis of MAPKs regulation in the brain and heart.

Despite the understanding of the importance of the time of initiation of ET in women for neuroprotection and cardioprotection gained from clinical studies, clear mechanistic insight is still lacking. I designed my study to model a main tenet of the timing hypothesis, as based on clinical observations [59, 202, 203]. One limitation is that rodent reproductive senescence is not comparable to the menopausal transition in women [204, 205]. However, the

surgically-induced menopause model used in rodents is the most accurate method to determine the length of time following total ovarian hormone depletion, and surgically-induced menopause is clinically relevant for some women. I have also demonstrated previously that 18 months of age is a physiologically relevant comparison to human in this strain of rat (Fisher 344), although Sprague Dawley rats demonstrate much earlier reproductive senescence [178]. The concepts referred as “window of opportunity” or “timing hypothesis” emerged from clinical studies that found that age of ET initiation determined the successful outcome of the study. Indeed estrogens reduced risk of cognitive decline and dementia when administered to women in early stage of menopause [56]. Postmenopausal women receiving ET in a 2012 Danish study also had significantly reduced risk of mortality and heart failure, without an increased risk of breast cancer or stroke [57]. The WHI ET follow-up showed that women 50-59 of age had statistically significant reduction in coronary heart disease (Hazard Ratio HR of 0.59), myocardial infarction (HR 0.54) and overall mortality (0.73) [58]. These are only a few examples of how cognitive and cardiovascular health of menopausal women can be improved if ET is started at the right time (i.e. in early menopause). My data highlights MAPKs as a possible focus of further analysis, as these kinases are critical regulators of cell signaling pathways.

CHAPTER V
QUANTITATIVE MASS SPECTROMETRY FOR *IN VIVO* ANALYSIS OF
PHOSPHORYLATED ER β
INTRODUCTION

Phosphorylation of ER β significantly alters its function as a transcription factor as shown in Chapter III [206]. ER β can be phosphorylated in its N-terminal domain at two sites, S87 and S105. This was shown first by mutating mouse ER β in the homologous Serines into Alanines and performing *in vitro* phosphorylation with radioactive p32ATP [128]. The Mutant ER β failed to incorporate p32ATP, indicating that S87 and S105 are phosphorylated at those sites. Separate groups have found that ER β can be phosphorylated *in vitro* by the MAPKs ERK1, ERK2, p38 but not Src or PKA [81, 128]. Later, phosphorylation of purified human ER β at S105 was verified following *in vitro* phosphorylation using mass spectrometry (MS) [81]. I have extended these findings by demonstrating detection of phosphorylated ER β , *in vivo*, in the brain and heart of aged rats using PhosTagTM immunoblotting (Chapter III). While this technique allowed for detection of phosphorylated forms of ER β , the site or sites at which the phosphates are attached cannot be determined with this technique. Importantly, site specific modifications altered ER β function, as shown in Chapter III, therefore the identification of distinct phosphorylated residues *in vivo* is a critical next step.

Phosphorylation of ER β *in vivo* was also detected using antibodies directed against the phosphoS105ER β peptide through immunohistochemical staining of human breast tissue samples [81]. While this is a positive indication of the presence of phosphoS105ER β in human breast, antibody based assays are often misleading when studying ER β . Indeed a thorough analysis of nine antibodies available revealed that while some do recognize ER β used in certain techniques, most lack specificity or only work correctly in a specific application [207]. The lack of reliable tools for investigating ER β *in vivo* is a recurring theme in the field and most experts attribute this to the partially unfolded state of the N-terminal domain of ER β [208-211]. The dynamic structural behavior of ER β gives it the ability to rapidly interact with different coregulatory proteins, localize to different intracellular organelles and transition on and off the DNA quickly, overall determining its functional heterogeneity that makes it an important target of investigation.

The activity of the MAPKs p38 and ERK, the kinases that have been shown to phosphorylate ER β , is sensitive to aging and estrogen treatment. Indeed the findings described in Chapter IV demonstrated that the length of estrogen deprivation prior to estrogen treatment altered MAPKs activation in the brain and heart of aged rats. Therefore, it is likely that levels of phosphorylated ER β are different in the tissues of rats that underwent the estrogen deprivation paradigm. ER β mediates important neuroprotective and cardioprotective effects of estrogens and its phosphorylation has functional consequences as shown in Chapter III. Therefore it is pivotal to detect and compare levels of phosphorylated ER β in brain and hearts.

The experimental approach I chose was to use Multiple Reaction Monitoring (MRM) (also referred to as Selected Reaction Monitoring or SRM); a mass spectrometry based method that allows for detection and quantification of low abundance peptides in complex samples. Briefly, during an MRM experiment a predefined peptide of interest is detected using a Triple Quadrupole mass spectrometer. By mixing a known amount of a peptide identical to the target peptide but incorporating heavy isotopes, the amount of unknown peptide can be readily quantified. Further, using heavy labelled peptides that are phosphorylated at the site of interest allows for the quantification of the phosphorylated form of the peptide.

There are multiple steps that must be performed in order to create the MRM including 1) analysis of the protein sequence of interest to obtain a theoretical digestion profile, 2) empirical testing of digestion profile with a purified protein, 3) optimization of instrumentation parameters using synthetically developed peptide fragments, 4) development of the MRM using increased sample complexity, 5) isolation of *in vivo* experimental protein samples and mass spectrometry analysis. Fig. 26 is a schematic representation of the experiments described in this Chapter and details the preliminary steps necessary for MRM method design.




Figure 26. Outline of the experiments described in this Chapter.

MRM experiments are usually performed using Liquid Chromatography (LC) coupled to Triple Quadrupole mass spectrometers. These types of instruments are designed to follow the work flow diagram depicted in Fig. 27. First, samples are injected in the chromatography column; typically a C18 column which is made of an 18 carbon chain bound on a silica substrate. Peptides adsorb to the column and by gradually increasing the amount of polar solvent in the mobile phase they elute separately according to their biochemical characteristics. This step reduces the complexity of the sample prior to injection in the mass spectrometer. Second, ionization of the peptides is achieved by applying a high voltage to the peptides to create an aerosol with the electrospray ionization (ESI) probe. ESI does not fragment the peptides and can create multiply charged ions ($z > 1$). Third, the ionized peptides move into the first quadrupole (Q1) and are analyzed by mass. Fourth, in the second quadrupole (Q2) the ions are collided with high pressure gas (argon) inducing dissociation of the ions in a process called collision induced dissociation (CID). Each ionized peptide that entered Q1 (precursor ion) will then be fragmented in Q2 into product ions that will be detected by Q3, which also analyzes each fragment by mass. The m/z values of precursor ions and product ions that will be generated after CID can be predicted based on the sequence for the peptide of interest. The collision induces breakage of the amide bond and loss of amino acids at the N- and C- termini of the peptide, and the resulting ions are called y- and b- ions. In MRM, the precursor ion of interest is selected in Q1 and the product ions of interest are monitored in Q3. MRM is an example of a targeted mass spectrometry approach, as this method only detects a selected peptide of interest. The

AQUA (absolute quantification) method was developed to directly quantify peptides using MRM [212]. Briefly, synthetic peptides of the same sequence as the peptide of interest are synthesized using a heavy labelled amino acid, shifting their mass by a known amount. These heavy peptides are used as internal standards and spiked with the unknown sample containing the light peptide of interest. The heavy peptides have the same retention time, ionization and fragmentation characteristics, but have a shift in mass which allows for comparison of intensity of endogenous (light) and heavy peptides.




Figure 27. Schematic representation of the Triple Quadrupole mass spectrometer used for MRM.

RESULTS

1) Analyze ER β Sequence

The first step in determining whether MRM is a feasible approach to detect and quantify ER β phosphorylation is to analyze its sequence. Indeed it is necessary to enzymatically cleave proteins in smaller peptides that can be detected by Triple Quadrupole mass spectrometers for MRM experiments. Protein digestion is a common procedure in proteomics and several proteolytic enzymes are available commercially. Each protease has very specific cleavage sites; empirical digestion of the protein of interest can be tested using bioinformatics tools such as ExPASy Peptide Cutter [213]. The size of the peptide of interest is also an important consideration for MRM experiments. A maximum length of 25 amino acids is indicated for a few main reasons. First, mass of larger peptides is over the limit of detection of Triple Quadrupole mass spectrometers. Furthermore long peptides are typically unsuitable for synthesis. Finally amino acid side chains can potentially be modified during ionization and dissociation in the mass spectrometer, and longer sequences have more potential for modifications which would complicate the analysis. Another crucial factor when deciding which enzyme to use for digestion is the uniqueness of the sequence of the peptide of interest. Therefore, to avoid false positive results, it is essential to scan the NCBI database to confirm that the target peptide fragment is unique to the protein of interest. Finally, protease efficiency is high, however some cleavage sites are more optimal than others, and bioinformaticians have developed algorithms to predict the likeliness of a “missed cleavage” to occur [214].

I performed the steps described above using the rER β sequence available from Uniprot (accession number Q62986). The goal was to identify a protease that would digest ER β containing the desired S87 and S105 sites in peptide fragments that met the optimal criteria for MRM. I first used ExPASy peptide cutter to obtain ER β digestion profiles for eight common proteases. Figure 28 shows the results of the theoretical digestion. The right column lists the cleavage sites for each proteases and I focused on proteases that cleaved the protein at residues close to S87 and S105. I calculated the size of the peptides containing S87 and S105 and evaluated my options. Arg-C, Asp-N, low-specificity-Chymotrypsin and Proteinase K were not feasible enzymes as they would not yield ER β peptides I could use for MRM. Cleavage of ER β with Lys-C or Lys-N yielded S87 and S105 containing fragments of 100 or 21 amino acid length each. On average MRM experiments use peptide of 10 amino acids, however it is possible to use peptides up to 25 amino acid long. Chymotrypsin digestion of ER β generated a 43 amino acid peptide with S87 and an 8 amino acid peptide with S105. Trypsin digestion resulted in a 33 amino acid peptide encompassing S87 and a 7 amino acid peptide encompassing S105. This preliminary analysis revealed that none of the available enzymes would digest ER β so that S87 would be contained in a fragment of the length required for MRM. This depends on the protein in the region surrounding S87, and makes the study of phosphorylation of S87 with the MRM approach unfeasible. However, as shown in chapter III, phosphorylation of S87 leads to more modest changes in ER β function compared to S105, suggesting that phosphorylation at that site is less important *in vivo*. Furthermore, phosphorylated S105-ER β was detected in

breast tissue samples and inhibited breast cancer cells invasiveness and migration [81]. Together, these data suggested that S105 was the best target for additional proteomics analysis and both high-specificity Chymotrypsin and Trypsin are feasible proteolytic enzymes (Fig. 28). Trypsin is the universal enzyme used in proteomics because it is readily available, economical, and several validated protocols are published. Furthermore, large data sets using mass spectrometry are available online allowing for preliminary identification about whether a protein of interest has been detected using similar techniques and most of the data collected used Trypsin digestion. Analysis of the available data sets showed that human and rat sequences are identical in the N-terminal region containing S105. Also, *in vitro* phosphorylated human ER β at S105 was detected following tryptic digestion [81]. In that study, an Orbitrap mass spectrometer was used to detect the phosphorylated form of ER β , but this was a positive indication that empirical tryptic digestion of ER β would result in that peptide fragment (i.e. it is not a missed cleavage), and that the peptide can be ionized and detected using a mass spectrometer.

These enzymes cleave the sequence:

Name of enzyme	No. of cleavages	Positions of cleavage sites
Arg-C proteinase	30	40 71 111 121 126 144 175 197 198 205 207 220 221 223 227 230 231 233 247 254 284 329 346 364 386 388 424 454 466 501
Asp-N endopeptidase	16	37 65 144 153 181 193 302 325 348 358 362 364 377 434 488 516
Chymotrypsin-high specificity (C-term to [FYW], not before P)	30	16 31 36 43 48 49 56 99 107 148 155 159 161 164 172 173 183 210 226 289 312 319 345 356 377 387 397 439 488 503
Chymotrypsin-low specificity (C-term to [FYWML], not before P)	125	1 10 16 25 27 31 36 41 43 46 48 49 54 56 65 72 79 85 86 89 92 97 98 99 107 113 115 124 128 147 148 155 159 160 161 164 172 173 180 183 206 210 214 226 240 242 251 258 259 260 263 268 270 272 273 281 289 294 295 296 298 301 306 309 312 319 322 324 325 330 331 336 339 340 343 344 345 354 356 360 362 374 377 379 380 381 387 390 392 394 397 398 403 405 406 413 426 428 429 430 437 439 455 458 459 460 461 462 464 467 473 475 476 477 479 488 490 491 492 494 495 498 500 503 527
LysC	31	4 104 125 127 143 170 174 195 199 208 216 244 246 256 300 304 314 315 353 368 391 395 401 425 443 471 480 482 504 519 521
LysN	31	3 103 124 126 142 169 173 194 198 207 215 243 245 255 299 303 313 314 352 367 390 394 400 424 442 470 479 481 503 518 520
Proteinase K	231	2 3 10 14 16 22 23 25 26 30 31 32 36 37 42 43 45 47 48 49 52 53 56 58 62 65 70 72 74 78 79 80 82 86 89 90 91 97 98 99 100 101 107 109 110 113 114 116 117 119 122 123 124 128 134 137 138 142 146 148 151 155 156 159 161 163 164 167 171 172 173 177 183 184 187 188 192 193 203 206 210 211 212 215 222 226 228 229 237 239 242 245 252 255 257 258 259 260 262 263 266 268 269 270 271 272 273 274 275 276 280 281 282 289 290 291 292 298 299 301 302 305 306 307 310 312 313 316 319 320 321 322 324 325 328 330 331 332 335 337 338 339 341 343 345 348 354 355 356 357 360 361 362 366 370 371 373 374 375 376 377 380 381 382 383 384 387 389 390 392 396 397 398 400 402 404 405 406 411 413 414 416 419 420 421 426 427 429 430 432 433 434 436 437 438 439 440 441 442 446 453 455 456 458 459 461 462 465 468 474 476 477 484 485 487 488 490 491 492 493 495 497 499 500 503 507 511 515 516 522 527
Trypsin	60	4 40 71 104 111 121 125 126 127 143 144 170 174 175 195 197 198 199 205 207 208 216 220 221 223 227 230 231 233 244 246 247 254 256 300 304 314 315 329

Fig. 28 Theoretical digestion of rER β with 8 available enzymes. (PeptideCutter, ExPASy.org)

Next, analysis of the predicted ER β tryptic digestion was done using PeptideMass, an ExPasy bioinformatics tool, to analyze the mass of the peptide of interest. Common to most digestion protocols is the treatment of the samples with Dithiothreitol (DTT), a reducing agent, following by Iodacetamide, an alkylating reagent. The first step is necessary to convert cysteine side chains from disulfide bonds into free cysteine side chains. Iodacetamide treatment then alkylates the free sulfhydryl side chains adding a carbamidomethyl group (CAM), ensuring that no free sulfhydryl groups reform. These steps are necessary to allow for Trypsin's full access to all cleavage sites and results in a 57.021 Da increase in mass to all cysteine containing peptides. Fig. 29, shows that following tryptic digestion of ER β S105 results in a 7 amino acid peptide: SPWCEAR. The mass of the peptide is 905.3934 Da following CAM modification on the cysteine, which is ideal for detection using a Triple Quadrupole. This same peptide was detected, with the CAM modification, in the Lam et al. study, indicating successful digestion and modification [81].

While commercially available Trypsin is highly efficient, missed cleavage can occur. As explained earlier, missed cleavage probability can be predicted by algorithms created after analysis of all peptides that contain a missed cleavage in a large data repository (PeptideAtlas). Therefore, I tested the probability of missed cleavage upstream and downstream of the SPWCEAR sequence using the missed cleavage predictor program developed by King's University [214], and the results are shown in Fig. 30. The right column indicates a score from 0-1, with the missed cleavages resulting in a higher score. Both N- and C- terminal cleavage sites have a

relatively low score, a positive indication that digestion with trypsin will successfully yield the target peptide containing S105.

Figure 29. Analysis of ER β tryptic peptides (PeptideMass, ExPASy.org).

[Theoretical pl: 8.86 / Mw (average mass): 59152.20 / Mw (monoisotopic mass): 59113.66]

mass	position	#MC	artif.modification(s)	modifications	peptide sequence
4843.5255	257-300	0			ELLSTLSPEQLVLTLEAE PPNVLVSRSPMPFTEASMMM SLTK
3879.8494	5-40	0	Cys_CAM: 18	3936.8708	NSPSSLSPASYNCSQSILP LEHGPIYIPSSYVDNR
3562.7998	72-104	0	Cys_CAM: 93	3619.8213	LSTSPNLWPTSGHLSPLAT HCQSSLLYAEPOK
3334.5143	41-71	0			HEYSAMTFYSPAVMNYSPG STSNLDGGPVR
2884.1258	145-170	0	Cys_CAM: 149, 152, 166, 169	3112.2117	DAHFCPVCSDYASGYHYGVW SCEGCK
2483.1905	402-424	0			AMILLNSSMYPLASANQAE SSR
2221.0012	176-195	0	Cys_CAM: 185, 191	2335.0441	SIQGHNDYICPATNQCTIDK
2210.2001	483-501	0			NVVPVYDLLLEMLNAHTLR
2096.0199	330-346	0	Cys_CAM: 334	2153.0414	LLESCWMEVLMVGLMWR
2011.0238	369-386	0	Cys_CAM: 369	2068.0453	CVEGILEIFDMLLATTSR
1977.1531	426-443	0			LTHLLNAVTDALVWVIAK
1585.8948	316-329	0			IPGFVELSLLDQVR
1505.7264	128-143	0	Cys_CAM: 133	1562.7479	LSGSSCASPVTSNPAK
1503.6115	505-519	0	Cys_CAM: 512	1560.6330	SSISGSECSSTEDSK
1379.8191	455-466	0			LANLLMLLSHVR
1271.7357	354-364	0			LIFAPDLVLR
1204.5626	234-244	0	Cys_CAM: 241	1261.5841	SSSEQVHCLSK
1183.6292	305-314	0			ELVHMIGWAK
1176.5967	444-454	0			SGISSQQQSVR
1165.6324	112-121	0			SLEHTLPVNR
1045.5169	472-480	0			GMEHLLSMK
1020.4592	522-530	0			ESSQNLQSQ
928.4267	209-216	0	Cys_CAM: 209	985.4481	CYEVGMVK
848.3719	105-111	0	Cys_CAM: 108	905.3934	SPWCEAR
754.3804	396-401	0	Cys_CAM: 399	811.4018	EYLCVK
753.3889	347-353	0			SIDHPGK
708.3536	248-254	0			NGGHAPR
667.2650	200-205	0	Cys_CAM: 201, 204	781.3080	SCQACR
598.3307	467-471	0			HISNK
525.3143	392-395	0			LQHK
520.2799	1-4	0			MEIK
512.2867	171-174	0			AFFK

MC:pred

29 peptides found in 1 proteins.

Results are available to download from [here](#)
 ("--" denotes the N or C terminus of the protein and therefore is not a tryptic site).

Protein	peptide	N-terminal	C-terminal
SPIQ62986 ESR2_RAT ESTROG..	NSPSSLSSPASYNCSQSILPLEHGPIYIPSSYVDNR	0.45	0.60
SPIQ62986 ESR2_RAT ESTROG..	HEYSAMTFYSPAVMNYVPGSTSNLDGGPVR	0.60	0.46
SPIQ62986 ESR2_RAT ESTROG..	LSTSPNVLWPTSGHLSPLATHCQSLLYAEQPK	0.46	0.53
SPIQ62986 ESR2_RAT ESTROG..	SPWCEAR	0.53	0.42
SPIQ62986 ESR2_RAT ESTROG..	SLEHTLPVNR	0.42	0.74
SPIQ62986 ESR2_RAT ESTROG..	LSGSSCASPVTSNAK	1.00	0.66
SPIQ62986 ESR2_RAT ESTROG..	DAHFCPCVDYASGYHYGVWSCEGCK	0.77	0.49
SPIQ62986 ESR2_RAT ESTROG..	SIQGHNDYICPATNQCTIDK	0.66	0.81
SPIQ62986 ESR2_RAT ESTROG..	SCQACR	1.00	0.53
SPIQ62986 ESR2_RAT ESTROG..	CYEVGMVK	0.76	0.43
SPIQ62986 ESR2_RAT ESTROG..	SSSEQVHCLSK	0.81	0.41
SPIQ62986 ESR2_RAT ESTROG..	NGGHAPR	1.00	0.47
SPIQ62986 ESR2_RAT ESTROG..	ELLLSTLSPEQLVLTLLAEPPNVLVSRPMPFTEASMMMSLTK	0.64	0.45
SPIQ62986 ESR2_RAT ESTROG..	ELVHMIGWAK	0.86	0.50
SPIQ62986 ESR2_RAT ESTROG..	IPGFVELSLDDQVR	0.86	0.44
SPIQ62986 ESR2_RAT ESTROG..	LLESCWMEVLMVGLMWR	0.44	0.43
SPIQ62986 ESR2_RAT ESTROG..	SIDHPGK	0.43	0.43
SPIQ62986 ESR2_RAT ESTROG..	LIFAPDLVDR	0.43	1.00
SPIQ62986 ESR2_RAT ESTROG..	CVEGILEIFDMLLATTSR	0.51	0.45
SPIQ62986 ESR2_RAT ESTROG..	EYLCVK	0.60	0.38
SPIQ62986 ESR2_RAT ESTROG..	AMILLNSSMYPLASANQEAESSR	0.38	0.75
SPIQ62986 ESR2_RAT ESTROG..	LTHLLNAVTDALVWVIAK	0.78	0.37
SPIQ62986 ESR2_RAT ESTROG..	SGISSQQQSVR	0.37	0.40
SPIQ62986 ESR2_RAT ESTROG..	LANLMLLSHVR	0.40	0.42
SPIQ62986 ESR2_RAT ESTROG..	HISNK	0.42	0.43
SPIQ62986 ESR2_RAT ESTROG..	GMEHLLSMK	0.43	0.41
SPIQ62986 ESR2_RAT ESTROG..	NVVPVYDLLLEMLNAHTLR	0.62	0.60
SPIQ62986 ESR2_RAT ESTROG..	SSISGECSSSTEDSK	0.46	0.50
SPIQ62986 ESR2_RAT ESTROG..	ESSQNLQSQ	0.88	--

Figure 30. Analysis of Tryptic digestion of ER β for potential missed cleavage sites. (Missed Cleavage Predictor described in [214]).

2) Empirical ER β digestion

2a) Obtain recombinant ER β

While theoretical digestion analyses are the basis of all targeted mass spectrometry experiments, empirical digestion has to be performed before moving on with the synthesis of the heavy labelled peptides that will be used for the MRM. In collaboration with Mengjie Zhang, Research Specialist in Dr. Pieter de Tombe's laboratory, I used an *in vitro* bacterial expression system to obtain large amounts of purified ER β [215]. First, the rER β sequence was cloned into the pEXP5-CT/TOPO expression vector, so that a 6histidine tag is co-translated at the C-terminus of ER β . In this vector, the T7 RNA polymerase necessary for translation of ER β -His is under regulation of a Lac promoter. Therefore, induction with the lactose metabolite IPTG (Isopropyl β -D-1-thiogalactopyranoside) was required to obtain ER β -His6. BL21 DE3 competent cells were transformed with the ER β -His6 plasmid and plated overnight. Five colonies were picked and grown in liquid culture before being split into 2 aliquots. One of the aliquots (B) was induced with IPTG, the other (A), was not induced and served as the control. Following overnight incubation, cells were lysed and protein isolated. Screening of the colonies that most efficiently produced ER β -His6 after induction was done by analyzing Coomassie stained gels containing the protein. As seen in Fig. 31, IPTG induced samples showed a strong band at the expected 50KDa mass (see arrow), which was not present in the in control (IPTG-free = A) samples. Clone 5 had the highest intensity band, indicating a stronger induction of translation

of the ER β -His6 protein, and was chosen for large-scale protein production.




Figure 31. Screening of 5 clones following protein induction with IPTG. Protein visualized with Coomassie staining. Arrows indicate induced protein of the expected molecular weight of ER β -His6.

Next, protein was isolated from 4 liters of bacterial culture and purified using a nickel affinity column that binds to the His6-tag of the ER β -His6 protein. After binding to the column and a wash cycle, elution buffer containing Imidazole (which competes for binding to the nickel column) was added and eluted protein fractions were collected. The example in Fig. 32 shows protein fractions 12-21; as the arrow indicates, fraction 19 contained the target ER β -His6 protein. Western blot analysis of the protein confirmed that both ER β and the His-tag6 were correctly translated (Fig. 33).




Figure 32. Screening of eluted fractions 12-21 after IMAC. Protein visualized with Coomassie staining. Arrow indicates induced protein of the expected molecular weight of ER β -His.




Figure 33. Representative Western blot staining of protein from the eluted fractions containing putative ER β based on Coomassie stain. Membrane was incubated with primary antibody targeting N-terminal ER β confirming expression at expected molecular weight.

2b) Recombinant ER β digestion

Confirmation of the theoretical and previously published results were then accomplished by tryptic digestion of the recombinant ER β -His6 protein (obtained by pooling and concentrating IMAC fractions) [81]. First, ER β -His6 protein was run on a SDS-PAGE gel and the gel band containing ER β was excised, as well as a portion of the gel void of protein to be used as a negative control (see arrows in Fig. 34). Second, a standard in gel Trypsin digestion protocol was used to clean, reduce and alkylate the protein prior to an overnight incubation with Trypsin (see Methods for details). Digested peptides were then washed out from the gel and concentrated to a smaller volume using a SpeedVac centrifuge. The peptides were then mixed with a matrix (α -Cyano-4-hydroxycinnamic acid, CHCA) which facilitates ionization in MALDI-TOF mass spectrometry (Matrix Assisted Laser Desorption ionization-Time of Flight). Briefly, the samples mixed with the matrix are irradiated with a laser, causing the matrix together with the peptides to ionize and vaporize. Using an Axima-CFR Plus MALDI-TOF MS system in “reflecton mode”, the charged ions are reflected using an electrical field and are accelerated in a vacuum. The time of flight to the detector is dependent on the mass of the peptides. Therefore, using calibrants of known mass and measuring their TOF, it is possible to calculate the mass of the sample peptides. I used a 7-point calibration curve and recalibrated the instrument between each sample. Repetitively, I was able to detect several expected tryptic peptides of ER β , including the peptide of interest containing S105. Fig. 35 is an example of a spectrum acquired as described above. The y-axis shows the normalized % intensity of the ions and the x-axis shows the mass to charge ratio (m/z).

Importantly, only charged ions can be analyzed and detected by the mass spectrometer, hence the need of the matrix and laser bombardment. The red and blue traces represent two separate duplicates of the in-gel digestion products of ER β -His6 protein. The numbers indicate m/z of ions that were automatically detected by having high intensity. Indeed several of those, and others at lower m/z not showed in this example, match the mass of tryptic products of ER β . Importantly a peak of 905.4 m/z is present in this example and others; this matches the mass of a singly charged SPWCEAR peptide containing S105. Ions are usually only singly charged in MALDI because it is a milder form of ionization compared to others such as ESI, which will be introduced in the next section.

The empirical digestion of ER β -His6 protein with Trypsin successfully led to the peptide of interest containing S105. This process confirmed the theoretical results and the empirical results with the human form of ER β [81]. These steps were necessary to evaluate whether the MRM approach would be feasible and the synthesis of target peptide would be necessary.




Figure 34. ER β -His6 protein was run on a SDS-PAGE gel in duplicate and stained with Coomassie stain. Gel bands containing the protein of interest and a negative control were excised (See arrows).




Figure 35. Representative MALDI-TOF spectrum of gel digestion products of ER β -His6.

3) Use target ER β peptides to develop the MRM

The target SPWCEAR peptides required for development and validation of AQUA-MRM were synthesized by ThermoFisher Scientific with heavy Arginine which is 10 Da heavier due to the presence of C13 and N15 isotopes. Phosphorylated peptides were also synthesized in the light and heavy version (Fig. 36).

										Thermo SCIENTIFIC
										12/1/2015 5:59
										12/1/2015 5:59
le ID	Peptide Name	Solvent	Nterm	Peptide Sequence	CTerm	MW	Amount [mg]	Volume[μ L]	Conc[mg/mL]	QC
	KS35084 FF40632									
'113	KS35084.1 ERB-light	50% ACN / 0,1%TFA	[H]	SPWCEAR	[OH]	847.94	1.9	400	4.7	passed
'094	KS35084.2 pERB-light	50% ACN / 0,1%TFA	[H]	[S]PWCEAR	[OH]	927.92	3.1	400	7.7	passed
i880	KS35084.3 ERB-Heavy	50% ACN / 0,1%TFA	[H]	SPWCEA(R)	[OH]	857.87	1.5	400	3.7	passed
i891	KS35084.4 pERB-Heavy	50% ACN / 0,1%TFA	[H]	[S]PWCEA(R)	[OH]	937.85	1.2	400	3.0	passed

Figure 36. Characteristics of the four SPWCEAR peptides purchased.

To develop a reliable MRM method, each peptide has to be tested for both its ionization and fragmentation characteristic. After electrospray the peptides can be multiply charged and the most prevalent ion form needs to be selected in Q1. Then the ion has to go through CID and the full spectrum of the product ions scanned. From all the product ions that are generated after dissociation, the most prevalent will be selected in Q3 in the MRM method.

The predicted y- and b- product ions of each peptide, can be obtained using bioinformatics tool such as MS-product, a program developed by the University of California. Fig. 37 shows the precursors and products m/z for the light and heavy SPWCEAR peptides. Note that the heavy peptide is 10m/z heavier than the light form in both the precursor and product ions that contain the heavy arginine.

SPWCEAR

User AA Formula 1: **C2 H3 N1 O1**

Elemental Composition: [C36 H54 N11 O11 S1](#)

MH ⁺¹ (av)	MH ⁺¹ (mono)	MH ⁺² (av)	MH ⁺² (mono)	MH ⁺³ (av)	MH ⁺³ (mono)
848.9615	848.3719	424.9844	424.6896	283.6588	283.4622

[−] Main Sequence Ions

b	y	y ⁺²
---	1 S 7	---
185.0921	2 P 6 761.3399	381.1736
371.1714	3 W 5 664.2872	332.6472
474.1806	4 C 4 478.2078	239.6076
603.2232	5 E 3 375.1987	188.1030
674.2603	6 A 2 246.1561	123.5817
---	7 R 1 175.1190	88.0631

SPWCEAR(+10)

User AA Formula 1: **C2 H3 N1 O1**

MH ⁺¹ (av)	MH ⁺¹ (mono)	MH ⁺² (av)	MH ⁺² (mono)	MH ⁺³ (av)	MH ⁺³ (mono)
858.9615	858.3719	429.9844	429.6896	286.9921	286.7955

[−] Main Sequence Ions

b	y	y ⁺²
---	1 S 7	---
185.0921	2 P 6 771.3399	386.1736
371.1714	3 W 5 674.2872	337.6472
474.1806	4 C 4 488.2078	244.6076
603.2232	5 E 3 385.1987	193.1030
674.2603	6 A 2 256.1561	128.5817
---	7 R(+10) 1 185.1190	93.0631

Figure 37. Predicted precursor and product ions for the light and heavy unphosphorylated SPWCEAR peptide.

A full scan analysis of each peptide, with no dissociation induced, shows which charged species are generated for each peptide. The spectrum in Fig.38 was collected from a directly infused short unphosphorylated light peptide. As indicated by the arrows, both the 1+ and 2+ species are generated. Because of the double charge the m/z of the 2+ species is equal to $1/2$ of the ion's mass. The most prevalent species was the 2+ ion, and was selected in Q1 for the MRM experiment. For all four peptides the doubly charged ion was the most prevalent following electrospray ionization, therefore the 2+ ions was selected for fragmentation.

The subsequent step used Q3 to detect the full spectrum of product ions derived from dissociation of the 2+ precursor ions. Representative spectra of the light and heavy unphosphorylated peptides are shown in Fig. 39. As indicated by the arrows, several of the predicted product ions were detected.




Figure 38. Spectrum for the SPWCEAR peptide. Arrows indicate the 1+ and 2+ species.




Figure 39. Spectra detected in Q3 showing product ions of the 424.66 (above) and 429.63 (below) precursor ions, the 2+ ion of the light unphosphorylated light (above) and heavy (below) peptides. Arrows indicate the m/z values that match the predicted products (for a list see Fig. 37).

Collision energy (CE) applied in Q2 to induce ion dissociation must be optimized in order to determine that all of the precursor ions are dissociated into product ions. Optimal CE can be theoretically calculated, but then must be empirically verified. My results showed that the phosphorylated peptides required slightly higher energy for a complete dissociation, due to their larger size because of the 79Da addition of the phosphate, however efficient dissociation was obtained with similar CE.

In AQUA-MRM experiments, confident detection and quantification is best achieved through the use of four transitions (precursor and product ions pairs). In addition, the MRM method must be designed to target the CAM modified peptides to mimic the true MRM experiment, in which the peptides go through the trypsin digestion protocol. The four transitions that were highly reproducible and were chosen for the final MRM design are listed in Fig. 40.

	Protein Name	Peptide Modified Sequence	Ion Formula	Precursor Mz	Precursor Charge	Product Mz	Fragment Ion	Product Charge	Cleavage Aa
light unphosphorylated peptide	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	453.504846	2	721.30862	y5	1	W
	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	453.504846	2	535.229307	y4	1	C
	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	453.504846	2	375.198659	y3	1	E
	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	453.504846	2	246.156066	y2	1	A
heavy unphosphorylated peptide	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	458.469178	2	731.316889	y5	1	W
	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	458.469178	2	545.237576	y4	1	C
	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	458.469178	2	385.206928	y3	1	E
	ERBETA	SPWC[+57.1]EAR	C38H56N12O12S	458.469178	2	256.164335	y2	1	A
light phosphorylated peptide	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	493.494796	2	721.30862	y5	1	W
	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	493.494796	2	535.229307	y4	1	C
	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	493.494796	2	375.198659	y3	1	E
	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	493.494796	2	246.156066	y2	1	A
heavy phosphorylated peptide	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	498.459129	2	731.316889	y5	1	W
	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	498.459129	2	545.237576	y4	1	C
	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	498.459129	2	385.206928	y3	1	E
	ERBETA	S[+80]PWC[+57.1]EAR	C38H57N12O15PS	498.459129	2	256.164335	y2	1	A

Figure 40. List of transitions chosen for each target peptide.

4) Develop LC-MRM method

The initial development of the MRM established the ionization and fragmentation characteristics of the pure peptides directly injected in the mass spectrometer by-passing the LC stage. However the final experiment is based on the ability of the endogenous (light) and exogenously added heavy peptides to be detected in a complex tissue protein sample following liquid chromatography. Therefore the LC step of the experiment must be optimized to determine the elution time of the peptide (i.e. retention time). During a LC-MRM method, the instrument cycles through the list of defined transitions for the duration of the program. Using the Skyline software, created by the MacCoss lab at the University of Washington, the transitions acquired across time can be easily viewed. To first test the LC-MRM method, I mixed equal amounts of each peptide to detect each retention time and tested whether the transitions observed with the pure peptides were reproducible.

Fig. 41 shows a screenshot of the Skyline software analysis of the LC-MRM of the sample mix. On the left panel, each transition is highlighted and assigned a different color. The chromatogram shows a zoomed in window of the retention times at which the peptides eluted. The green and light orange traces represent the unphosphorylated light and heavy peptides which co-elute. This result confirmed that the incorporation of the heavy arginine does not affect retention time. The red traces represent the phosphorylated peptides which also co-eluted as expected. Each peptide should only elute once, when the amount of organic solvent in the mobile phase is enough for the peptide to come off the C18 column and elute.




Figure 41. Chromatograph of the 4 pure peptides after LC-MRM program. On the x-axis is retention time, the y-axis is the signal intensity. For color legend see panel of the left. (Skyline software, MacCoss lab)

Analysis of the intensity of each transition is also possible, and the prevalence of each product ion should be consistent across replicates. Fig. 42 shows the four transitions monitored for the light unphosphorylated peptide in separate runs of the peptide alone (on the left) and mixed with the other peptides. As expected the pattern of each transition is conserved, with the 245.15 product (in orange) being the more intense in both samples.




Figure 42. The four transitions monitored for the light unphosphorylated peptide are shown in a run of the peptide alone (on the left) and mixed with all other peptides. Retention time and prevalence of each transition are conserved.

After optimization of the LC-MRM and establishment of retention time for each peptide, a standard curve will be prepared using the heavy labeled peptides. LC-MRM of serial fold dilutions of the unphosphorylated and phosphorylated heavy peptide will be used for the standard curve. Using the Xcalibur software, the intensity of the area under the curve of each dilution will be plotted and fit to a linear curve. The standard curve will be used for quantification of light (endogenous) peptide in the experimental tissue samples.

Perform MRM with experimental samples

The LC-MRM method developed above will be used to measure the ratio of ER β that is phosphorylated at S105 in the brain and heart of animals that underwent the estrogen deprivation paradigm. A known amount of the heavy peptide will be spiked with the tissue sample and, following LC-MRM, the ratio of the intensity of the endogenous peptide and the added heavy peptide will be calculated for both the phosphorylated and unphosphorylated peptides.

Comparison of trypsin digestion of the unphosphorylated and phosphorylated peptide fragment.

The S105 of interest is directly downstream of the lysine residue recognized by trypsin in the cleavage site. It is possible that trypsin might not recognize and, therefore cleave, as efficiently when S105 is phosphorylated. To evaluate this possibility, I designed a longer peptide with 7 additional amino acids upstream of S105 (Fig.43). The heavy LYAEPQKSPWCEAR peptide was synthesized with and without phosphorylation of S105 and then tested using the same digestion parameters as the shorter peptide. The

results demonstrated that the heavy phosphorylated peptide was cleaved after successful digestion with trypsin (Fig. 44, left panel) and the retention time and most prevalent product ions were similar to the short peptide (Fig. 44, right panel).

20 30 40 50 60
IPASYNCSQ SILPLEHGPI YIPSSYVDNR HEYSAMTFYS PAVMNYSVPG
80 90 100 110 120
.STSPNVLW PTSGHLSPLA THCQSSLIYA EPCKSPICEA RSLLEHTLPVN
140 150 160 170 180
ICASPVTSP NAKRDAHFCP VCSDYASGYH YGVWSCEGCK AFFKRSIQGH

Figure 43. The blue box highlights the longer peptide synthesized to study whether phosphorylation at S105 affects recognition and cleavage by Trypsin.




Figure 44. The long phosphorylated ER β peptide (left) is successfully cleaved and yields transitions that match the short heavy phosphorylated peptide (right).

DISCUSSION

In this chapter I have delineated the development of a LC-MRM experiment that can be used to detect and quantify phosphorylated ER β . Optimization of the LC-MRM method is necessary before moving on to assaying the tissue samples, however I am confident that this experiment is the best approach to answer the fundamental next questions in this study. I have already demonstrated that phosphorylated ER β is functionally distinct and alters downstream gene expression compared to the unphosphorylated form of the receptor (Chap. 3). Moreover, these functional differences are sensitive to the presence or absence of E2 in the cell, raising the possibility that ER β differentially alters gene expression in postmenopausal women. Adding to this complexity, the activation of kinases that putatively phosphorylate ER β is differentially altered by age and E2 in the brain and the heart (Chap. 4), thereby providing a mechanism for differential phosphorylation of ER β with advanced age. The next step is to identify phosphorylated ER β in the brain and heart of aged rats, and quantify changes in phosphorylation based on age and circulating levels of E2. These data will allow us to predict whether this functionally important modification is changed following longer deprivation of estrogen, and potentially is a basis for explaining the discrepant effects of E2 replacement therapy in postmenopausal women.

CHAPTER VI

FINAL DISCUSSION

SUMMARY OF KEY FINDINGS

The aim of this dissertation was to uncover potential molecular mechanisms of the age related switch of estrogen treatment post menopause. The project stemmed from the clinical observations brought about from the Women's Health Initiative study and the Timing Hypothesis. Important findings of the WHI were that the neurological and cardiovascular systems specifically benefit from E2 administration closely in time to the menopausal transition. *The underlying hypothesis of this dissertation was that age and estrogen deprivation lead to altered kinase activation which could result in altered phosphorylation of ER β in the brain and heart.*

The first goal was to test whether phosphorylation on ER β would alter its activity as a transcription factor in neurons, where estrogens can be beneficial. Indeed the data presented in Chapter III show that phosphorylation of ER β increases its activation of transcription at ERE sites, while abolishing the ligand independent inhibition of AP-1 sites (see Fig. 45). These represent two very different modalities of ER β activity as a transcription factor; the first requiring direct binding to the DNA at ERE sequences, the second by interacting with other transcription factors at the AP-1 sequences on the DNA.




Figure 45. Phosphorylation of ER β at S105 increases ERE dependent transcription (above) and abolishes ligand independent inhibition of AP-1 sites (below).

The possibility that phosphorylation of ER β alters its ability to bind to the DNA at ERE sequences was also tested in Chapter III. The results showed that ERE binding is not altered when ER β is phosphorylated in the N-terminal domain which is not known to participate in this interaction. However, the N-terminal domain (specifically S87 and S105) is important in mediating interactions with coregulatory proteins and participates in homo and heterodimerization.

The Timing Hypothesis relates to the whole organism physiology, therefore aging and estrogen deprivation need to be investigated *in vivo*. The animal paradigm used in this study was designed to investigate the findings of the WHI study and the Timing Hypothesis. Briefly, aged female rats were ovariectomized to remove endogenous sources of estrogens. E2 or vehicle was administered after different lengths of time following the surgery. This design was chosen due to the clinical studies which showed that the beneficial effects of E2 depend on how long after menopause women started ET. The initial hypothesis that MAPKs are differentially activated depending on age and estrogen deprivation could be tested in this model. Indeed, measuring the activation of p38 and ERK, members of the MAPK family, revealed a clear interaction between length of estrogen deprivation and estrogen treatment. Namely, the length of time between ovariectomy and beginning of treatment resulted in altered effects of E2 on the activation of MAPKs. Among the striking results described in Chapter IV, are the clear brain region-specific and kinase-specific effects detected. Also, the factors of length of estrogen deprivation and E2 treatment showed significant

interactions, indicating that different effects of E2 treatment were detected depending on the time at which it was administered.

Additionally, in Chapter V this dissertation provides the description of a novel method for detecting and quantifying phosphorylated ER β *in vivo*. The mass spectrometry technique described has been successful for the detection of lowly expressed proteins but has never been attempted to study ER β . Indeed, because of the difficulties experienced in the use of antibody based assays, the MRM method described offers a reliable alternative.

Taken together, the data presented in this dissertation demonstrate that alternative regulation of MAPKs signaling in the brain and heart could provide a novel mechanism explaining the variable effects of E2 following menopause. Furthermore, phosphorylated ER β was detected in the heart and brain and the consequences of phosphorylation of ER β on its regulation of transcription were determined.

PHOSPHORYLATION OF ER β AND LIGAND INDEPENDENT ACTIONS

The findings presented in Chapter III add to the renowned complexity of ER β signaling. ER β has been found to function completely differently from its cognate steroid receptor ER α . ER α binds to DNA and regulates transcription only in the presence of a ligand, as has been shown by ChIP-seq experiments in breast cancer cells [216]. Conversely, ER β can bind to EREs in absence of ligand, with microarray data showing that ER β regulates transcription of three classes of genes [70, 148, 217]. The first and larger class of genes was regulated by unliganded ER β . The second class of genes was regulated only in the presence of ligand, and genes in the smaller third class were regulated by ER β both in presence or absence of ligand. Interestingly, several of the Class I genes in the Vivar et al. study were enriched for AP-1 sites, demonstrating that unliganded ER β targets genes under AP-1 regulation. This is important to consider in light of the results shown in Chapter III that the ligand independent inhibition of AP-1, which is characteristic of ER β , was abolished when either phosphorylation site (S87 or S105) were mutated. This points to the possibility that the N-terminal domain is involved in ER β interaction with a coregulatory protein or directly with transcription factor Jun/Fos that binds to the AP-1 DNA sequence. Mutation of either S87 or S105 abolished the ligand independent inhibition of AP-1 sites, indicating that the genes that Vivar et al. identified as Class I would not be regulated by phosphorylated ER β . This could be a potential way of directing ER β towards other sets of genes that do not have AP-1 sites in their promoters. Indeed we found that phosphorylation of ER β at S105 increased ERE dependent transcription both in presence or absence of ligand. It is

possible that when unphosphorylated, ER β regulates both Class I and Class II genes but after phosphorylation it is limited to Class II, ERE genes.

As estrogen levels are low after menopause, ER β is constantly functioning unliganded causing regulation of only Class I genes. Therefore it is possible that following menopause, in absence of estrogen, phosphorylation of ER β would determine the set of genes it regulates. This modification would have critical consequences on ER β signaling at a time when estrogen is low.

PHOSPHORYLATION OF ER β AND THE DYNAMIC STRUCTURE OF THE N- TERMINAL DOMAIN

The dynamic structure of ER β can also be the cause of the profound consequences of mutations of S87 and S105. The ligand binding domain and DNA binding domains of ERs have been described via X-ray crystallography in complex with ligands and ERE sequences respectively [218-224]. However, the three dimensional structure of the N- terminal domain of ER β , along with many other nuclear receptors, has not yet been resolved. Indeed it has been shown that the AF-1 domains of nuclear receptors possess an intrinsically disordered (ID) conformation [225, 226]. The lack of particular structures has been attributed as the cause for the ability of nuclear receptors to interact with a variety of partners by easily changing structure to adapt and bind to a partner when the cellular milieu promotes that interaction. Both ER α and ER β have an intrinsically disordered nature, however analysis of predicted secondary structural elements in the ER N-terminal domain shows that ER α has more α -helix and β -sheet elements than ER β . The N-terminal domain of ER α contains 67% random coil conformation, whereas more than 80% of ER β is unstructured. The possibility that an unstructured part of a transcription

factor becomes structured following interaction with a component of the transcriptional machinery or a coregulatory has been shown for nuclear receptors such as the glucocorticoid receptor and progesterone receptor [227-229]. This is true for ER α as well, which by interacting with TBP (TATA binding protein) loses its disordered characteristics and becomes folded as shown by surface plasmon resonance and circular dichroism spectroscopy [225]. The same study was not able to replicate the experiments performed with the N-terminal domain of ER α with ER β . This was attributed to the impossibility of ER β to interact with TBP or the need for other proteins that form the transcriptional complex.

It is also possible that phosphorylation alters the intrinsically disordered nature of the N-terminal domain and determines the binding partners of ER β . Much of what we know about the structure of the N-terminal domain of ER β comes from sequence analysis prediction. The “Network Protein Sequence Analysis” for example, is a web service that was developed by a biocomputing team from analysis of sequence and structure information available in large databases [230]. Analysis of the N-terminal domain of ER β with a prediction model shows that the biggest majority of it is unstructured and made of random coil (see Fig. 46) [231]. Strikingly the amino acids close to S87 form a short α -helix right next to an extended strand region, followed by a random coil and another short α -helix following S105. Intuitively, it is plausible to think that even a small change in this sequence at the interface of unstructured regions and short helices might result in large effects on the structure of the region. Furthermore, a modification such as phosphorylation that brings the addition of a negative charge could also result in a

conformational switch in the area. Changing S87 or S105 into Glutamic acid (E) would mimic the effect of the phosphate, as experimentally done in Chapter III, and could help obtain a prediction of the structural conformation of the N-terminal domain of ER β following phosphorylation. Indeed when S87 was changed into Glutamic acid, it destabilized the short α -helix close to the extended strand region and turned it into a random coil. Changing S105 into S105E had the opposite effect. Even if S105 is further away from the short helix than S87, S105E induces a conversion of the random coil into a helix (Fig. 46). This extends the α -helix from 5 to 8 amino acids; a longer α -helix could limit the dynamic movement of the region and direct ER β towards interacting with one binding partner rather than another. As shown in Chapter III, phosphorylation of ER β at S105 increased the ligand independent and ligand dependent activation of ERE dependent transcription which could result from the stabilization of the α -helix structure and the recruitment of the transcriptional machinery.

It has been proposed that the unstructured and dynamic status of the N-terminal domain of ER β is at the base of its heterogeneous function [210, 226]. Phosphorylation in that region could result in different structural conformation leading ER β to interact with a certain binding partner and therefore towards a specific function.

PHOSPHORYLATION OF ER β AND THE INTERACTING PROTEINS

The interactome of ER β is vast, depending on the tissue under analysis, and can be altered by hormone treatment *in vitro* [86, 87]. Indeed ER β interacting proteins in the ventral hippocampus were altered by aging and E2 as shown by a study from our group [86]. It is possible that the observed changes in ER β interacting proteins in E2 treated versus vehicle treated animals might be due to ER β phosphorylation. As described above, phosphorylation could deeply alter the structure of the N-terminal domain which is known to mediate interactions with several proteins such as coregulators or TATA-binding proteins [128, 225, 232]. Furthermore, as described in Chapter IV, E2 treatment in the ventral hippocampus inhibits both ERK and p38 activity. This could cause decreased levels of phosphorylated ER β and altered recruitment of interacting proteins, which serves as a potential explanation for the changes detected in the previous study. Many of the interactions of ER β are transient and make determining the effect of phosphorylation on these interactions difficult. An alternative approach to determine how phosphorylation of ER β alters its interactome is using proteomics techniques such as APEX and BioID [233, 234]. These techniques are based on biotinylation of proteins proximal to the protein of interest which is tagged with a biotinylating enzyme. All biotinylated proteins have therefore interacted with the protein of interest and can be isolated using affinity chromatography. Mass spectrometry analysis is then used to reveal protein identity. While this is an *in vitro* approach to study if phosphorylated ER β interacts with different proteins, it would potentially explain some of the

observed differences in its function.

MAPKS IN THE AGING FEMALE BRAIN AND HEART

Aging can be defined as “a progressive, generalized impairment of function, resulting in an increased vulnerability to environmental challenge and a growing risk of disease and death” [235]. Aging is a continuous process affecting the whole organism which is changed at all levels, from the molecular and cellular level to tissue and system levels. In women, reproductive aging is the decline in fertility that ends at menopause, when levels of circulating estrogens are low. The decline of circulating estrogens is accompanied by a decline in health and rise in neurological and cardiovascular disease [56, 58]. It is plausible to think that the concurrent aging and estrogen decline together lead to a continuous change in the brain and heart. Indeed the effects of ET are different depending on how long following menopause they are administered, indicating that something in the cellular milieu has changed. It was shown that there is a critical window at which estrogen can be protective, but the molecular basis for this change is unknown. It is also not understood whether there is one critical window for all systems or if estrogens might be beneficial for a larger span of time in one tissue or another. It was proposed that estrogen action has a “healthy cell bias”, meaning that if cells are healthy at time of estrogen exposure their response to estrogen will be beneficial [236]. In contrast, if estrogen is administered to a cell that is not healthy, estrogen will exacerbate the cellular stress.




Figure 47. Context dependent effects of Estrogen.

The results shown in Chapter IV support the idea that the effects of estrogen treatment depend on the time of administration. Furthermore there is a clear difference between the results obtained in the heart and in the brain. In the brain E2 inhibited ERK activity; in the hypothalamus this was true at all times post OVX, in the hippocampus E2 was only effective 1 week post OVX. In the heart, however, E2 did not alter ERK or p38 at any time point. This differential regulation of MAPKs signaling could be indicating that the critical window of time is different for the brain and the heart, and indeed these two organs age differently. The brain is very sensitive to aging which is the biggest risk factor for neurodegenerative disease. The aging brain is characterized by underlying oxidative stress, neuroinflammation, glial activation, impaired protein processing and dysfunctional mitochondria [237]. The cardiovascular

system is also affected by aging which leads to atherosclerosis, thickening and loss of elasticity of the arterial walls, hypertrophy of the heart, and fibrosis [238].

A POTENTIAL ROLE FOR PROTEIN PHOSPHATASES

Protein phosphorylation is a reversible and transient mark placed by kinases and removed by phosphatases. These enzymes are part of a network that regulates cell signaling pathways and downstream effector proteins. In the last decade researches have started to focus their studies on the phosphatases that are responsible in removing the phosphorylation mark placed by kinases as a potential tool for drug development [239]. Indeed kinases are the target of several common medications for diseases such as diabetes, obesity, cancer etc. yet fewer phosphatase modulators are currently available [239]. Phosphatases can be broadly categorized based on their substrate recognition as protein Serine/Threonine phosphatases (PSTPs), Tyrosine phosphatases (PTPs) or dual-specificity phosphatases. Interestingly, phosphatases have been shown to be differentially expressed and activated by aging and hormonal status similar to many kinases [240-244]. A 2015 study showed that in primates aging significantly inhibited protein phosphatase 2A (PP2A) and consequently increased α -synuclein phosphorylation and oligomerization [243]. Similarly, STEP (Striatal-enriched Tyrosine phosphatase) is less active in the aged rats in several brain regions [242]. The activity of STEP has also been linked to age-associated neurologic disorders possibly because it is regulated by oxidative stress. Furthermore, the hormonal regulation of phosphatases is complex as previously discussed

for kinases. It was shown that both PSTPs and PTPs can be regulated by estrogen in healthy and cancer cells [244-248].

The specific phosphatases that target ER β 's S87 and S105 have not been investigated, but *in vitro* experiments could specifically identify which enzymes are responsible for removing the PTM placed by the MAPKs. It is plausible that these phosphatases are regulated by age and estrogen similarly to the results shown in Chapter IV for the MAPKs p38 and ERK. While it was not a focus of this dissertation, Tyrosine 36 has been recently identified as a phosphorylation site of ER β [249]. Using *in vitro* and *in vivo* approaches T36 phosphorylation was identified as a switch in determining the antitumor activity of ER β in breast cancer. Indeed, phosphorylation of T36 was necessary for recruitment of coregulatory proteins at promoters of antitumor genes. Furthermore, the phosphatase EYA2 was shown to remove the phosphate mark placed by the kinase c-ABL. This is the first example of a well-defined signaling circuitry that regulates ER β 's antitumor activity based on a specific phosphorylation mark.

Identifying the phosphatases responsible for removal of phosphorylation at S87 and S105 and measuring its changes with age and estrogen are promising avenues that would complement and strengthen the data presented in Chapter IV.

MITOCHONDRIAL DYSFUNCTIONS WITH AGE AND ESTROGEN EFFECTS

Known targets of estrogen regulation are mitochondria [250-255]. Interestingly mitochondrial dysfunction is common with age, and the “Mitochondrial theory of aging” proposes that the large amount of reactive oxygen species (ROS) produced in the mitochondria makes them a prime target for oxidative damage, which in turns decreases mitochondrial function and activates signaling pathways such as MAPKs [235, 256]. The three factors of aging, estrogen signaling and mitochondria are clearly intertwined and likely play an important role in the insurgence of the neurological and cardiovascular diseases associated with aging in women.

Estrogen can regulate mitochondrial function both in a genomic way, by regulating transcription of mitochondrial proteins, and in a non-genomic way by regulating signaling pathways such as MAPKs that converge on mitochondria. Interestingly, two studies have looked at the mitochondrial proteome of the heart or the brain following estrogen treatment or estrogen deprivation via ovariectomy [257, 258]. The majority of the proteins that were altered by estrogen were involved with regulation of oxidative stress, apoptosis, and electron transport complex proteins. Furthermore, the respiratory rate and activity of respiratory chain enzymes were increased in brain mitochondria 24 hours following E2 treatment, indicating the possibility for either a genomic regulation of transcription of genes in those functions or a non-genomic activation of signaling pathways that led to regulation of mitochondrial respiration [259].

Many of the beneficial effects of estrogen on mitochondria are thought to be due to ER dependent transcription of NRF-1, nuclear respiratory factor-1 [260]. NRF-1 is a transcription factor that regulates transcription of mitochondrial genes in the nuclear DNA. Interestingly, the NRF-1 promoter has ERE and AP-1 sites in its promoter and both ER α and ER β can induce its transcription [260, 261]. In breast cancer cells, it was found that unliganded ER β represses the NRF-1 promoter via the AP-1 site, but E2 or Tamoxifen treatment relieves this repression [261]. An *in vivo* study E2 treatment in ovariectomized rats determined an increase in NRF-1 and several mitochondrial protein levels and enzymatic activity in mitochondria isolated from cerebral blood vessels [262]. The authors conclude that vasoprotection by estrogen treatment might be due to the measured improved mitochondrial function, improved respiration and reduced production of ROS.

The non genomic effects of estrogens on mitochondria often include MAPKs signaling regulation. In *in vitro* experiments of human lens epithelial cells, E2 treatment reduced ROS produced by the mitochondria by activating ERK signaling which in turn stabilized the mitochondrial membrane potential [263]. Similarly, in cultured hippocampal neurons, brief E2 treatment reduced toxicity of elevated Glutamate which usually results in elevated Ca²⁺ [264]. Instead, brief E2 treatment increases the storage of Ca²⁺ in mitochondria and an elevation of the antiapoptotic gene Bcl2 [264]. In an *in vitro* model of AD, treatment with E2 inhibited the amyloid induced translocation of the proapoptotic protein Bax to the mitochondria and increased the antiapoptotic Bcl2 levels [265].

This estrogen regulation of mitochondrial function via MAPKs has been identified *in vivo* as well. Exercise-induced myocardial hypertrophy is a physiological response to exercise that does not lead to fibrosis and is reversible. Interestingly females develop larger physiological hypertrophy which is proposed to contribute to the more favorable remodeling in response to pathological stimuli seen in females [266]. It was shown that exercise in females induces activation of ERK and p38 which phosphorylate transcription factors that activate expression of mitochondrial proteins, leading to increased mitochondrial mass to better cope with the increased size of myocytes. This process was not present in ER β knockout mice, indicating that ER β is necessary for the activation of MAPKs and improved response to exercise [266].

As shown above, often the non-genomic effects of estrogen on mitochondrial function require activation of MAPKs which does not correlate with the results from our deprivation paradigm. In the hypothalamus, for example, E2 treatment strongly inhibited ERK at all time points. Does that mean that mitochondrial function is repressed in these samples? It is difficult to predict, because of the complexity of ERK signaling. However, if mitochondrial function was indeed reduced this could mean that the window for estrogen's protective effects is closed in the hypothalamus. Interestingly in this brain region, longer deprivation caused stronger inhibition of ERK, possibly leading to an even worse phenotype. This could be an example of the "healthy cell bias": longer deprivation from estrogen and aging could lead to unhealthier cells which more drastically respond to E2 treatment. In the heart both ERK and p38 were decreased by prolonged estrogen deprivation

and E2 treatment did not rescue this phenotype. This could again determine a failed protective response by E2, potentially due to altered cellular milieu.

Because many of the protective effects of estrogen on mitochondrial functions are mediated by genomic regulation, it would be important to determine whether the NRF-1 transcription factor or the mitochondrial proteins known to be transcribed following estrogen treatment are increased in the E2 treated animals.

In conclusion, the role of mitochondria in the beneficial effects of estrogens is known and could be a mechanism by which aging and estrogen together lead to time dependent effects.

FUTURE DIRECTIONS

The studies presented here contribute to the understanding of estrogen receptor signaling and kinase regulation in the context of menopause. Importantly, these data support the ideas that post translational modifications alter ER β 's functions and that the length of estrogen deprivation alone can affect the intracellular milieu of the aged brain and heart.

There are many new possible lines of investigation brought about from these findings. First, the *in vitro* evaluation of the effects of ER β phosphorylation on its activity as a transcription factor was a necessary starting point. While the abolished ligand independent activity of ER β by mutation of either phosphorylation site was striking, the data presented do not provide an explanation for this change. The idea proposed above, that phosphorylation alters ER β 's network of interactions, is compelling also due to the dynamic structure of ER β near its phosphorylation sites. Using an *in vitro* approach such as BioID or APEX, the consequences of ER β phosphorylation on its interaction with other proteins could be investigated [233, 234]. Furthermore the phosphorylation status of ER β *in vivo* needs to be determined. The proteomics approach described in Chapter V will conclusively determine how phosphorylation of ER β changes *in vivo*. This is crucial because of the results of Chapter III; namely ER β 's regulation of transcription is altered by phosphorylation. Furthermore, in light of the results of Chapter IV, it is likely that phosphorylation of ER β will be decreased in the brain and heart following E2 treatment, because ERK and p38 kinase were overall depressed.

The other potential for investigation that is opened by these studies is the possibility that the altered MAPKs signaling after prolonged estrogen deprivation might result in mitochondrial dysfunctions. Indeed, I would hypothesize that following prolonged estrogen deprivation mitochondrial function in the brain and the heart would be reduced. Measuring mitochondrial function in the deprivation paradigm used here could be a meaningful assessment of cellular health. Furthermore, *in vitro* studies have shown that activation of MAPKs signaling is necessary for estrogen's positive effects on mitochondrial function. According to the data shown in Chapter IV, however, ERK and p38 were in general not activated by E2, suggesting that either MAPKs signaling is differentially regulated *in vivo* or potentially that the window of opportunity is closed in these tissues. Finally, the beneficial effects of E2 on mitochondrial function can be determined by increased NRF-1 levels which could be measured in the brain and heart in our deprivation paradigm. If the beneficial effects of E2 are mediated via the genomic pathway, NRF-1 will be increased, resulting in higher levels of mitochondrial proteins necessary for efficient mitochondrial respiration.

CHAPTER VIII
BROAD CLINICAL IMPLICATIONS
CLINICAL POTENTIAL OF ERB

The Timing Hypothesis that resulted from the Women's Health Initiative study is at the base of this dissertation work. Because of the age dependent effects of estrogen treatment in post-menopausal women physicians are often uncertain on whether it is a good option for their patients. Furthermore, the activation of ER α in the uterus or breast with estrogen treatment could lead to proliferation and cancer. This is often a concern of physicians and patients who decide to avoid ET. Therefore, ER β selective agonists have been evaluated in the past 10 years, because ER β does not induce reproductive tissue proliferation and is active in non-reproductive organs such as the brain and heart. For its neuroprotective and cardioprotective roles, ER β is a potential target of regulation for age and menopause related diseases.




Figure 48. Potentials for ER β specific treatment in post-menopausal women

NEED FOR BETTER UNDERSTANDING OF ERB SIGNALING

A potential pitfall of using ER β specific ligands in the clinic is that many aspects of ER β signaling are still unknown. The characteristic ligand independent activity of ER β in activating ERE dependent transcription and inhibiting AP-1 dependent transcription remains mostly unexplained. Indeed ER β can interact with coregulatory proteins or transcription factors, bind to DNA and regulate transcription in absence of ligand. Furthermore while classically steroid receptors only translocate to the nucleus following ligand binding, ER β can be found in the nucleus or other subcellular locations in absence of ligand. It is thought that the ligand independent functions of ER β are particularly important after menopause when estrogens are low. Taking advantage of the functional and structural differences between ER α and ER β several receptor specific ligands (SERMs) have been developed. ER β specific botanical compounds known as phytoestrogens had been used for centuries in Chinese medicine. Different formulations of phytoestrogens have been tested in preclinical and clinical studies and have been deemed viable options for postmenopausal symptoms such as hot flashes, decreased memory function and menopause associated neurological decline [267-270]. Several phytoestrogens can bind to both ER isoforms, but selectively act on ER β to induce recruitment of coregulatory proteins and activate transcription [271]. This selectivity ensures that ER α in reproductive tissues such as the breast and uterus is not activated and does not lead to proliferation and possibly cancer [271]. An approach used to limit ER α activation in postmenopausal women with breast cancer is to use Aromatase inhibitors [272]. Inhibition of aromatase leads to decreased circulating estrogens and reduced ER α

activation. Because ER β can act in absence of ligand, use of Aromatase inhibitors could reduce endogenous estrogens thereby highlighting ligand independent actions of ER β . More agreement on the beneficial effects of ER β 's activation post menopause is leading to development of pharmaceuticals that take advantage of the growing understanding of ER β 's to improve post-menopausal women's life.

Clinical and basic science studies have evaluated the use of SERMs on ER β ; however it is possible that following phosphorylation of ER β treatment with SERMs does not lead to the same effects. Indeed in Chapter III I show that phosphorylation of ER β alters its E2 dependent and independent regulation of transcription in neurons. It is a possibility that treatment with other ligands could have alternate effects. The results in Chapter IV show that MAPKs are differentially activated following estrogen deprivation and E2 treatment which could correlate with altered levels of ER β phosphorylation *in vivo*. While it is difficult to speculate on the physiological consequences of altered levels of phosphorylated ER β in the brain and heart, *in vitro* studies point out that a big effects would be the abolished ligand independent inhibition of AP-1 dependent transcription. This would result in increased transcription of the genes that are usually repressed by ER β in absence of ligand when ER β phosphorylation is high. The other important effect of ER β phosphorylation was the increased activation of ERE dependent transcription. Taken together, increased phosphorylation of ER β *in vivo* due to increased MAPKs activity would lead to a shift in its action from the inhibition of AP-1 to the activation of ERE.

A further complicating factor is that while only ER β 1 transcriptional regulation was tested in Chapter III, several splice variants exist. Interestingly all splice variants still include the N-terminal domain, therefore could be phosphorylated as ER β 1 is. Furthermore the human ER β splice variants are truncated in the C-terminal domain, therefore lack the ligand binding domain. These ER β splice variants can regulate transcription in absence of ligand, indicating that the N-terminal domain is necessary for its constitutive activity [70]. A recent study by our group detected ER β 2 splice variant, which has an insertion of 18 amino acids in the ligand binding domain, in the brain regions analyzed in Chapter IV [273]. Therefore it is possible that both ER β 1 and ER β 2 are differentially phosphorylated correlating with the altered MAPKs activation measured. Indeed more understanding on the dynamics of ER β splicing and phosphorylation in the context of aging and estrogen deprivation might uncover a potential target for regulation. Drugs targeting splicing and phosphorylation are available, therefore understanding which splice variant and phosphorylation status are optimal for ER β to have most benefits would be highly important for physicians.

CLOSING REMARKS

My findings shed light on the molecular characteristics of phosphorylated ER β as well as highlighting the potential contribution of MAPKs signaling in the brain and heart in response to estrogen deprivation and E2. As predicted, I found that the cellular milieu of the aged brain and heart is altered by prolonged estrogen deprivation. While MAPKs signaling could affect brain and heart physiology through many critical cellular pathways, we found that when phosphorylated ER β differentially activates

transcription. Therefore, if indeed MAPKs and consequently ER β are differentially modulated by age and estrogen deprivation this could provide a molecular basis for altered response to ET. These findings highlight the need for further investigations on the effects of prolonged estrogen deprivation in post-menopausal women and provide a molecular explanation for the Timing Hypothesis.

While the understanding of the molecular underpinnings of the Timing Hypothesis is still unclear, the clinical evidence that points toward the benefits of ET in post-menopausal women is strong. Studies enrolling large numbers of women and with the appropriate experimental design show that ET is neuroprotective and cardioprotective following menopause. Furthermore, recent studies evaluating ER β selective agonists are very encouraging and could remove the disadvantage of activating ER α in reproductive tissues. The societal and economical burden of post-menopausal issues ranging from hot flashes to dementia or atherosclerosis should serve as an incentive for doctors to prescribe ET to women, but at the right time (i.e. in perimenopause). In conclusion, I would recommend the use of ET to perimenopausal women, and I predict that soon ER β specific agonists will have strong evidence in support of their use in the clinic.

CHAPTER VIII
GENERAL METHODS
Ethics Statement

Animal procedures were designed to minimize pain and suffering. All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at Loyola University Chicago, permit number 2009018.

Animals and deprivation paradigm

Female Fischer 344 rats were obtained from the National Institute of Aging (NIA) colony (Taconic) at 18 months (N = 80) of age. The animals were allowed to acclimate to the housing facility for 7 days after arrival. Animals were housed two per cage and were allowed free access to standard rat chow and tap water. One week after arrival, animals were deeply anesthetized with vaporized isoflurane and bilaterally ovariectomized (OVX). Briefly, the ovary and distal end of the uterine horn were pulled from the body cavity through a 1 cm incision made through the skin and body wall. The uterine horn was clamped with a hemostat and ligated proximal to the clamp. The entire ovary and distal uterine horn were then removed. Animals were singly housed and provided with acetaminophen analgesic (122.7 mg/kg) in their water for 3 days postoperative.

During this time, animals were weighed once/day and their water intake was measured. Following 3 days of analgesia the animals were pair-housed with their previous cage mate for the duration of the experiment. Following OVX animals recovered for 1, 4, 8, or 12 weeks (N=20/age group, Fig. 7). After the designated recovery time the animals were given a subcutaneous injection of either safflower oil (vehicle) (N=10/age group) or 2.5 µg/kg 17β-estradiol (E2, N=10/age group) dissolved in safflower oil once/day for 3 days. This dose of E2 elevated levels in OVX female rats (56.5 ± 6.3 pg/ml, which is within physiological range of women who received hormone replacement therapy during post-menopause (17-75 pg/ml)[178]. Animals were euthanized 24 hours after the last injection, trunk blood was collected, brain and heart rapidly removed and flash frozen.

Tissue Collection

The hypothalamus, dorsal and ventral hippocampus were microdissected using a Palkovit's brain punch tool (Stoelting, Inc., Wood Dale, IL) according to "The Rat Brain in Stereotaxic coordinates" [274]. The left ventricle was also rapidly removed from heart that had been flash frozen and homogenized using silica beads and a Mini Beadbeater-8 (Biospec Products, Bartlesville OK).

CHAPTER III METHODS

PhosTag™ Electrophoresis

50 ug of dorsal hippocampus or heart (left ventricle) protein was run on precast PhosTag™ Acrylamide 12.5% Acrylamide gels, (Wako Pure Chemical Industries, Osaka, Japan). The gel was then transferred on a PVDF membrane (Promega, Madison WI), blocked for 1 hour with 5% BSA, then

incubated with the Estrogen receptor β antibody H150 (epitope: 1-150 fragment of hER β , N-terminal domain) (Santa Cruz, sc-8974, Dallas TX) at a 1:250 dilution in 5% BSA TBST overnight. Blots were washed twice with TBST for 10 minutes prior to application of 1:5000 goat α -rabbit-HRP (Santa Cruz, sc-2004, Dallas TX) in 5% BSA TBST. Blots were washed twice with TBST for 10 minutes and imaged on the Bio-rad Chemidoc XRS+ imager (Bio-rad, Hercules, CA) using ECL Chemiluminescent substrate (Pierce Scientific, Rockford IL). Densitometry was performed using ImageLab software. Antibody specificity was confirmed with parallel Western Blots and PhosTagTM blots using ER α H-184 antibody (Santa Cruz, sc-7207, 1:1000 dilution; data not shown).

Alkaline Phosphatase treatment

Specificity of phosphorylated proteins were confirmed by treating 50 μ g of dorsal hippocampus protein (vehicle-treated animals) with 0, 30 or 60 units of alkaline phosphatase (Roche, Basel, Switzerland) for 2 hours at 37°C to dephosphorylate all phosphorylated proteins.

Cell culture

The mouse hippocampal-derived cell line HT-22 (generously provided by Dr. David Schubert, Scripps Institute, San Diego, CA) was maintained in DMEM (Corning, Tewksbury, MA) containing 4.5% glucose and L-glutamine supplemented with 1x nonessential amino acids (Corning, Tewksbury, MA) and 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA). Cells were used at 70-80% confluency for all experiments.

Hormone treatments

Cells at 70-80% confluency were rinsed with 1x PBS and then media replaced with phenol red-free DMEM plus 10% charcoal-stripped FBS (Atlanta Biologicals, Norcross, GA) at least 36 hours prior to hormone treatments in order to remove all exogenous hormone sources. 17β -estradiol (Sigma, St. Louis, MO) and 4-OH Tamoxifen (Sigma, St. Louis, MO) were diluted in molecular grade ethanol (EtOH) (Sigma, St. Louis, MO) and used at a final concentration of 100 nM as described previously [70, 136].

Expression vectors and reporter constructs

Plasmid expression vector (pcDNA 3.0; Invitrogen, Carlsbad, CA) containing inserts for rER- β 1 was provided by Dr. Tom Brown (Pfizer Corp., Cambridge, MA) and has been extensively characterized [8]. The ERE-tk-luciferase reporter construct (generously donated by Dr. Paul Budworth, Case Western Reserve University, Cleveland, OH) contains two repeats of the consensus vitellogenin ERE sequence upstream of the minimal thymidine kinase promoter-firefly luciferase (2xERE-tk-luc) in pGL2-basic plasmid (Promega, Madison, WI). The AP-1-tk-luciferase reporter construct (generously provided by Dr. Colin Clay, Colorado State University, Fort Collins, CO) contains three repeats of the AP-1 sequence into pGL2-basic plasmid. The renilla luciferase pGL4 reporter construct (Promega, Madison, WI) was used as an internal control for transfection efficiency.

Site directed mutagenesis

The pcDNA3.0 plasmid expression vector (Invitrogen, Carlsbad, CA) containing a cDNA insert coding rat ER β 1 was mutated using the Quick Change II XL site-directed mutagenesis kit (Agilent, Santa Clara, CA) to create the phospho-mutants (see Table 1). Primers were designed using the

QuickChange primer design available from the Agilent website and point mutations were inserted following manufacturer's instructions. Vectors were validated by DNA sequencing (ACGT, Inc, Wheeling, IL) to confirm successful site directed mutagenesis.

Transient Transfections

HT-22 cells were plated at a density of 20000 cells /well in 96-well plates for 48 h before transfection. Transfections were carried out using Fugene6 (Roche, Basel, Switzerland) or Fugene9 (Roche, Basel, Switzerland) according to manufacturer's instructions. Twenty-four hours after transfection, cells were washed with 1x PBS and incubated with dextran charcoal-stripped media containing hormone treatment or vehicle (EtOH) for 15 h and then lysed for luciferase assays. Transfection efficiency and expression was verified prior to luciferase experiments using GFP-tagged constructs (data not shown).

Luciferase assays

Following lysis, control reporter (Renilla Luciferase) and reporter (Firefly Luciferase) activities were measured using the Dual-Luciferase Reporter Assay system (DLR; Promega, Madison, WI). Relative light units (RLU) were detected using a Biotek Synergy HT plate reader (Biotek, Winooski, VT) with automatic dual injector system and represented as a ratio of Firefly/Renilla Luciferase RLU. All experiments were conducted with 6 replicates for each condition in each 96 well plate and each assay was repeated in 4 or more independent experiments.

Statistics

Two way ANOVA was performed to determine statistical significance and interaction between the groups followed by Tukey post hoc test for comparisons between mutants and wild type vector. Significance was set at P value < 0.05. All transfection data are represented as the mean percent change in fLUC/rLUC compared to vehicle-treated cells transfected with empty vector \pm SEM.

CHAPTER IV METHODS

RNA Isolation

Trizol reagent (Invitrogen, Carlsbad CA) was used to isolate total RNA from the hypothalamus, ventral hippocampus, dorsal hippocampus, and left ventricle of the heart. All RNA samples were quantified using Nanodrop spectrophotometry and analyzed for quality by visualization of the RNA on 1.5% agarose gel.

Quantitative reverse transcription PCR (RT-qPCR)

Following RNA isolation, 1.0 μ g total RNA was reverse transcribed using the SuperMix VILO cDNA synthesis kit for RT-qPCR (Invitrogen, Carlsbad, CA). Roche FastStart SYBR Green Master Mix was added to intron-spanning ERK and p38 primers: ERK forward: 5'CTCGGATTCCGCCATGAGAA3', reverse: 5'GGTCGCAGGTGGTGTGATA3'; p38 forward: 5'CAGGAAACGGGACGAACAGA3', reverse: 5'CCACAGAACTGCATGTCCCT3'. Then, 2 μ L cDNA templates were added to duplicate reactions performed in 96 well plates. The following program was used for RT-qPCR: 1) 95°C for 10 minutes, 2) 95°C for 30 seconds, 3) 59°C for 30 seconds, 4) 72°C for 30 seconds, and melting curve analysis. All samples were normalized to the hypoxanthine guanine phosphoribosyl transferase 1 (HPRT) housekeeping gene (primers: forward:

5'AGCAGTACAGCCCCAAAATGG3', reverse:

5'TGCGCTCATCTTAGGCTTTGT3'), as it is not altered by E2 treatment [178, 179]. Quantification of the target gene expression was achieved using the $\Delta\Delta\text{CT}$ method [275].

Protein Isolation

Total protein was extracted from the hypothalamus, dorsal hippocampus and ventral hippocampus using T-Per reagent (ThermoFisher Scientific, Waltham MA) supplemented with Pierce Protease and Phosphatase Inhibitor Tablet, EDTA Free (ThermoFisher Scientific, Waltham MA). Similarly, total protein was extracted from the left ventricle of the heart using RIPA buffer supplemented with Pierce Protease and Phosphatase Inhibitor Tablet, EDTA Free (ThermoFisher Scientific, Waltham MA). Protein concentrations were measured using the Pierce BCA Protein Assay kit according to manufacturer's directions (ThermoFisher Scientific, Waltham MA).

Western Blot

10 μg of isolated protein was electrophoresed on a 10% acrylamide gel. The gel was then transferred on a PVDF membrane (Promega, Madison WI), blocked for 1 hour with 5% Bovine Serum Albumin (BSA, ThermoFisher Scientific, Waltham MA) in Tris Buffered Saline with 0.1% Tween (TBST), then incubated with primary antibodies in 5% BSA TBST overnight (Table 4 – detailed antibody information). Blots were washed twice with TBST for 10 minutes prior to application of a secondary antibody in 5% BSA TBST for 2 hours, then blots were washed twice with TBST for 10 minutes and imaged using a Bio-rad Chemidoc XRS+ imager following application of the Pierce Enhanced Chemiluminescence (ECL) Western Blot substrate (ThermoFisher

Scientific, Waltham MA). PonceauS staining (MP Biomedicals, Santa Ana CA) was used to detect total protein. Quantification of bands was achieved by measuring the intensity of the bands following normalization to total protein with ImageLab software. Biological replicates were 6-8 per treatment/time point and samples were repeated in 2-3 technical replicates.

Peptide/Protein target	Name of Antibody	Catalog #, ,manufacturer	Species raised in; monoclonal or polyclonal	Dilution Used
Total ERK1/2	ERK1 antibody (K-23)	sc-94, Santa Cruz, Dallas TX	Rabbit, polyclonal	1:500
Total p38 α , p38 β , p38 γ	p38 MAPK (D13E1)	8690S, Cell Signalling Technology , Danvers MA	Rabbit, monoclonal	1:500
PhosphoERK1/2	Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)	9101s, Cell Signalling Technology , Danvers MA	Rabbit, polyclonal	1:500
Phosphop38 α , p38 β , p38 γ	Phospho-p38 MAPK (Thr180/Tyr182)	4511s, Cell Signalling Technology , Danvers MA	Rabbit, monoclonal	1:500
Rabbit IgG	Anti-rabbit IgG, HRP-linked	7074s, Cell Signalling Technology , Danvers MA	Goat, polyclonal	1:5000

CHAPTER V METHODS

Expression vectors and reporter constructs

Rat ER β sequence was cloned in the plasmid expression vector pEXP-CT/TOPO (Invitrogen, Carlsbad, CA) using EcoRI (NEB, Ipswich, MA) restriction enzyme digestion. The insertion was verified by sequencing which confirmed that 6His were inserted after the last amino acid of ER β .

Recombinant His-Tagged Protein Expression and Purification

BL21 DE3 (generously donated by the Lab of Dr. de Tombe) competent cells were transformed with ER β -6His plasmid DNA, and grown on LB-Amp plate overnight. Five colonies were picked for screening and grown in duplicates until culture turbidity reached OD₆₀₀=0.4. Then IPTG was added to one duplicate (B, induced cells) of each colony to induce expression of ER β -His6 under control of the Lac promoter. After additional incubation at 37°C for 5 hours, cells were centrifuged and resuspended in Lysis Buffer. After sonication (10" pulses/4 times), supernatant was resuspended in Laemmli buffer, heated for 5" at 95°C and electrophoresed on a 4-15% acrylamide gel (Bio-rad, Hercules, CA). The gel was then stained with 1% Coomassie R-250, 10% Acetic Acid, 40% Methanol solution for 30', destained for 30" and imaged with Bio-rad Chemidoc XRS+ imager (Bio-rad, Hercules, CA). Based on the result, the highest expressing culture was inoculated in 10 ml of LB-Amp. After overnight growth the large scale protein production started by inoculating 8 ml of the culture in 2 L of LB-Amp. The culture was then induced with IPTG and incubated at 37 °C. Cell pellet was then sonicated (30" pulses/4 times) and centrifuged at 10000rpm, 20', 4°C. Supernatant was used for protein purification performed by Menjie Zhang (Dr. de Tombe lab) with an

automated FPLC system (AKTÄ FPLC, GE Healthcare). The sample was loaded on a HisTrap nickel affinity column (GE Healthcare). The column was then washed until ultraviolet absorbance at 280 nm reached equilibrium. ER β -His6 was then eluted using a buffer containing imidazole (which competes for binding the column) and the flow through was collected in separate fractions. Fractions were then electrophoresed and stained with Coomassie R-250 to verify which fractions contained ER β -His6. The positive fractions were combined and concentrated using Pierce Protein Concentrator tubes (Pierce Scientific, Rockford IL). Protein concentration was measured using the Pierce BCA Protein Assay kit according to manufacturer's directions (ThermoFisher Scientific, Waltham MA). To verify correct expression, ER β -His6 protein was then electrophoresed on an Acrylamide 4-15% gels (Bio-rad, Hercules, CA). The gel was then transferred on a PVDF membrane (Promega, Madison WI), blocked for 1 hour with 5% BSA, then incubated with the Estrogen receptor β antibody H150 (epitope: 1-150 fragment of hER β , N-terminal domain) (Santa Cruz, sc-8974, Dallas TX) at a 1:500 dilution in 5% BSA TBST overnight. Blot was washed twice with TBST for 10 minutes prior to application of 1:5000 goat α -rabbit-HRP (Santa Cruz, sc-2004, Dallas TX) in 5% BSA TBST. Blot was washed twice with TBST for 10 minutes and imaged on the Bio-rad Chemidoc XRS+ imager (Bio-rad, Hercules, CA) using ECL Chemiluminescent substrate (Pierce Scientific, Rockford IL). After confirmation of ER β -His6 expression, recombinant His- tagged protein was aliquoted and stored at -80 °C.

Tryptic digestion and MALDI-TOF analysis

5 to 20 ug of ErbA-His6 protein was electrophoresed on a 4-15% Acrylamide gel (Bio-rad, Hercules, CA). The gel was then stained with Coomassie G250 (1% Coomassie G-250, 10% acetic acid, 40% Methanol) for 1 hour and destained overnight. The band corresponding to the ER β -His6 protein was excised using a sterile scalpel; a negative control band with no protein was also excised. Gel bands were individually put in a 1.5 ml tube and washed with 50% Acetonitrile 50 % 100mM Ammonium Bicarbonate for 15' at 37°C while shaking at 800 rpm. Then the "wash cycle" was performed. First bands were washed with a 100% 100mM Ammonium Bicarbonate for 15' at 37°C while shaking at 800 rpm. Then they were washed with a 50% Acetonitrile 50% 100mM Ammonium Bicarbonate solution for 15' at 37°C while shaking at 800 rpm. Then they were washed with 100% Acetonitrile for 15' at 37°C while shaking at 800 rpm. The gel bands were reduced using 10 mM DTT for 30' at 37°C while shaking at 550 rpm. The "wash cycle" was then repeated. Then gel bands were alkylated with 55mM Iodacetamide in 100 mM Ammonium Bicarbonate solution for 45' at 37°C while shaking at 550 rpm. The "wash cycle" was then repeated. The gel bands were then treated with 1 ug of Trypsin on ice 1 hour, then overnight at 37°C while shaking at 550 rpm. The supernatant containing most digested peptides was saved. The gel bands were then washed according to the "wash cycle" to collect all possible remaining peptides from the gel. The washes were collected and pooled. Peptides were concentrated using a Speedvac. Peptides were then resuspended in 0.1% Formic Acid.

The standard curve calibrants for MALDI-TOF and the peptides were then mixed with the α -Cyano-4-hydroxycinnamic acid matrix (CHCA) matrix (ThermoFisher Scientific, Waltham MA). The Axima-CFR Plus MALDI-TOF in reflecton mode was calibrated using a mix of the calibrants spotted on the target plate. Calibrants mix solution was pipetted next to each sample and calibration was repeated between each measurement.

LC-MRM development

A Thermo Scientific TSQ Vantage MS system was used for these experiments. The target peptides (SPWCEAR) were synthesized by ThermoFisher Scientific (Waltham MA) and used for the development of the MRM method. Peptides were resuspended in 50% Acetonitrile 0.1% Formic Acid to a 10picomole/ul concentration, aliquoted and stored at -80 °C. Peptides were diluted at 1picomol/ul and full scan was collected after direct injection of 5ul. Parent ions were then detected and identified. The 2+ parent ion was then selected for fragmentation and a full MS/MS scan was collected. Four transitions (precursor-product ions combinations) were picked for each peptide to be used for the MRM method. The MRM method was prepared using the Xcalibur software (ThermoFisher Scientific, Waltham MA). Peptides were combined in equal amounts and injected through in a Biobasic C18 HPLC column (ThermoFisher Scientific, Waltham MA) in a 66 minutes long LC-MRM method. The MS/MS spectra collected were analyzed using the Skyline software, created by the MacCoss lab at the University of Washington.

REFERENCES

1. Cui, J., Y. Shen, and R. Li, *Estrogen synthesis and signaling pathways during aging: from periphery to brain*. Trends Mol Med, 2013. **19**(3): p. 197-209.
2. Stuenkel, C.A., et al., *Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline*. J Clin Endocrinol Metab, 2015. **100**(11): p. 3975-4011.
3. Miller, W.L. and R.J. Auchus, *The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders*. Endocr Rev, 2011. **32**(1): p. 81-151.
4. Suzuki, N., et al., *A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density*. Maturitas, 1995. **22**(1): p. 9-12.
5. Murphy, N., et al., *A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women*. J Natl Cancer Inst, 2015. **107**(10).
6. Miyoshi, Y., et al., *Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women*. Clin Cancer Res, 2003. **9**(6): p. 2229-33.
7. Zhu, B.T., et al., *Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding*. Endocrinology, 2006. **147**(9): p. 4132-50.
8. Ozers, M.S., et al., *Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization*. Mol Endocrinol, 2005. **19**(1): p. 25-34.
9. Kuiper, G.G., et al., *Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta*. Endocrinology, 1997. **138**(3): p. 863-70.
10. Sicotte, N.L., et al., *Treatment of multiple sclerosis with the pregnancy hormone estriol*. Ann Neurol, 2002. **52**(4): p. 421-8.
11. Watson, B.M.C.a.R.I., *An evaluation of Psychilogic effects of sex hormone administration in aged women*. J. Gerontology, 1952. **7**(2): p. 228-244.
12. Zec RF, T.M., *The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review*. Neuropsychol Rev, 2002. **12**(2): p. 65-109.
13. Woolley, C.S. and B.S. McEwen, *Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat*. J Neurosci, 1992. **12**(7): p. 2549-54.
14. Woolley, C.S., *Electrophysiological and cellular effects of estrogen on neuronal function*. Crit Rev Neurobiol, 1999. **13**(1): p. 1-20.
15. Liu, F., et al., *Activation of estrogen receptor- β regulates hippocampal synaptic plasticity and improves memory*. Nature Neuroscience, 2008. **11**(3): p. 334-343.
16. Spencer-Segal, J.L., et al., *Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation*. Neuroscience, 2012. **202**: p. 131-146.
17. Korol, D.L., et al., *Shifts in preferred learning strategy across the estrous cycle in female rats*. Hormones and Behavior, 2004. **45**(5): p. 330-338.
18. Kiss, Á., et al., *17 β -Estradiol replacement in young, adult and middle-aged female ovariectomized rats promotes improvement of spatial reference memory and an antidepressant effect and alters monoamines and BDNF levels in memory- and*

- depression-related brain areas*. Behavioural Brain Research, 2012. **227**(1): p. 100-108.
19. Kramár, E.A., et al., *BDNF upregulation rescues synaptic plasticity in middle-aged ovariectomized rats*. Neurobiology of Aging, 2012. **33**(4): p. 708-719.
 20. Murphy, D.D., N.B. Cole, and M. Segal, *Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons*. Proc Natl Acad Sci U S A, 1998. **95**(19): p. 11412-7.
 21. Scharfman, H.E. and N.J. Maclusky, *Similarities between actions of estrogen and BDNF in the hippocampus: coincidence or clue?* Trends Neurosci, 2005. **28**(2): p. 79-85.
 22. Scharfman, H.E., et al., *Hippocampal excitability increases during the estrous cycle in the rat: a potential role for brain-derived neurotrophic factor*. J Neurosci, 2003. **23**(37): p. 11641-52.
 23. K. Yaffe, G.S., I. Lieberburg, D. Grady, *Estrogen therapy in postmenopausal women effects on cognitive function and dementia*. Jama, 1998. **279**(9): p. 688-695.
 24. ES LeBlanc, J.J., B.K.S. Chan, H.D. Nelson *Hormone replacement therapy and cognition*. Jama, 2001. **285**(11): p. 1489- 1499.
 25. George, S., et al., *Nonsteroidal Selective Androgen Receptor Modulators and Selective Estrogen Receptor β Agonists Moderate Cognitive Deficits and Amyloid- β Levels in a Mouse Model of Alzheimer's Disease*. ACS Chemical Neuroscience, 2013. **4**(12): p. 1537-1548.
 26. Zhao, L., et al., *Early intervention with an estrogen receptor beta-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease*. J Alzheimers Dis, 2013. **37**(2): p. 403-19.
 27. Bourque, M., et al., *Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity*. Biochem Pharmacol, 2007. **74**(9): p. 1413-23.
 28. Sanchez, M.G., et al., *Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders*. CNS Neurosci Ther, 2010. **16**(3): p. e43-71.
 29. McFarland, K., et al., *AC-186, a selective nonsteroidal estrogen receptor beta agonist, shows gender specific neuroprotection in a Parkinson's disease rat model*. ACS Chem Neurosci, 2013. **4**(9): p. 1249-55.
 30. Al Sweidi, S., et al., *Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease*. J Neuroendocrinol, 2012. **24**(1): p. 48-61.
 31. Khalaj, A.J., et al., *Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects*. J Steroid Biochem Mol Biol, 2016.
 32. Gardell, L.R., et al., *Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist*. Eur J Pharmacol, 2008. **592**(1-3): p. 158-9.
 33. Piu, F., et al., *Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist*. Eur J Pharmacol, 2008. **590**(1-3): p. 423-9.
 34. Sareddy, G.R., et al., *Therapeutic significance of estrogen receptor beta agonists in gliomas*. Mol Cancer Ther, 2012. **11**(5): p. 1174-82.
 35. Appelros, P., B. Stegmayr, and A. Terent, *Sex differences in stroke epidemiology: a systematic review*. Stroke, 2009. **40**(4): p. 1082-90.
 36. Wilson, M.E., *Stroke: Understanding the Differences between Males and Females*. Pflügers Archiv - European Journal of Physiology, 2013. **465**((5):): p. 595-600.
 37. Westberry, J.M., A.K. Prewitt, and M.E. Wilson, *Epigenetic regulation of the estrogen receptor alpha promoter in the cerebral cortex following ischemia in male and female rats*. Neuroscience, 2008. **152**(4): p. 982-989.

38. Arai, K., et al., *Periodic 17 β -Estradiol Pretreatment Protects Rat Brain from Cerebral Ischemic Damage via Estrogen Receptor- β* . PLoS ONE, 2013. **8**(4): p. e60716.
39. Lund, T.D., *Novel Actions of Estrogen Receptor- on Anxiety-Related Behaviors*. Endocrinology, 2004. **146**(2): p. 797-807.
40. Foster, T.C., *Role of estrogen receptor alpha and beta expression and signaling on cognitive function during aging*. Hippocampus, 2012. **22**(4): p. 656-669.
41. Varas-Lorenzo, C., et al., *Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction : A Population-Based Nested Case-Control Study*. Circulation, 2000. **101**(22): p. 2572-2578.
42. Murphy, E., *Estrogen Signaling and Cardiovascular Disease*. Circulation Research, 2011. **109**(6): p. 687-696.
43. Babiker FA, D.W.L., van Eickels M, Grohe C, Meyer R, Doevendans PA., *Estrogenic hormone action in the heart: regulatory network and function*. Cardiovascular Research, 2002. **53**: p. 709-719.
44. Arias-Loza, P.A., V. Jazbutyte, and T. Pelzer, *Genetic and pharmacologic strategies to determine the function of estrogen receptor α and estrogen receptor β in cardiovascular system*. Gender Medicine, 2008. **5**: p. S34-S45.
45. Gabel, S., et al., *Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury*. Journal of Molecular and Cellular Cardiology, 2005. **38**(2): p. 289-297.
46. Jazbutyte, V., et al., *Ligand-dependent activation of ER lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats*. Cardiovascular Research, 2007. **77**(4): p. 774-781.
47. Mendelsohn, M.E., *Nongenomic, ER-Mediated Activation of Endothelial Nitric Oxide Synthase: : How Does It Work? What Does It Mean?* Circulation Research, 2000. **87**(11): p. 956-960.
48. Skavdahl, M., et al., *Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy*. Am J Physiol Heart Circ Physiol, 2005. **288**(2): p. H469-76.
49. Gabel, S.A., et al., *Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury*. J Mol Cell Cardiol, 2005. **38**(2): p. 289-97.
50. Nikolic, I., et al., *Treatment with an estrogen receptor-beta-selective agonist is cardioprotective*. J Mol Cell Cardiol, 2007. **42**(4): p. 769-80.
51. Sandberg, K. and H. Ji, *Is the Dog in Estrogen Receptor-Mediated Protection From Hypertension?* Hypertension, 2013. **61**(6): p. 1153-1154.
52. Joynt, K.E., *Lessons From SADHART, ENRICHED, and Other Trials*. Psychosomatic Medicine, 2005. **67**(Supplement_1): p. S63-S66.
53. Rubinow, D.R. and S.S. Girdler, *Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater*. Depression and Anxiety, 2011. **28**(6): p. E1-E15.
54. Glassman AH, O.C.C., Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group., *Sertraline treatment of Major Depression in patients with acute MI or Unstable Angina*. JAMA, 2002. **288**(6): p. 701-9.
55. Freedland KE, C.R., *Depression as a risk factor for adverse outcomes in coronary heart disease*. BCM Med., 2013. **15**(11): p. 131.
56. Rocca, W.A., B.R. Grossardt, and L.T. Shuster, *Oophorectomy, Menopause, Estrogen, and Cognitive Aging: The Timing Hypothesis*. Neurodegenerative Diseases, 2010. **7**(1-3): p. 163-166.

57. Schierbeck, L.L., et al., *Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial*. *BMJ*, 2012. **345**(oct09 2): p. e6409-e6409.
58. Hodis, H.N., et al., *The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective*. *Climacteric*, 2012. **15**(3): p. 217-228.
59. Writing Group for the Women's Health Initiative, I., *Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial*. *Jama*, 2002. **288**(3): p. 321-333.
60. Philip M. Sarrel, V.Y.N., Valentina Vinante, and David L. Katz, *The Mortality Toll of Estrogen Avoidance: An Analysis of Excess Deaths Among Hysterectomized Women Aged 50 to 59 Years*. *American Journal of Public Health*, 2013 **103**(9): p. 1583-1588
61. Böttner, M., P. Thelen, and H. Jarry, *Estrogen receptor beta: Tissue distribution and the still largely enigmatic physiological function*. *The Journal of Steroid Biochemistry and Molecular Biology*, 2013.
62. Kuiper GG, E.E., Pelto-Huikko M, Nilsson S, Gustafsson JA., *Cloning of a novel receptor expressed in rat prostate and ovary*. *Proc Natl Acad Sci U S A.*, 1996. **93**(12): p. 5925-30.
63. Bhat RA, H.D., Stevis PE, Lyttle CR, Komm BS., *A novel human estrogen receptor beta: identification and functional analysis of additional N-terminal amino acids*. *J Steroid Biochem Mol Biol.*, 1998. **67**(3): p. 233-40.
64. Petersen DN, T.G., Koza-Taylor PH, Turi TG, Brown TA., *Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues*. *Endocrinology*, 1998. **139**(3): p. 1082-92.
65. Shughrue, P.J., M.V. Lane, and I. Merchenthaler, *Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system*. *J Comp Neurol*, 1997. **388**(4): p. 507-25.
66. Sanchez, M., et al., *Challenging estrogen receptor β with phosphorylation*. *Trends in Endocrinology & Metabolism*, 2010. **21**(2): p. 104-110.
67. Kumar, R. and G. Litwack, *Structural and functional relationships of the steroid hormone receptors' N-terminal transactivation domain*. *Steroids*, 2009. **74**(12): p. 877-883.
68. Andre´ Tremblay, G.B.T., Fernand Labrie, and Vincent Giguere, *Ligand-Independent Recruitment of SRC-1 to Estrogen Receptor β through Phosphorylation of Activation Function AF-1*. *molecular Cell*, 1999. **3**: p. 513-519.
69. Pak, T.R., et al., *The androgen metabolite, 5 α -androstane-3 β , 17 β -diol, is a potent modulator of estrogen receptor-beta1-mediated gene transcription in neuronal cells*. *Endocrinology*, 2005. **146**(1): p. 147-55.
70. Mott, N.N. and T.R. Pak, *Characterisation of human oestrogen receptor beta (ERbeta) splice variants in neuronal cells*. *J Neuroendocrinol*, 2012. **24**(10): p. 1311-21.
71. Gruber, C.J., et al., *Anatomy of the estrogen response element*. *Trends in Endocrinology & Metabolism*, 2004. **15**(2): p. 73-78.
72. Pike AC, B.A., Hubbard RE., *A structural biologist's view of the oestrogen receptor*. *J Steroid Biochem Mol Biol.*, 2000. **74**(5): p. 261-8.
73. Skafar, D.F. and C. Zhao, *The multifunctional estrogen receptor-alpha F domain*. *Endocrine*, 2008. **33**(1): p. 1-8.
74. Cowley, S.M., *Estrogen Receptors alpha and beta Form Heterodimers on DNA*. *Journal of Biological Chemistry*, 1997. **272**(32): p. 19858-19862.

75. Li, X., et al., *Single-Chain Estrogen Receptors (ERs) Reveal that the ER / Heterodimer Emulates Functions of the ER Dimer in Genomic Estrogen Signaling Pathways*. *Molecular and Cellular Biology*, 2004. **24**(17): p. 7681-7694.
76. Hall JM, M.D., *The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens*. *Endocrinology*, 1999. **140**(12): p. 5566-78.
77. Ward RD, W.N., *Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation*. *Biofactors*, 2009. **5**(6): p. 528-36.
78. Marquez, D.C., et al., *Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor*. *Endocrine*, 2001. **16**(2): p. 73-81.
79. Nelson, K.G., et al., *Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation*. *Proc Natl Acad Sci U S A*, 1991. **88**(1): p. 21-5.
80. Sauve, K., et al., *Positive Feedback Activation of Estrogen Receptors by the CXCL12-CXCR4 Pathway*. *Cancer Research*, 2009. **69**(14): p. 5793-5800.
81. Lam, H.-M., et al., *Phosphorylation of human estrogen receptor-beta at serine 105 inhibits breast cancer cell migration and invasion*. *Molecular and Cellular Endocrinology*, 2012. **358**(1): p. 27-35.
82. Warner, M. and J.A. Gustafsson, *The role of estrogen receptor beta (ERbeta) in malignant diseases--a new potential target for antiproliferative drugs in prevention and treatment of cancer*. *Biochem Biophys Res Commun*, 2010. **396**(1): p. 63-6.
83. Halachmi, S., et al., *Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription*. *Science*, 1994. **264**(5164): p. 1455-8.
84. York, B. and B.W. O'Malley, *Steroid Receptor Coactivator (SRC) Family: Masters of Systems Biology*. *Journal of Biological Chemistry*, 2010. **285**(50): p. 38743-38750.
85. McKenna, N.J., R.B. Lanz, and B.W. O'Malley, *Nuclear receptor coregulators: cellular and molecular biology*. *Endocr Rev*, 1999. **20**(3): p. 321-44.
86. Mott, N.N., et al., *Age-dependent Effects of 17beta-estradiol on the dynamics of estrogen receptor beta (ERbeta) protein-protein interactions in the Ventral Hippocampus*. *Mol Cell Proteomics*, 2014. **13**(3): p. 760-79.
87. Nassa, G., et al., *Comparative analysis of nuclear estrogen receptor alpha and beta interactomes in breast cancer cells*. *Mol Biosyst*, 2011. **7**(3): p. 667-76.
88. Malovannaya, A., et al., *Analysis of the human endogenous coregulator complexome*. *Cell*, 2011. **145**(5): p. 787-99.
89. Pearson, G., et al., *Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions*. *Endocr Rev*, 2001. **22**(2): p. 153-83.
90. Kim, E.K. and E.J. Choi, *Compromised MAPK signaling in human diseases: an update*. *Arch Toxicol*, 2015. **89**(6): p. 867-82.
91. Ubersax, J.A. and J.E. Ferrell, Jr., *Mechanisms of specificity in protein phosphorylation*. *Nat Rev Mol Cell Biol*, 2007. **8**(7): p. 530-41.
92. Tibbles, L.A. and J.R. Woodgett, *The stress-activated protein kinase pathways*. *Cell Mol Life Sci*, 1999. **55**(10): p. 1230-54.
93. Sheridan, D.L., et al., *Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs*. *J Biol Chem*, 2008. **283**(28): p. 19511-20.
94. Kyriakis, J.M., et al., *The stress-activated protein kinase subfamily of c-Jun kinases*. *Nature*, 1994. **369**(6476): p. 156-60.
95. Roux, P.P. and J. Blenis, *ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions*. *Microbiol Mol Biol Rev*, 2004. **68**(2): p. 320-44.

96. Kim, E.K. and E.-J. Choi, *Compromised MAPK signaling in human diseases: an update*. Archives of Toxicology, 2015.
97. Dhillon, A.S., et al., *MAP kinase signalling pathways in cancer*. Oncogene, 2007. **26**(22): p. 3279-90.
98. Giraldo, E., et al., *Abeta and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E*. Redox Biol, 2014. **2**: p. 873-7.
99. Marber, M.S., B. Rose, and Y. Wang, *The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure*. J Mol Cell Cardiol, 2011. **51**(4): p. 485-90.
100. Martin, E.D., G.F. De Nicola, and M.S. Marber, *New Therapeutic Targets in Cardiology: p38 Alpha Mitogen-Activated Protein Kinase for Ischemic Heart Disease*. Circulation, 2012. **126**(3): p. 357-368.
101. Zarubin, T. and J. Han, *Activation and signaling of the p38 MAP kinase pathway*. Cell Res, 2005. **15**(1): p. 11-8.
102. Han, J., et al., *Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14*. J Biol Chem, 1993. **268**(33): p. 25009-14.
103. Han, J., et al., *A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells*. Science, 1994. **265**(5173): p. 808-11.
104. Lee, J.C., et al., *A protein kinase involved in the regulation of inflammatory cytokine biosynthesis*. Nature, 1994. **372**(6508): p. 739-46.
105. Han, S.J., et al., *Molecular cloning and characterization of a Drosophila p38 mitogen-activated protein kinase*. J Biol Chem, 1998. **273**(1): p. 369-74.
106. Li, Z., et al., *Age-induced augmentation of p38 MAPK phosphorylation in mouse lung*. Exp Gerontol, 2011. **46**(8): p. 694-702.
107. Suh, Y., *Age-specific changes in expression, activity, and activation of the c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinases by methyl methanesulfonate in rats*. Mechanisms of Ageing and Development, 2001. **122**(15): p. 1797-1811.
108. Abidi, P., et al., *Evidence that age-related changes in p38 MAP kinase contribute to the decreased steroid production by the adrenocortical cells from old rats*. Aging Cell, 2008. **7**(2): p. 168-78.
109. Zhen, X., et al., *Age-associated impairment in brain MAPK signal pathways and the effect of caloric restriction in Fischer 344 rats*. J Gerontol A Biol Sci Med Sci, 1999. **54**(12): p. B539-48.
110. Simone Nuedling a, S.K.a., Kerstin Loebbert a, Rainer Meyer b, Hans Vetter a, Christian Grohe', *Differential effects of 17[3-estradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes*. FEBS Letters, 1999. **454** p. 271-276.
111. Zhao, L. and R.D. Brinton, *Estrogen receptor α and β differentially regulate intracellular Ca²⁺ dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons*. Brain Research, 2007. **1172**: p. 48-59.
112. Ito, M., et al., *Age-associated changes in the subcellular localization of phosphorylated p38 MAPK in human granulosa cells*. Molecular Human Reproduction, 2010. **16**(12): p. 928-937.
113. J. Craig Hunter, D.H.K., *Age and sex-dependent alterations in protein kinase C (PKC) and extracellular regulated kinase 1/2 (ERK1/2) in rat myocardium*. Mechanism of Ageing and development, 2005.
114. Taguchi, K., et al., *Enhanced estradiol-induced vasorelaxation in aortas from type 2 diabetic mice may reflect a compensatory role of p38 MAPK-mediated eNOS activation*. Pflügers Archiv - European Journal of Physiology, 2012. **464**(2): p. 205-215.

115. Marber, M.S., B. Rose, and Y. Wang, *The p38 mitogen-activated protein kinase pathway—A potential target for intervention in infarction, hypertrophy, and heart failure*. Journal of Molecular and Cellular Cardiology, 2011. **51**(4): p. 485-490.
116. Liu, J., et al., *Pressure overload induces greater hypertrophy and mortality in female mice with p38 α MAPK inhibition*. Journal of Molecular and Cellular Cardiology, 2006. **41**(4): p. 680-688.
117. Isaksson, I.-M., et al., *Methods for 17 β -oestradiol administration to rats*. Scandinavian Journal of Clinical & Laboratory Investigation, 2011. **71**(7): p. 583-592.
118. Gavaler, J.S., *Oral hormone replacement therapy: factors that influence the estradiol concentrations achieved in a multiracial study population*. J Clin Pharmacol, 2002. **42**(2): p. 137-44.
119. Yasui, T., et al., *Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women*. Maturitas, 2005. **50**(1): p. 19-29.
120. Lund, T.D.R., T. Chung, W. C. Handa, R. J., *Novel Actions of Estrogen Receptor-beta on Anxiety-Related Behaviors*. Endocrinology, 2004. **146**(2): p. 797-807.
121. Böttner, M., P. Thelen, and H. Jarry, *Estrogen receptor beta: Tissue distribution and the still largely enigmatic physiological function*. The Journal of Steroid Biochemistry and Molecular Biology, 2014. **139**: p. 245-251.
122. Ward, R.D. and N.L. Weigel, *Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation*. Biofactors, 2009. **35**(6): p. 528-36.
123. Weigel, N.L. and N.L. Moore, *Steroid Receptor Phosphorylation: A Key Modulator of Multiple Receptor Functions*. Molecular Endocrinology, 2007. **21**(10): p. 2311-2319.
124. Weigel, N.L. and N.L. Moore, *Kinases and protein phosphorylation as regulators of steroid hormone action*. Nuclear Receptor Signaling, 2007. **5**: p. e005.
125. Muralidharan Anbalagan, B.H., Leigh Murphy and Brian G. Rowan, *Post-translational modifications of nuclear receptors and human disease*. Nuclear Receptor Signaling, 2012. **10**(1): p. 1-13.
126. Le Romancer, M., et al., *Cracking the estrogen receptor's posttranslational code in breast tumors*. Endocr Rev, 2011. **32**(5): p. 597-622.
127. Saunders, P.T., *Oestrogen receptor beta (ER beta)*. Rev Reprod, 1998. **3**(3): p. 164-71.
128. Tremblay, A.T., G. B. Labrie, F. Giguere, V., *Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1*. Mol Cell, 1999. **3**(4): p. 513-9.
129. Kinoshita E, K.-K.E., Takiyama K, Koike T., *Phosphate-binding Tag, a New Tool to Visualize Phosphorylated Proteins*. Molecular & Cellular Proteomics, 2005. **5**(4): p. 749-757.
130. Paul J. Shughrue, M.V.L., And Istvan Merchenthaler, *Comparative Distribution of Estrogen Receptor-a and -b mRNA in the Rat Central Nervous System*. The Journal of Comparative Neurology, 1997. **388**: p. 507-525.
131. Spencer, J.L., et al., *Uncovering the mechanisms of estrogen effects on hippocampal function*. Frontiers in Neuroendocrinology, 2008. **29**(2): p. 219-237.
132. Chu, S. and P.J. Fuller, *Identification of a splice variant of the rat estrogen receptor beta gene*. Mol Cell Endocrinol, 1997. **132**(1-2): p. 195-9.
133. Price, R.H., Jr., N. Lorenzon, and R.J. Handa, *Differential expression of estrogen receptor beta splice variants in rat brain: identification and characterization of a novel variant missing exon 4*. Brain Res Mol Brain Res, 2000. **80**(2): p. 260-8.
134. Lu, B., et al., *Functional characteristics of a novel murine estrogen receptor-beta isoform, estrogen receptor-beta 2*. J Mol Endocrinol, 2000. **25**(2): p. 229-42.

135. Zisch, A.H., et al., *Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses*. *Oncogene*, 2000. **19**(2): p. 177-87.
136. Pak, T.R.C., W. C. Lund, T. D. Hinds, L. R. Clay, C. M. Handa, R. J., *The Androgen Metabolite, 5alpha-Androstane-3beta, 17beta-Diol, Is a Potent Modulator of Estrogen Receptor-beta 1-Mediated Gene Transcription in Neuronal Cells*. *Endocrinology*, 2004. **146**(1): p. 147-155.
137. Tremblay, G.B., et al., *Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta*. *Mol Endocrinol*, 1997. **11**(3): p. 353-65.
138. Lund, T.D., L.R. Hinds, and R.J. Handa, *The androgen 5alpha-dihydrotestosterone and its metabolite 5alpha-androstan-3beta, 17beta-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus*. *J Neurosci*, 2006. **26**(5): p. 1448-56.
139. Webb, P., et al., *Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens*. *Mol Endocrinol*, 1995. **9**(4): p. 443-56.
140. Paech, K., et al., *Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites*. *Science*, 1997. **277**(5331): p. 1508-10.
141. Tremblay, G.B., et al., *Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens*. *Cancer Res*, 1998. **58**(5): p. 877-81.
142. Bi, R., et al., *Effects of estrogen, age, and calpain on MAP kinase and NMDA receptors in female rat brain*. *Neurobiology of Aging*, 2003. **24**(7): p. 977-983.
143. Parveen Abidi, S.L.-S., Yuan Cortez, Jiahuai Han, Salman Azhar, *Evidence that age-related changes in p38 MAP kinase contribute to the decreased steroid production by the adrenocortical cells from old rats*. *Aging Cell*, 2008. **7**(2): p. 168-178.
144. Williamson, D., et al., *Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle*. *The Journal of Physiology*, 2003. **547**(3): p. 977-987.
145. Simonyi A, M.K., Sun GY., *Extracellular signal-regulated kinase 2 mRNA expression in the rat brain during aging*. *Neurochemical Research*, 2003. **28**(9): p. 1375-8.
146. Kim, M.Y., et al., *Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor*. *Mol Endocrinol*, 2006. **20**(7): p. 1479-93.
147. Tremblay, A.M., et al., *Phosphorylation-dependent sumoylation regulates estrogen-related receptor-alpha and -gamma transcriptional activity through a synergy control motif*. *Mol Endocrinol*, 2008. **22**(3): p. 570-84.
148. Vivar, O.I., et al., *Estrogen Receptor Binds to and Regulates Three Distinct Classes of Target Genes*. *Journal of Biological Chemistry*, 2010. **285**(29): p. 22059-22066.
149. Zhao, C., et al., *Genome-Wide Mapping of Estrogen Receptor- Binding Regions Reveals Extensive Cross-Talk with Transcription Factor Activator Protein-1*. *Cancer Research*, 2010. **70**(12): p. 5174-5183.
150. Cui, Y., et al., *Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity*. *Cancer Res*, 2004. **64**(24): p. 9199-208.
151. Picard, N., et al., *Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta*. *Mol Endocrinol*, 2008. **22**(2): p. 317-30.
152. Kuiper, G.G. and J.A. Gustafsson, *The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and antiestrogens*. *FEBS Lett*, 1997. **410**(1): p. 87-90.

153. Kuiper, G.G., et al., *The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems*. Front Neuroendocrinol, 1998. **19**(4): p. 253-86.
154. Levy, N., et al., *Unliganded estrogen receptor- β regulation of genes is inhibited by tamoxifen*. Molecular and Cellular Endocrinology, 2010. **315**(1-2): p. 201-207.
155. Lund, T.D., et al., *Novel Actions of Estrogen Receptor- β on Anxiety-Related Behaviors*. Endocrinology, 2005. **146**(2): p. 797-807.
156. Paterni, I., et al., *Estrogen receptors alpha (ERalpha) and beta (ERbeta): subtype-selective ligands and clinical potential*. Steroids, 2014. **90**: p. 13-29.
157. Tomas Barkhem, B.C., Yvonne Nilsson, Eva Enmark, Jan-Åke Gustafsson, And Stefan Nilsson, *Differential Response of Estrogen Receptor a and Estrogen Receptor b to Partial Estrogen Agonists/Antagonists*. Molecular Pharmacology, 1998. **54**(1): p. 105-112.
158. Watters JJ1, C.J., Cunningham MJ, Krebs EG, Dorsa DM., *Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription*. Endocrinology, 1997. **138**(9): p. 4030-3.
159. Brzozowski, A.M., et al., *Molecular basis of agonism and antagonism in the oestrogen receptor*. Nature, 1997. **389**(6652): p. 753-8.
160. Shiau, A.K., et al., *The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen*. Cell, 1998. **95**(7): p. 927-37.
161. Wang, Y., et al., *A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta*. Proceedings of the National Academy of Sciences, 2006. **103**(26): p. 9908-9911.
162. Hodis, H.N. and W.J. Mack, *A "window of opportunity:" The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent*. Brain Research, 2011. **1379**: p. 244-252.
163. Pedram, A., et al., *Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin*. Endocrinology, 2008. **149**(7): p. 3361-9.
164. Benmansour, S., et al., *Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats*. Neuroendocrinology, 2015.
165. Benmansour, S., et al., *Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance*. Int J Neuropsychopharmacol, 2014. **17**(5): p. 765-77.
166. Cookson, M.R., et al., *Beneficial Effects of Estrogen in a Mouse Model of Cerebrovascular Insufficiency*. PLoS ONE, 2009. **4**(4): p. e5159.
167. Xu, X., et al., *Bisphenol A promotes dendritic morphogenesis of hippocampal neurons through estrogen receptor-mediated ERK1/2 signal pathway*. Chemosphere, 2014. **96**: p. 129-137.
168. Seval, Y., et al., *Estrogen-Mediated Regulation of p38 Mitogen-Activated Protein Kinase in Human Endometrium*. The Journal of Clinical Endocrinology & Metabolism, 2006. **91**(6): p. 2349-2357.
169. Wang, M., et al., *17- β -Estradiol decreases p38 MAPK-mediated myocardial inflammation and dysfunction following acute ischemia*. Journal of Molecular and Cellular Cardiology, 2006. **40**(2): p. 205-212.
170. Wade, C.B., et al., *Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway*. Endocrinology, 2001. **142**(6): p. 2336-42.
171. Seval, Y., *Estrogen-Mediated Regulation of p38 Mitogen-Activated Protein Kinase in Human Endometrium*. Journal of Clinical Endocrinology & Metabolism, 2006. **91**(6): p. 2349-2357.

172. Yamaguchi T, A.H., Katayama N, Ishikawa T, Kikumoto K, Atomi Y., *Age-Related Increase of Insoluble, Phosphorylated Small Heat Shock Proteins in Human Skeletal Muscle*. J Gerontol A Biol Sci Med Sci, 2007. **62** (5): p. 481-489.
173. Franceschi, C., et al., *Inflamm-aging. An evolutionary perspective on immunosenescence*. Ann N Y Acad Sci, 2000. **908**: p. 244-54.
174. McGregor, C., et al., *Novel ligands balance estrogen receptor beta and alpha agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause*. Endocrinology, 2014. **155**(7): p. 2480-91.
175. Fanselow, M.S. and H.W. Dong, *Are the dorsal and ventral hippocampus functionally distinct structures?* Neuron, 2010. **65**(1): p. 7-19.
176. Barrick, C.J., et al., *Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner*. J Mol Cell Cardiol, 2012. **52**(1): p. 165-74.
177. Bal, U.A., et al., *The effect of raloxifene on left ventricular hypertrophy in postmenopausal women: A prospective, randomized, and controlled study*. Anatol J Cardiol, 2015. **15**(6): p. 480-4.
178. Shults, C.L., et al., *Aging and Loss of Circulating 17beta-Estradiol Alters the Alternative Splicing of ERbeta in the Female Rat Brain*. Endocrinology, 2015. **156**(11): p. 4187-99.
179. Rao, Y.S., et al., *Prolonged ovarian hormone deprivation alters the effects of 17beta-estradiol on microRNA expression in the aged female rat hypothalamus*. Oncotarget, 2015. **6**(35): p. 36965-83.
180. Song, G., et al., *Region-specific reduction of Gβ4 expression and induction of the phosphorylation of PKB/Akt and ERK1/2 by aging in rat brain*. Pharmacological Research, 2007. **56**(4): p. 295-302.
181. Parmar, M.S., et al., *The role of ERK1, 2, and 5 in dopamine neuron survival during aging*. Neurobiology of Aging, 2014. **35**(3): p. 669-679.
182. Laredo, S.A., R. Villalon Landeros, and B.C. Trainor, *Rapid effects of estrogens on behavior: environmental modulation and molecular mechanisms*. Front Neuroendocrinol, 2014. **35**(4): p. 447-58.
183. Simone Nuedlinga, R.H.K., Michael E. Mendelsohnc, John A. Katzenellenbogend, Benita S. Katzenellenbogene, Rainer Meyera, Hans Vetterb, Christian Grohe^{b,*}, *Activation of estrogen receptor L is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes*. FEBS Letters, 2001. **502**: p. 103-108.
184. Hershberger, P.A., et al., *Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells*. J Steroid Biochem Mol Biol, 2009. **116**(1-2): p. 102-9.
185. Suzuki, T., et al., *17 beta-estradiol administration following trauma-hemorrhage prevents the increase in Kupffer cell cytokine production and MAPK activation predominately via estrogen receptor-alpha*. Surgery, 2006. **140**(2): p. 141-8.
186. Zhao, L. and R.D. Brinton, *Estrogen receptor alpha and beta differentially regulate intracellular Ca(2+) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons*. Brain Res, 2007. **1172**: p. 48-59.
187. Witty, C.F., et al., *Increasing hippocampal estrogen receptor alpha levels via viral vectors increases MAP kinase activation and enhances memory in aging rats in the absence of ovarian estrogens*. PLoS ONE, 2012. **7**(12): p. e51385.

188. Nguyen, L.K., W. Kolch, and B.N. Kholodenko, *When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling*. Cell Commun Signal, 2013. **11**: p. 52.
189. Wetzel-Strong, S.E., et al., *Cohort of estrogen-induced microRNAs regulate adrenomedullin expression*. Am J Physiol Regul Integr Comp Physiol, 2016. **310**(2): p. R209-16.
190. Rao, Y.S., et al., *MicroRNAs in the aging female brain: A putative mechanism for age-specific estrogen effects*. Endocrinology, 2013. **154**(8): p. 2795-806.
191. Peng, T., et al., *Downregulation of miR-151-5p Contributes to Increased Susceptibility to Arrhythmogenesis during Myocardial Infarction with Estrogen Deprivation*. PLoS ONE, 2013. **8**(9): p. e72985.
192. Queiros, A.M., et al., *Sex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart*. Int J Cardiol, 2013. **169**(5): p. 331-8.
193. Tuscher JJ1, L.V., Frankfurt M3, Frick KM4., *Estradiol-Mediated Spine Changes in the Dorsal Hippocampus and Medial Prefrontal Cortex of Ovariectomized Female Mice Depend on ERK and mTOR Activation in the Dorsal Hippocampus*. J Neurosci., 2016. **36**(5): p. 1483-9.
194. Das, A., et al., *ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice*. Am J Physiol Heart Circ Physiol, 2009. **296**(5): p. H1236-43.
195. Lips, D.J., et al., *MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo*. Circulation, 2004. **109**(16): p. 1938-41.
196. Hausenloy, D.J. and D.M. Yellon, *Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection*. Heart Fail Rev, 2007. **12**(3-4): p. 217-34.
197. Messeguer, X., et al., *PROMO: detection of known transcription regulatory elements using species-tailored searches*. Bioinformatics, 2002. **18**(2): p. 333-4.
198. Nilsson, S., et al., *Mechanisms of estrogen action*. Physiol Rev, 2001. **81**(4): p. 1535-65.
199. Vogel, C. and E.M. Marcotte, *Insights into the regulation of protein abundance from proteomic and transcriptomic analyses*. Nat Rev Genet, 2012. **13**(4): p. 227-32.
200. Baek, D., et al., *The impact of microRNAs on protein output*. Nature, 2008. **455**(7209): p. 64-71.
201. Hotta, K., et al., *Efficacy and safety of endoscopic interventions using the short double-balloon endoscope in patients after incomplete colonoscopy*. Dig Endosc, 2015. **27**(1): p. 95-8.
202. Rocca, W.A., B.R. Grossardt, and L.T. Shuster, *Oophorectomy, menopause, estrogen treatment, and cognitive aging: Clinical evidence for a window of opportunity*. Brain Research, 2011. **1379**: p. 188-198.
203. Resnick, S.M., et al., *The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline*. Clinical Trials, 2004. **1**(5): p. 440-450.
204. LeFevre, J. and M.K. McClintock, *Reproductive senescence in female rats: a longitudinal study of individual differences in estrous cycles and behavior*. Biol Reprod, 1988. **38**(4): p. 780-9.
205. Savonenko, A.V. and A.L. Markowska, *The cognitive effects of ovariectomy and estrogen replacement are modulated by aging*. Neuroscience, 2003. **119**(3): p. 821-30.
206. Pinceti, E., et al., *Phosphorylation alters Oestrogen Receptor beta-mediated transcription in neurons*. J Neuroendocrinol, 2015.
207. Snyder, M.A., et al., *Multiple ERβ antisera label in ERβ knockout and null mouse tissues*. Journal of Neuroscience Methods, 2010. **188**(2): p. 226-234.

208. Nair, S.K., et al., *Conformational dynamics of estrogen receptors alpha and beta as revealed by intrinsic tryptophan fluorescence and circular dichroism*. J Mol Endocrinol, 2005. **35**(2): p. 211-23.
209. Gee, A.C. and J.A. Katzenellenbogen, *Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release*. Mol Endocrinol, 2001. **15**(3): p. 421-8.
210. Kumar, R., et al., *The dynamic structure of the estrogen receptor*. J Amino Acids, 2011. **2011**: p. 812540.
211. Metivier, R., et al., *Function of N-terminal transactivation domain of the estrogen receptor requires a potential alpha-helical structure and is negatively regulated by the A domain*. Mol Endocrinol, 2000. **14**(11): p. 1849-71.
212. Gerber, S.A., et al., *Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS*. Proceedings of the National Academy of Sciences, 2003. **100**(12): p. 6940-6945.
213. Wilkins, M.R., et al., *Protein identification and analysis tools in the ExpASY server*. Methods Mol Biol, 1999. **112**: p. 531-52.
214. Lawless, C. and S.J. Hubbard, *Prediction of missed proteolytic cleavages for the selection of surrogate peptides for quantitative proteomics*. OMICS, 2012. **16**(9): p. 449-56.
215. Zhang, M., et al., *Rapid large-scale purification of myofilament proteins using a cleavable His6-tag*. Am J Physiol Heart Circ Physiol, 2015. **309**(9): p. H1509-15.
216. Welboren, W.J., et al., *ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands*. EMBO J, 2009. **28**(10): p. 1418-28.
217. Pak, T.R., et al., *The androgen metabolite, 5alpha-androstane-3beta, 17beta-diol, is a potent modulator of estrogen receptor-beta1-mediated gene transcription in neuronal cells*. Endocrinology, 2004. **146**(1): p. 147-55.
218. Fuchs, S., et al., *Proline primed helix length as a modulator of the nuclear receptor-coactivator interaction*. J Am Chem Soc, 2013. **135**(11): p. 4364-71.
219. Roberts, L.R., et al., *Sulfonamides as selective oestrogen receptor beta agonists*. Bioorg Med Chem Lett, 2011. **21**(19): p. 5680-3.
220. Phillips, C., et al., *Design and structure of stapled peptides binding to estrogen receptors*. J Am Chem Soc, 2011. **133**(25): p. 9696-9.
221. Mocklinghoff, S., et al., *Design and evaluation of fragment-like estrogen receptor tetrahydroisoquinoline ligands from a scaffold-detection approach*. J Med Chem, 2011. **54**(7): p. 2005-11.
222. Mocklinghoff, S., et al., *Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain*. Chembiochem, 2010. **11**(16): p. 2251-4.
223. Schwabe, J.W., L. Chapman, and D. Rhodes, *The oestrogen receptor recognizes an imperfectly palindromic response element through an alternative side-chain conformation*. Structure, 1995. **3**(2): p. 201-13.
224. Schwabe, J.W., et al., *The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements*. Cell, 1993. **75**(3): p. 567-78.
225. Warnmark, A., et al., *The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties*. J Biol Chem, 2001. **276**(49): p. 45939-44.
226. Kumar, R. and E.B. Thompson, *Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions*. Mol Endocrinol, 2003. **17**(1): p. 1-10.

227. Radhakrishnan, I., et al., *Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator:coactivator interactions*. Cell, 1997. **91**(6): p. 741-52.
228. Kussie, P.H., et al., *Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain*. Science, 1996. **274**(5289): p. 948-53.
229. McEwan, I.J., et al., *Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding*. Biochemistry, 1996. **35**(29): p. 9584-93.
230. Combet, C., et al., *NPS@: network protein sequence analysis*. Trends Biochem Sci, 2000. **25**(3): p. 147-50.
231. Guermeur, Y., et al., *Improved performance in protein secondary structure prediction by inhomogeneous score combination*. Bioinformatics, 1999. **15**(5): p. 413-21.
232. Tremblay, G.B., et al., *Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex*. Mol Cell Biol, 1999. **19**(3): p. 1919-27.
233. Roux, K.J., et al., *A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells*. J Cell Biol, 2012. **196**(6): p. 801-10.
234. Rhee, H.W., et al., *Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging*. Science, 2013. **339**(6125): p. 1328-31.
235. Bratic, I. and A. Trifunovic, *Mitochondrial energy metabolism and ageing*. Biochim Biophys Acta, 2010. **1797**(6-7): p. 961-7.
236. Brinton, R.D., *The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications*. Trends Neurosci, 2008. **31**(10): p. 529-37.
237. Thal, D.R., K. Del Tredici, and H. Braak, *Neurodegeneration in normal brain aging and disease*. Sci Aging Knowledge Environ, 2004. **2004**(23): p. pe26.
238. Stern, S., S. Behar, and S. Gottlieb, *Cardiology patient pages. Aging and diseases of the heart*. Circulation, 2003. **108**(14): p. e99-101.
239. McConnell, J.L. and B.E. Wadzinski, *Targeting protein serine/threonine phosphatases for drug development*. Mol Pharmacol, 2009. **75**(6): p. 1249-61.
240. Moorhead, G.B., L. Trinkle-Mulcahy, and A. Ulke-Lemee, *Emerging roles of nuclear protein phosphatases*. Nat Rev Mol Cell Biol, 2007. **8**(3): p. 234-44.
241. Zhang, Z.-Y., *Emerging new techniques for studying protein phosphatases*. Methods, 2007. **42**(3): p. 205-206.
242. Rajagopal, S., et al., *Aging is associated with dimerization and inactivation of the brain-enriched tyrosine phosphatase STEP*. Neurobiol Aging, 2016. **41**: p. 25-38.
243. Liu, G., et al., *Increased oligomerization and phosphorylation of alpha-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains*. Neurobiol Aging, 2015. **36**(9): p. 2649-59.
244. Urban, G., et al., *Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively*. J Biol Chem, 2001. **276**(29): p. 27638-46.
245. Albert, J.L., S.A. Sundstrom, and C.R. Lyttle, *Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line*. Cancer Res, 1990. **50**(11): p. 3306-10.
246. Leung, K.C., et al., *Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases*. Endocrinology, 2007. **148**(5): p. 2417-23.
247. Lowe, J., et al., *Regulation of the Wip1 phosphatase and its effects on the stress response*. Front Biosci (Landmark Ed), 2012. **17**: p. 1480-98.

248. Zhang, Y., et al., *Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation*. J Biol Chem, 2009. **284**(36): p. 24542-52.
249. Yuan, B., et al., *A phosphotyrosine switch determines the antitumor activity of ERbeta*. J Clin Invest, 2014. **124**(8): p. 3378-90.
250. Velarde, M.C., *Mitochondrial and sex steroid hormone crosstalk during aging*. Longev Healthspan, 2014. **3**(1): p. 2.
251. Velarde, M.C., *Pleiotropic actions of estrogen: a mitochondrial matter*. Physiol Genomics, 2013. **45**(3): p. 106-9.
252. Hunter, J.C., A.M. Machikas, and D.H. Korzick, *Age-dependent reductions in mitochondrial respiration are exacerbated by calcium in the female rat heart*. Gend Med, 2012. **9**(3): p. 197-206.
253. Yao, J. and R.D. Brinton, *Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease*. Adv Pharmacol, 2012. **64**: p. 327-71.
254. Henderson, V.W. and R.D. Brinton, *Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy*. Prog Brain Res, 2010. **182**: p. 77-96.
255. O'Lone, R., et al., *Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species*. Mol Endocrinol, 2007. **21**(6): p. 1281-96.
256. Cui, H., Y. Kong, and H. Zhang, *Oxidative stress, mitochondrial dysfunction, and aging*. J Signal Transduct, 2012. **2012**: p. 646354.
257. Nilsen, J., et al., *Estradiol in vivo regulation of brain mitochondrial proteome*. J Neurosci, 2007. **27**(51): p. 14069-77.
258. Lancaster, T.S., et al., *Quantitative proteomic analysis reveals novel mitochondrial targets of estrogen deficiency in the aged female rat heart*. Physiol Genomics, 2012. **44**(20): p. 957-69.
259. Brinton, R.D., *Investigative Models for Determining Hormone Therapy-Induced Outcomes in Brain: Evidence in Support of a Healthy Cell Bias of Estrogen Action*. Annals of the New York Academy of Sciences, 2005. **1052**(1): p. 57-74.
260. Mattingly, K.A., et al., *Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis*. Mol Endocrinol, 2008. **22**(3): p. 609-22.
261. Ivanova, M.M., et al., *Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites*. FASEB J, 2011. **25**(4): p. 1402-16.
262. Stirone, C., et al., *Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels*. Mol Pharmacol, 2005. **68**(4): p. 959-65.
263. Flynn, J.M., et al., *RNA suppression of ERK2 leads to collapse of mitochondrial membrane potential with acute oxidative stress in human lens epithelial cells*. Am J Physiol Endocrinol Metab, 2008. **294**(3): p. E589-99.
264. Nilsen, J. and R. Diaz Brinton, *Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression*. Proc Natl Acad Sci U S A, 2003. **100**(5): p. 2842-7.
265. Nilsen, J., et al., *Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function*. BMC Neurosci, 2006. **7**: p. 74.
266. Dworatzek, E., et al., *Sex differences in exercise-induced physiological myocardial hypertrophy are modulated by oestrogen receptor beta*. Cardiovasc Res, 2014. **102**(3): p. 418-28.

267. Zhao, L., et al., *Estrogen receptor beta-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause*. *Menopause*, 2011. **18**(10): p. 1131-42.
268. Leitman, D.C. and U. Christians, *MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms*. *Expert Opin Investig Drugs*, 2012. **21**(7): p. 1031-42.
269. Tagliaferri, M., et al., *Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101*. *Climacteric*, 2012. **15**(6): p. 607-10.
270. Lewis, V., *Undertreatment of menopausal symptoms and novel options for comprehensive management*. *Curr Med Res Opin*, 2009. **25**(11): p. 2689-98.
271. Cvorovic, A., et al., *Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract*. *Endocrinology*, 2007. **148**(2): p. 538-47.
272. Fabian, C.J., *The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer*. *Int J Clin Pract*, 2007. **61**(12): p. 2051-63.
273. Shults, C.L., et al., *Aging and Loss of Circulating 17 β -Estradiol Alters the Alternative Splicing of ER β in the Female Rat Brain*. *Endocrinology*, 2015. **156**(11): p. 4187-4199.
274. Paxinos G., W.C., *The Rat Brain in Stereotaxic Coordinates, 4th Ed.*, . Academic Press, Waltham, MA (1998)
275. Livak, K.J. and T.D. Schmittgen, *Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) Method*. *Methods*, 2001. **25**(4): p. 402-8.

VITA

The author Elena Pinceti was born in Genova, Italy, to Paolo and Laura. She is the oldest of three; Anna and Andrea are her siblings. In 2005 she spent a year as a High School foreign exchange student with the family of Thomas, Terri and Eliza Slanker and graduated from Plainfield Central High School. She attended the Università degli Studi di Genova (Italy) and earned a Bachelor of Science in Biology *cum laude*, in Cell and Molecular Physiology. She worked in the lab of Dr. Ilaria Demori and defended her undergraduate thesis titled: "Nonalcoholic fatty acid disease: an *in vitro* system".

In August 2010, Elena came to the Integrative Cell Biology program at Loyola University Chicago. In the summer of 2011 Elena joined the lab of Dr. Toni Pak where she studied phosphorylation of ER β in the aging female heart and brain. While at Loyola, Elena has given oral and poster presentations at national and international meetings and published first author and contributing author articles. She obtained a Schmitt Fellowship award as well as a fellowship to attend the 8th International Meeting Steroids and Nervous System in Torino, Italy.